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Chapter 1 Introduction
1.1 Acute Myeloid leukemia: the disease
Acute Myeloid Leukemia (AML) is a clonal myeloproliferative disease characterized by an
uncontrolled proliferation and block in differentiation of myeloid committed blood cells in
the bone marrow (BM). The diagnosis of AML is made when over 30% of myeloid blast
cells are observed in the BM of the patient. The excessive amount of myeloid blast cells in
the BM causes a lack of space for normal hematopoiesis to occur. This results in anemia,
thrombocytopenia and granulocytopenia with symptoms as fatigue, dizziness, bleedings
and infections. AML occurs as a result of genetic changes often evident as cytogenetic
changes, which can be detected in the majority of patient samples. The type of cytogenetic
abnormality is considered the most powerful independent risk factor for outcome and the
various genetic changes can be classified in a favourable, intermediate or poor risk-group
(Table 1 and Figure 1).1 AML can also be classified according to its morphology using the
French-American-British (FAB) classification (Table 2). Recently, a more clinical relevant
classification has been proposed by the World Health Organization (WHO). This
classification stratifies hematologic malignancies according to a combination of
morphology, immunophenotype, genetic features and clinical syndromes.2 According to
the WHO classification the diagnosis of AML is made when over 20% instead of 30% blast
cells are present in the BM. In Table 3, the WHO classification of AML is depicted. 
The incidence of AML is 2.4/100,000 people per year in the United States and it occurs
mainly in elderly patients with a median age of onset of 63-65 years.3 AML patients under
50 years of age, treated with curative intent chemotherapy, have complete remission (CR)
rates that average 70% with a median relapse free survival (RFS) of nearly 2 years.4 In
contrast, in the elderly AML patient, CR rates only average 50% with a median RFS in
these patients of only 9 to 12 months.5-8 The poorer outcome of AML in the elderly may
result from adverse cytogenetics, expression of multi drug resistance proteins, reduced
patient tolerance to chemotherapy or a combination of these factors.3 However, despite age
or biological differences, most patients eventually relapse and die of the disease.
CR or partial remission can be obtained after intensive chemotherapy currently often
consisting of high/low dose cytarabine plus daunorubicin/idarubicin. After a CR is
obtained, patients under 60 years have three main options: intensive chemotherapy,
autologous stem cell transplantation or allogeneic stem cell transplantation. In general, the
advantage of an allogeneic stem cell transplant is its graft versus leukemia effect with lower
relapse rates. However, an HLA-matched sibling is available for only a minority of patients
and the occurrence of graft-versus host disease necessitates long-lasting
immunosuppressive medication. An autologous stem cell transplant, available for every
patient in CR, does not have the advantage of the graft versus leukemia effect. In addition,
Brenner et al. demonstrated that an autologous stem cell transplant can contribute to
relapse of the disease.9 Overall, transplantation with autologous or allogeneic blood or
bone marrow derived stem cells carries substantial procedure-related mortality and
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morbidity and the 5 year overall survival rates do not differ much between intensive
chemotherapy and autologous or allogeneic stem cell transplants.10,11 Recently, as an
alternative to conventional stem cell transplantation, non-myeloablative stem cell
transplantation has been performed and this strategy appears safe and minimally toxic
while retaining its graft-versus-leukemia effect.12,13 This novel strategy could provide
transplantation opportunities for patients that are ineligible for conventional stem cell
transplantation because of age or medical contraindications. In addition, some new
therapies specifically targeting the AML cells have been used in clinical trials including
antibody-targeted chemo- or radiotherapy.14-16 The effect of those therapies on long-term
survival is not yet known. Altogether we can conclude that although CR rates have
dramatically improved in the last few decades, overall survival is still relatively short
mainly due to relapse of the disease. 
Table 1: Riskgroups of cytogenetic abnormalities observed in AML patients
* Whether alone or in conjunction with other abnormalities
• Presence of a clone with ≥ 5 unrelated cytogenetic abnormalities
Risk group Abnormality
Favourable * t(8;21)
t(15;17)
Inv(16)
Intermediate normal
cytogenetic abnormality not classified as 
Favourable or Adverse
Unfavourable * -5
-7
Del(5q)
Del(7q)
t(6;9)
t(9;22)
abnormal 11q
abnormal 3q
complex •
Figure 1: Overall survival of patients with favourable, intermediate and adverse
cytogenetic abnormalities. Adapted from Grimwade et al. Blood. 1998;92:2322-2333.
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1.2 Acute Myeloid leukemia: the biology
The hematopoietic system is a complex and tightly regulated process in which pluripotent
stem cells undergo proliferation and differentiation to produce mature blood cells of the
various lineages while maintaining a compartment of uncommitted cells. As mentioned
above AML occurs as a result of genetic changes. Such changes occur in a primitive
hematopoietic cell, which gives rise to the malignant clone. Despite the lack of mature cells
derived from the leukemic clone in the majority of AML patients, there is considerable
heterogeneity among the leukemic blasts even within individual patients, particularly with
respect to their capacity to proliferate and or self-renew.17-19 This suggests that subsequent
to transformation and prior to the maturation arrest some differentiation of AML blasts
occurs, which creates a hierarchy of AML progenitors just as is seen in normal
hematopoiesis. The ability to phenotypically and functionally characterize the AML stem
cell, which is thought to be responsible for maintaining the disease, is not only essential for
a better understanding of the disease, but can also contribute to new therapies in which
these AML stem cells are specifically targeted. 
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FAB classificiation Morphology
M0 Acute Myeloblastic Leukemia with minimal differentiation
M1 Acute Myeloblastic Leukemia without maturation
M2 Acute Myeloblastic Leukemia with maturation
M3 Acute Promyelocytic Leukemia 
M4 Acute Myelomonocytic Leukemia
M4eo Acute Myelomonocytic Leukemia with abnormal eosinophils
M5a Acute Monoblastic Leukemia
M5b Acute Monocytic Leukemia  
M6 Acute Erythroleukemia
M7 Acute Megakaryocytic leukaemia
Table 2: FAB Classification of AML
WHO classificiation Definition
I AML with recurrent cytogenetic translocations
II AML with myelodyplasia-related features
III Therapy-related AML and MDS
IV AML not otherwise categorized
Table 3: WHO Classification of AML
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Over the years several in vitro assays have been developed to detect normal hematopoietic
progenitors. Lineage committed progenitor cells can be detected in the colony forming cell
assay (CFU assay), in which hematopoietic cells are plated in semi-solid media
complemented with growth factors (GF).20,21 More primitive progenitors can be assayed in
the long-term culture assay (LTC).22 In this assay, cells are cultured for 5 to 8 weeks on
murine stromal feeders producing human GFs and after 5 to 8 weeks the cells are
harvested and plated in semi-solid media upon which the LTC-initiating cell (LTC-IC)
content can be determined. It is thought that the most primitive pluripotent stem cells
can only be detected in vivo. Multi-lineage engraftment of human cells can be detected in
the non-obese diabetic severe combined immunodeficient (NOD/SCID) mice, which
have defects in DNA double-strand break repair and in V(D)J recombination, creating
B and T cell deficiencies, and a defect in their natve killer (NK) cells and antigen
presenting cells.21,23,24
AML progenitors and stem cells can also be assayed using the same detection assays used
for normal hematopoietic cells. A subpopulation of the malignant cells from an AML
patient gives rise to clusters (10-20 cells) or colonies (>20 cells) of terminally differentiated
blasts (CFU-blasts) when plated in a CFU assay.25,26 More primitive progenitors can be
detected in vitro using the LTC assay.27 More recently, the suspension culture (SC) assay
described by McCulloch et al.28 was adapted in our laboratory by using recombinant GFs,
serum free media and extension of the culture period to 8 weeks.17 The cells capable of
producing CFU-blasts after 2 to 8 weeks in SC as quantitated by limiting dilution analysis,
are called SC-IC and are thought to have the same biological properties as LTC-IC. For
the evaluation of AML progenitors in vivo, NOD/SCID mice can be utilized.19,29-31 About
70% of the AML patient samples can successfully engraft NOD/SCID mice, with the cells
responsible for engraftment called SCID leukemia-initiating cells (SL-IC).29 The
frequency of SL-IC in a study by Ailles et al. was reported to be 0.7-45 per 107 cells 29,
while a higher frequency of 20-1000 SL-IC per 107 cells had been reported in an earlier
study.19 Each SL-IC was shown to produce more than 106 leukemic blasts as well as many
AML CFU and AML LTC-IC as detected 8 weeks post-injection into mice in support of
the proposed hierarchy in AML stem and progenitor cells.29 Ailles study also showed that
higher levels of engraftment were obtained with AML samples with cytogenetic changes
associated with a poor clinical prognosis compared to those with a good prognosis.29
Furthermore, cells from FAB subtype M3 and to a lesser extent, M2 engrafted more
poorly.29 To obtain more consistent engraftment and engraftment with more patient
samples variants of the NOD/SCID model were tested.32 NOD/SCID mice transgenic for
the human GFs Steel Factor, GM-CSF and IL-3, did not reveal a major improvement in
engraftment of AML cells.32 Another model tested is the ß2-microglobulin deficient
NOD/SCID mice, which have a reduced innate immunity due to a lack of NK cell
activity.33 These mice revealed an 11-fold increase in NOD/SCID repopulating cells
(SRC) frequency compared to the standard NOD/SCID mice. In addition, they showed
improved detection of progenitors with myeloid restricted and short-term lympho/myeloid
repopulating potential when transplanted with normal human cord blood (CB) cells.34,35
Engraftment using this model allowed detection of some AML progenitors which were not
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detectable in the NOD/SCID mouse model, but the added benefit of either of these models
seemed modest.32
The phenotype of primitive AML progenitors was studied by sorting cells into phenotypic
subpopulations, which were then assayed by their long-term growth in vitro (CFU, SC-IC
or LTC-IC) or by their growth in the immunocompromised NOD/SCID mice.19,30,31 As in
the normal hematopoietic system, LTC-IC and SL-IC represent a very rare population in
AML cells. Primitive AML progenitors express CD34 and lack the expression of CD38,
CD71 and HLA-DR18 just like their normal counterparts36,37 and can be enriched 2~3 logs
by sorting for this phenotype.18 AML progenitors express only low levels of c-kit
(CD117)38, which may differ from the expression on normal progenitor cells.39,40 Recently,
a normal CD34- stem cell has been proposed41,42 and a CD34- AML SL-IC has also been
described.43 Despite the similarities Blair et al. showed that CD90 (Thy.1), which is
expressed on normal LTC-IC44, is not expressed on primitive AML progenitors, giving this
marker a possible role in future positive selection strategies for autologous transplants.24
Interestingly, crosslinking of CD90 on normal hematopoietic cells inhibited their
proliferation, suggesting that loss of CD90 could release AML cells from such inhibiting
constraints.45
1.3 CD133 (AC133)
In search of novel cell surface markers on hematopoietic stem cells to improve stem cell
enrichment, Yin et al. produced a novel monoclonal antibody (MoAb), AC133.46 This
antibody recognizes a 5-transmembrane antigen (CD133), which is the human orthologue
of the mouse prominin.47 CD133 is a heavily glycosylated 120kDa protein, containing five
transmembrane domains and two large extracellular loops.48 Recently, novel isoforms of
human CD133 and murine prominin have been described, which both differ from the
originally described proteins by a 9-amino acid deletion in the N-terminal extracellular.49,50
Initially, CD133 expression appeared to be restricted to hematopoietic progenitors.46,48
However, more recent studies showed CD133 expression in epithelial51, endothelial
progenitor cells52 and neuronal stem cells.53 A characteristic feature of the CD133 protein
is its rapid down regulation upon cell differentiation. This property makes it a unique cell
surface marker for the identification and isolation of stem cells and progenitor cells.47,49,54
The ability of CD133 isoforms to localize to the plasma membrane suggests a possible role
for CD133 in cell-cell interactions or ligand-receptor interactions.47,48 Prominin has been
shown to specifically interact with membrane cholesterol implying a role in membrane
organization and membrane-to-membrane interactions for this protein.55 However, to date
no ligands have been identified for CD133 and its precise function remains to be
elucidated. 
As mentioned above, CD133 was first identified as a hematopoietic stem cell antigen. Expression
of CD133 is found on a subset (30-90%) of the CD34+ cells in the human bone marrow (BM),
fetal liver, umbilical cord blood and growth-factor primed peripheral blood (PB).46,56 Although
it was initially thought that CD133 expression was restricted to the CD34+ subset57, later studies
demonstrated that CD133 is also expressed on a rare population of CD34- cells.58
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In vitro colony assays using normal adult BM and CB cells have shown that the CD133+
population contains CFU-GM, BFU-E, CFU-Mix (containing granulocytic and erythroid
cells) and CFU-Mk (megakaryocytic).46,56,59 In addition, the majority of LTC-IC were
detected in the CD34+CD133+ subset as were the NOD/SCID repopulating cells.
CD34+CD133+ cells also successfully engrafted primary and secondary recipients using
the fetal sheep model.46 Recent evidence suggests that cells with stem cell properties are
enriched in a rare subpopulation of CD34-lineage- cells and that these CD34- cells are the
precursors of the CD34+ cells.42,60 The CD34- cells with stem cell properties express
CD133, suggesting that CD133 is an excellent stem cell marker and useful to purify
normal hematopoietic stem cells.58
It was of interest to see whether CD133 expression could also be detected on leukemic
cells. First Miraglia et al. showed that CD133 was co-expressed with CD34 in 4/5 AML
and 3/6 acute lymphocytic leukemia (ALL) samples, while CD133 expression could not be
detected in one CD34- AML sample.48 Later reports confirmed this observation with the
majority of CD34+ AML samples expressing CD133.61,62 However, CD133+ AML blasts
that lacked CD34 expression could be identified in ± 10% of primary AML samples.62,63
A correlation between CD133 expression and FAB type has been reported with high levels
of the CD133 cell surface marker on M4 and M5 FAB leukemias48 and on FAB M0
leukemias.63 CD133 expression on FAB M3 cases has been low to absent in all reports and
this is consistent with an absence of CD34 expression on those samples. No correlation
between CD133 expression and cytogenetics or prognosis has been reported. 
CD133 expression could also be observed on CD34+ cells of patients with myelodysplastic
syndrome, but not on CD34- cells.63 In chronic myeloid leukemia (CML) CD133+
expression could be detected in both Philadelphia chromosome (genetic marker for CML)
positive and negative populations suggesting that CD133 selection is not useful as a
purging strategy for autologous transplants in CML patients.64 On the other hand, in
childhood B-cell precursor ALL no CD133 expression could be detected on the
leukemic blast cells of 40% of the samples and therefore could be a potential marker to
separate residual normal from leukemic cells in the subgroup of CD133 negative B-cell
precursor ALL.65,66
Overall, CD133 is expressed in a substantial number of leukemic samples especially
CD34+ samples. Larger scale studies are necessary to determine whether CD133 could be
a useful selection marker for the purging of autologous transplants in some samples of the
various types of leukemias.
1.4 CD33
CD33 is a cell surface antigen that was originally identified on human myeloid cells by a
panel of monoclonal antibodies.67,68 CD33 is a 67kD type I transmembrane glycoprotein
that belongs to the sialo-adhesion family of cellular interaction molecules also referred to
as the siglecs (sialic acid binding Ig-related lectins).69 CD33 is the smallest member of the
family and contains only two Ig-like extracellular domains: one V-set Ig-like domain that
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is conserved within the siglecs and is essential for the binding of sialic acid and one C2-set
Ig-like domain.69 The cytoplasmic tail of CD33 has two tyrosine-based motifs, which are
immunoreceptor tyrosine-based inhibition motifs (ITIM).70-72 Although the function of
CD33 is still largely unknown, the fact that CD33 contains ITIMs has suggested an
inhibitory function for CD33 through the recruitment of the Src homology (SH) 2
domain-containing protein tyrosine phosphatases (SHP-1 and SHP-2).70-72 Most of the
inhibitory receptors characterized to date are efficient at suppressing signals generated by
immunoreceptor tyrosine-based activation motifs (ITAM) containing receptor systems.73
Indeed, it has been shown that CD33 can inhibit activation mediated by CD64, an ITAM
containing receptor, in vitro.72 However, the physiological function of CD33 and its possible
inhibitory effect on CD64 remains to be elucidated. 
CD33 expression is restricted to the myeloid lineage.74 Its expression is low on the earliest
pluripotent progenitor cells75-77, but expression levels are higher on early myeloid
progenitors. During myelomonocytic differentiation CD33 remains present until it is
downregulated on granulocytes, but is retained on monocytes. CD33 is expressed in 75%-
90% of the primary AML samples at diagnosis.78-80 Although a few groups have found a
correlation between better overall survival80,81 or superior complete remission rates80,82 and
the expression of CD33, others have failed to do so79,83,84, suggesting that CD33 is not a
valuable prognostic factor in AML. Because of its myeloid-specific expression levels and
high expression levels in AML, CD33 mAbs are extensively used in the immunodiagnosis
of AML. Furthermore, it has been shown that CD33 is expressed on short-term clonogenic
leukemic cells85-87 and mAbs against CD33 have been used for purging in AML.68,88
More recently, mAbs against CD33 have been used to target myeloid leukemia cells
specifically. Treatment of patients with HuM195, a mAb against CD33, produced rare
CRs in patients with relapsed or refractory myeloid leukemia89,90 and showed activity
against minimal residual disease in patients with acute promyelocytic leukemia.91 Later, in
vitro studies demonstrated that addition of mAbs against CD33 to cultures of normal and
chronic myeloid leukemic cells resulted in an inhibition of proliferation.92 Those mAbs also
induced apoptosis in cultures with primary AML cells emphasizing the possible important
role of CD33 targeting in the treatment of myeloid leukemias.93 In the meanwhile, a variety
of immunotoxins using anti-CD33 mAbs were produced. Radio-active particles were
conjugated to anti-CD33 mAbs and these immunotoxins could kill the myeloid leukemia
cell line HL-60 in vitro and appeared to be relatively safe in both mouse and men.15,16,94 
In May 2000, the United States Food and Drug Administration approved gemtuzumab
ozogamicin (GO or Mylotarg®) for the treatment of relapsed CD33+ AML in patients
older than 60 years. GO consists of a humanized anti-CD33 mAb (IgG4) conjugated to
calicheamicin, a highly potent anti-tumor antibiotic that cleaves double-stranded DNA by
the abstraction of specific hydrogen atoms.95 GO selectively targets CD33+ cells and after
binding to the CD33 receptor rapid internalization occurs with subsequent induction of
cell death.96 In in vitro studies GO killed the myeloid leukemia cell line HL-60 and
clonogenic progenitors from primary AML samples96 and targeted HL-60 human
xenograft tumors in vivo.97 A phase I study demonstrated that leukemic cells were
eliminated from the peripheral blood in 20% of patients with relapsed or refractory CD33+
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AML and GO was reasonably well tolerated.14 Phase II studies showed that approximately
30% of CD33+ AML patients in first relapse obtained a CR after treatment with GO.98,99
Response rates were similar in younger and older patients and in patients with favorable,
intermediate and poor risk cytogenetics. Interestingly, increased CD33 expression did not
seem to improve response or survival, suggesting that a threshold level of CD33 molecules
is sufficient to induce the full response.96,98 In a recent study, the exact number of CD33
antigens on the cell surface was quantified but again no relation with the response to GO
was found.100 Side effects of GO treatment were relatively mild when compared with
classical multi-agent chemotherapy and consisted of infusion related symptoms like fever,
nausea and hypotension, infections due to neutropenia and thrombocytopenia.98,99
However, in a few cases severe liver toxicity (hepatic sinusoidal obstruction syndrome) has
been reported.101 There were no occurrences of cardiac or cerebellar toxicity. Despite the
promising clinical results with GO there is still heterogeneity of response among different
patients. One reason for this heterogeneity of response could be the activity of multi-drug
resistance proteins (MDR) resulting in the efflux of calicheamicin following
internalization of the mAb conjugate and dissociation of calicheamicin from the CD33
mAb. Interestingly, the efflux of calicheamicin appears to be correlated with pump activity,
but not always with the expression of MDR proteins like MDR1/Pgp, MRP1 and LRP.102-104
Addition of inhibitors of the MDR pumps rarely resulted in full restoration of the
cytotoxicity of GO, suggesting that other mechanisms play a role in GO resistance.102-104
The long-term effects of GO are not yet known. In general, patients, who responded to
GO therapy had a longer median survival compared to patients that did not respond, but
relapse still appears a major problem.98,99
1.5 Telomerase
Normal human somatic cells have a limited life span and telomeres and telomerase play an
important role in the regulation of the lifespan and senescence of human cells.105 
Telomeres are DNA tandem repeats of (TTAGGG/CCCTAA)n that cap the ends of
eukaryotic linear chromosomes and prevent chromosome fusion and genetic
instability.106,107 Depending on the age of the donor, the cell type and the number of cell
divisions of the cell, the length of telomeres in humans varies between 2-15 kilobase
pairs.108 With every cell division telomeric DNA is lost, presumably because of the inability
of DNA polymerase to fully replicate the ends of a linear DNA template (end replication
problem) and because of the lack of telomerase activity.105,109-111 The average rate of
telomere shortening in a cell that lacks telomerase is 50-150 base pairs per population
doubling.105,109,111 When telomeres reach a critical length, the cell will undergo cell cycle
arrest and enter a non-dividing state known as replicative senescence. 112 Telomerase is a
DNA polymerase that serves to maintain the telomeric ends of chromosomes.113,114 It
contains an RNA template, the catalytic subunit human telomerase reverse transcriptase
(hTERT) and proteins involved in telomerase assembly, nuclear localization and
stability.107,115-117 Telomerase is capable to extend the 3’ ends of telomeres. Most adult
human cells, including fibroblasts, neurons, kidney cells, endothelial cells and mammary
epithelial cells, have undetectable telomerase activity and these cells will eventually
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senescence.111,118,119 Ectopic overexpression of the hTERT gene in human fibroblasts,
endothelial cells and retinal pigment epithelial cells resulted in telomere elongation and an
extended replicative life span, suggesting that the absence of telomerase plays an important
role in the senescence of these cells.120,121
In contrast to most cell types, low telomerase levels can be detected in various
hematopoietic cells. For example, T lymphocytes have low telomerase activity, which is
upregulated during T cell development and during T cell activation.122 Primitive
hematopoietic progenitors also exhibit low telomerase activity.123-126 Despite telomerase
activity in the hematopoietic progenitors, telomere shortening occurs with age.
Furthermore, although telomerase activity is up-regulated during in vitro expansion of
hematopoietic progenitors, telomere length decreases.127 This suggests that telomerase
activity alone is not sufficient to maintain telomere length in these cells. 
Malignant cells have developed mechanisms with which to avoid senescence and to gain
unlimited proliferative ability. One of these mechanisms is the ability to maintain telomere
length. Telomerase appears responsible for telomere length maintenance in about 90% of
human cancers.118 In the remainder, telomeres appear to be maintained via a
recombination-mediated process named ALT (alternative lengthening of telomeres).118 To
investigate whether inhibition of telomerase could inhibit cancer growth, Zhang et al.
introduced a dominant negative form of human telomerase into cancer cells.128 This
resulted in telomerase shortening followed by proliferation arrest and cell death,
suggesting that the inhibition of telomerase could play an important role in the treatment
of cancer. More recently, Damm et al demonstrated that potent and selective telomerase
inhibitors could arrest the growth of human cancer cell lines of breast, prostate, lung and
fibrosarcoma.129
Telomerase activity in AML cell lines and total and CD34+ hematopoietic cells of AML
samples was higher compared to total and CD34+ cells of normal individuals, suggesting
that telomerase might be a critical factor in the unlimited proliferation of AML
cells.124,125,130-132 The literature is not clear regarding whether CD34+ or CD34- AML cells
express higher levels of telomerase.130,132 Higher telomerase activity appeared to be
associated with and abnormal karyotype and FAB type in AML samples.132 Furthermore,
patients with high telomerase activity had a significantly poorer prognosis compared to
those with low telomerase activity, indicating that telomerase activity may be a prognostic
factor in AML.133,134 However, Seol et al. found that higher telomerase levels in AML
samples were correlated with an increase in CR.130 Overall, most studies thus far showed
that an increase in telomerase levels was correlated with disease progression with higher
levels of telomerase upon relapse and lower levels after chemotherapy-induced
remissions.128,131,132 Interestingly, while telomerase activity is higher in AML, telomere
length is on average 1.2 kb shorter in AML cells compared to their normal
counterparts.131,135,136 These shorter telomeres probably result from the increased turn-over
in AML cells and telomerase activity could be required to maintain critically short
telomeres in AML stem cells. Furthermore, short telomeres can contribute to genomic
instability and therefore to disease progression. Telomerase activity is upregulated upon in
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vitro culture of normal hematopoietic progenitors in contrast to AML cells that
downregulate telomerase activity upon culture.131 Down-regulation of telomerase could be
one of the reasons why it is difficult to expand AML progenitors over normal progenitors
in ex-vivo cultures. A highly significant correlation was observed between high telomerase
activity and the expression levels of hTERT, the catalytic subunit of telomerase in AML.
A slight increase in mRNA levels of the RNA template could also be detected in AML
samples but no increase in the telomere associated protein (TP1).132 This suggests that
hTERT may be a rate-limiting component in the regulation of telomerase activity.
Recently, Delhommeau et al. overexpressed a dominant-negative hTERT (DN-hTERT)
mutant in two different AML cell lines (UT-7 and U937).137 Clones expressing the
transgene showed a drastic shortening of telomere length, cytogenetic instability and an
inhibition of the proliferation after two weeks in culture.137 However, 45-55% of the DN-
hTERT clones showed a reactivation of telomerase activity after 5-8 weeks in culture,
resulting in a recovery of the proliferation similar to control clones. Of note is that some
translocations in acute leukemias contain interstitial telomere repeats emphasizing the
important role of telomeres in leukemias.138,139
1.6 Notch
The Notch superfamily comprises a group of highly conserved proteins, which has been
shown to influence the cell fate in progenitors of numerous cell types in a wide range of
organisms.140,141 In humans four Notch receptors have been identified, Notch1-4. They
consist of an extracellular domain, containing tandem EGF repeats and 3 Notch repeats, a
transmembrane domain and an intracellular domain (IC), containing 6 cdc10/ankyrin
repeats, putative nuclear localization signals and a C-terminal OPA/EST region.140 Notch
activation occurs through binding of the receptor to one of its ligands, Jagged1, 2 and
Delta1, 3 or 4.142,143 These ligands share a Delta:Serrate:Lag2 (DSL) domain required for
Notch binding and activation. In general, upon ligation of Notch to its receptor, a member
of the ADAM metalloproteases cleaves the Notch receptor extracellularly resulting in the
shedding of the ectodomain.144,145 This is followed by a presenilin-mediated proteolysis
within the transmembrane domain, releasing the Notch-IC (Figure 2).146,147 Notch-IC can
then either bind the Numb protein in the cytosol, which prevents Notch translocation or
it can bind to the Deltex protein which results in Notch translocation to the nucleus.148,149
In the nucleus, Notch-IC can bind to various nuclear proteins like NRARP and
Mastermind.150,151 The best characterized Notch signalling pathway is mediated by binding
to the C Binding Factor (CBF)-1 with subsequently transcription of Hairy Enhancer of
Split (HES) genes or HES-related Repressor Protein (HERP) genes.152 HES and HERP
are Basic Helix Loop Helix (bHLH) genes, which act as transcriptional repressors.152 A
Notch pathway independent of CBF1 has also been described.153,154 Notch activation is
modulated by a variety of other proteins (Figure 2). For example, the Fringe protein
family, Radical, Lunatic and Manic Fringe, are glycosyl-transferases which modify the
EGF repeats on the Notch receptor, thereby modifying the binding specificity of the Notch
receptor to its ligands.155 With the availability of four Notch receptors and five ligands in
humans it is difficult to sort out the extent of redundancy which might exist in Notch
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functions, particularly since Notch1-4 all activate HES genes. It is known that Notch1 null
and Jagged1 null mice are embryo lethal.156,157 Jagged1 and Delta1 null mice have a
phenotype which is not identical, suggesting non-overlapping functions for Notch genes
and ligands, at least during development.156,158
Figure 2: A simplified diagram of the Notch signalling pathway. Upon Notch binding to
the ligand, Presinilin will cleave the receptor and the IC is released in the cytoplasm. In the
cytoplasm Notch can bind to Numb which prevents nuclear localization or Deltex after
which Notch-IC is translocated to the nucleus. In the nucleus Deltex-Notch-IC will
displace the Smrt corepressor complex from CBF-1. SKIP is not displaced with the
complex and is thought to have a role in converting CBF-1 from a repressor to an activator.
Mastermind and NRARP are recruited  and transcription of the repressors HES and/or
HERP occurs. HES and HERP can each form homodimers or heterodimers with each
other. The corepressor TLE will bind to HES whereas HERP recruits the mSin3
corepressor complex. Not all proteins,which can interact with Notch are depicted here. 
NRARP Notch Regulated Ankyrin Repeat protein; SKIP Ski-Interacting Protein; HES
Hairy Enhancer of Split; TLE Transducin-like Enhancer of Split; HERP HES Related
Repressor Protein; HDAC Histone Deacetylase; Smrt Silencing Mediator of retinoic acid
and thyroid hormone receptors; CIR CBF-1 Interacting Corepressor.
Notch1 was first identified in humans as the (7;9)(q34;q34.3) translocation, observed in a
subset of T cell ALL. This translocation, which involved the Notch1 gene, causes
overexpression of a truncated form of the Notch1 protein.159 In the adult human
hematopoietic system Notch1 was shown to be expressed in high levels on CD34+Lin- and
CD34+Lin+ human marrow cells and in lower levels on CD34- marrow cells.160 A later
study using single cell RT-PCR on human hematopoietic cells revealed high Notch1
expression in macrophage and macrophage progenitors. Notch4 was expressed in
macrophages and Notch3, Delta1 and Jagged1 and the Fringe genes were expressed in
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multiple lineages. Further studies showed that primary human BM stromal cells, HUVEC
cells as well as FACS sorted CD34+CD38-Lin-, CD34+CD38+Lin-, myeloid, T and B cells
expressed Notch1 and 2 and also Jagged1 although all to somewhat variable degrees.161
In addition, RT-PCR on human FACS purified populations demonstrated Notch1,
Notch2, and Delta1 and the metalloproteinase Kuzbanian expression in both
CD34+CD38+ and CD34+CD38-Lin- progenitors, and in myeloid, T and B cells. Delta4
was expressed in CD34+CD38+Lin- but not CD34+CD38- progenitors and in myeloid
cells but not T or B cells and Delta3 was not expressed in any of the cell populations.162
Functional studies revealed that Notch1-Jagged1 ligation promoted the survival and
expansion of primitive progenitors in both human and murine hematopoiesis in vitro.161,163-167
Furthermore, CD34+CD38-Lin- human CB stem cells cultured for up to 15 days with or
without soluble hJagged1 and transplanted into NOD/SCID mice showed higher
engraftment frequency and level of engraftment in the hJagged1 treated cells.161 Soluble
hDelta1 and hDelta4 expanded CFU and CD34+38- cells in vitro while only hDelta1
seemed to increase repopulating stem cells detected in NOD/SCID mice in vivo.162,168
In the murine system, studies using the IC domain of Notch have been limited by the
development of T cell leukemias usually ~ 3 weeks following transplantation of transduced
marrow.169 Recently, a study using Notch1-IC transduced BM cells from RAG-1-deficient
mice demonstrated that Notch1-IC transduced BM cells had fewer CFU as compared to
controls but the colonies present were larger.170 Furthermore, LTC-IC quantified by
limiting dilution were more frequent in the Notch1-IC cells and generated larger colonies
after secondary replating.170 Notch1-IC and control transduced cells competitively
transplanted into mice revealed a reduction in differentiated myeloid and erythroid cells
and an increase in primitive progenitors upon FACS analysis of the BM of the mice. In
secondary transplantation experiments primitive cells further expanded in the Notch1-IC
mice while control mice had a marked decline in stem cell numbers.170
In myeloid cell line studies, initial reports showed that Notch1 and Notch2 can inhibit
myeloid differentiation in the murine myeloid progenitor cell line 32D in a cytokine-
specific manner: Notch1 inhibited G-CSF induced myeloid differentiation of 32D cells,
whereas Notch2 inhibited GM-CSF induced myeloid differentiation.171,172 However, a
more recent study demonstrated that Notch activation in the 32D cell line resulted in
induction of differentiation and reduction of proliferation.173 The reason for these
conflicting results is not yet clear, however a dose effect or co-regulating molecules can
alter the response to Notch stimulation. Overexpression of Notch1 in the K562 cell line
resulted in suppression of erythroid and an increased megakaryocytic differentiation.174
The role of Notch and its ligands in myeloid leukemias has not been well studied thus far.
One study reported a new human leukemia cell line derived from blast cells of a patient
with de novo acute myeloblastic leukemia with tri-lineage myeloplasia.175 This cell line
expressed Notch1 and 2 and Jagged1 but lacked the expression of Delta1 (other Notch
receptors and ligands were not investigated). The proliferation of the AML cell line
increased significantly upon stimulation with Delta1 whereas a slight increase was
observed upon stimulation with Jagged1.175
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As mentioned above expression of constitutively active Notch1 in human and murine
hematopoietic cells leads to the development of a leukemic proliferation of CD4+CD8+ T
cells in the BM.139,159,176 169 Similarly, Delta4 transduced Lin- murine BM produced a
marked but non-transplantable proliferation of circulating CD4+CD8+ cells, which are
normally found only in the thymus, while the number of total and mature B cells was
markedly reduced.177,178 When mice were transplanted with BM of the Rag-2-/- mice (no
VDJ recombination and a lack in pre-TCR signalling) transduced with constitutive active
Notch1 the CD4+CD8+ population failed to develop but precursor T cells were seen.
When the lack of pre-TCR signalling was restored, the cells went on to proliferate and
underwent leukemic transformation.179 This suggests that Notch controls the initial T/B
decision but that subsequent proliferation depends on T cell specific signals.179 Activating
Notch signalling by co-culture with the stromal cell line S17 expressing Delta1 similarly
inhibited B cell differentiation, while promoting cells with a T cell/NK cell precursor
phenotype. Jagged1 expressing S17 cells did not alter B, T or NK cell development,
suggesting alternative signalling pathways for different Notch ligands.180 Further evidence
that Notch1 is important to control the T versus B cell developmental decision was derived
from Cre-LoxP conditional Notch1 knockout experiments. These mice had a block in early
T cell development in the thymus at the CD4-CD8-TCR- precursor stage while B cells
(B220+) accumulated in the thymus.181 Further studies demonstrated that the block in T
cell differentiation is not due to a failure of Notch1-/- precursors to home to the thymus, but
rather to the adoption of a B cell fate by the common lymphoid precursor in the absence
of Notch1.182 Moreover, ectopically expressed Lunatic Fringe also induced the lymphoid
progenitor to develop into B cells in the thymus.183 Early reports suggested Notch directed
the decision between αβ versus γδ T lineage with reduced Notch activity favoring the gd
T cell fate.184 It was also suggested that activated Notch1 favors an increase in CD8 with
a decrease in CD4 cells,185 however subsequent reports could not confirm this.186
Notch2 and Notch3 have also been shown to cause T cell tumors in humans and/or animal
models.159 Feline Leukemia Virus induced thymic lymphomas in cats resulted in
overexpression of a truncated Notch2 protein.187 Mice transgenic for Notch3-IC developed
aggressive multicentric T cell lymphomas and these lymphoma cells expressed high levels
of NF-κB.188
The transforming ability of Notch genes is not restricted to T cells. Notch1 expression in
Hodgkin’s Reed Sternberg cells and in tumor cells from T cell derived anaplastic large cell
lymphoma was elevated and stimulation by Jagged1 increased the growth and inhibited
apoptosis of these cells. Notch2 was overexpressed in B-CLL and contributed to the
overexpression of one of its target genes CD23.189 Notch4 was first identified as the int-3
oncogene associated with primary mouse mammary tumors.190 Deregulation of the
Notch/CBF1 signalling pathway has been associated with Epstein-Barr Virus induced B
cell malignancies.191,192 In addition, the Notch pathway has been shown to interact with
various signalling pathways involved in oncogenesis. The tumorigenic activity of Notch4-
IC in murine mammary tumor cell lines required active signals from the Erk/MAP kinase
and PI-3 kinase pathways downstream of Ras.193 Notch1 was essential to maintain the
neoplastic phenotype in Ras-transformed human cells in vitro and in vivo.194 Provirus
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insertion of the oncogene c-Myc occurs in close proximity to the Notch1 gene resulted in
high expression of the Notch1-IC in CD4+CD8+ T cell tumors in MMTVD/myc
transgenic mice .195 Notch can function as a negative regulator of NF-κB, by preventing
binding to its DNA binding sites.196 In contrast, NF-κB2 is a putative target gene of
activated Notch1 via the CBF1/RBP-Jκ pathway.197 One report showed that the Rel/NF-
κB pathway upregulated the expression of the Notch ligand, Jagged1, thereby triggering
the Notch signalling pathway.198 Members of the p53 tumor supressor gene family, p63 and
p73, have also been shown to upregulate Jagged1 and 2.199 Notch1 accelerated lymphoid
oncogenesis in E2A-PBX1 transgenic mice, suggesting a synergistic interaction between
the Notch and E2A-PBX1 pathways.200 201 Interestingly, a recent report suggested a tumor
suppressor role for Notch1 in mouse skin tumours.202 These studies suggest a complex but
interesting connection between Notch pathways and pathways implicated in oncogenesis. 203-205 
Project Overview
The work presented in this thesis can be divided in two sections:
1. Characterization and purification of AML stem cells based on the phenotype of
AML stem cells (CD133 and CD33).
2. Studies on genetic pathways and enzymes capable of modulating AML growth
(telomerase and Notch).
Work in both areas is complementary and typical of modern leukemia research combining
modern tools of cell biology, cell culture, xenotransplantation, flow cytometry and cell
sorting with increased knowledge of genetic pathways and information about the
molecular abnormalities that characterize the leukemic stem cell genome. Undoubtably,
these approaches will result in a beter understanding of the disease and hopefully resulting
in cures. 
Hypothesis
I. Within the AML blasts, a rare population of leukemic progenitors exists, responsible
for maintaining the disease.
II. The hematopoietic developmental program, controlled by sequential changes in gene
expression, is dysregulated in AML.
III. Overexpression of telomerase in AML stem cells contributes to the longeveity of
AML stem cells and targeting telomerase expression could result in senescence of
these cells. 
IV. The Notch gene family is involved in the maintenance and differentiation of
hematopoietic progenitors and therefore might play a role in the pathogenesis of AML. 
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Objectives
1. Phenotypically and biologically characterize primitive AML progenitors
a) Determine whether CD133, a novel stem cell marker, is differentially expressed on
primitive AML versus normal hematopoietic progenitors.
b) Study whether CD33, a cell surface antigen used for specific delivery of toxic
agents to AML cells, is expressed on primitive AML progenitors.
2. Investigate genetic pathways involved in the maintenance of AML stem cells.
a) Determine whether inhibition of telomerase can affect the growth of AML cells.
b) Study the expression of the four Notch genes in the hematopoietic system and in
AML cells.
c) Compare the function of Notch1 and 4 in normal human hematopoiesis.
d) Compare the effects of Notch signalling on normal and leukemic hematopoietic
progenitors. 
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Abstract
Background. Acute myeloid leukemia (AML) blasts differ in their functional capability,
creating a hierarchy of progenitors. CD133 (AC133) is a newly described transmembrane
protein expressed on CD34+ and CD34- normal progenitors. We characterised the
prognostic significance of CD133 expression in AML and expression of CD133 on AML
progenitors thought to be responsible for maintaining this disease.
Methods. AML cells of 102 patients were analyzed for CD133 and CD34 expression and
correlated with outcome in 92 treated patients. AML cells were also FACS sorted into
CD34+CD133+, CD34+CD133-, CD34-CD133+ and CD34-CD133- subfractions, and
assayed in vitro in colony forming assay (CFU) and in suspension culture (SC) assay for
up to 8 weeks, and in vivo in NOD/SCID mice to determine the phenotype of progenitors
detected in these assays. 
Results. CD133 expression was not correlated with event-free or overall survival, FAB
subtype, cytogenetic abnormality or white blood count but was correlated with CD34
expression. Primary AML CFU were present in all four sorted fractions. After an
increasing period of time in SC a higher proportion of cells capable of forming leukemic
CFU were found in the CD34+CD133+ subfraction. Cells capable of producing leukemic
engraftment in NOD/SCID mice were found in all subfractions including the CD34-
CD133- subfraction in many patients. 
Discussion. CD133 is not useful as a prognostic marker in AML. CD133 is expressed with
CD34 on most primitive leukemic progenitors detected in vitro, however, in vivo progenitors
could not be purified using CD133 in these patients.
Keywords: Acute myeloid leukemia-CD133-CD34-NOD/SCID mice- prognosis
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Introduction
The use of monoclonal antibodies to target malignant cells in a background of normal cells
has been useful for the diagnosis of minimal disease, for the specific delivery of
radioisotopes or toxins, and for purging prior to autologous transplantation. The
application of these approaches in AML has been complicated both by the similarity of
antigen expression between normal stem cells and AML cells, and by the recent
observation that the heterogeneity of antigen expression between AML blasts from the
same patient reflects also a heterogeneity in the function of these cells. Only a small
minority of AML blasts are capable of extensive long-term proliferation in vitro and
engraftment into NOD/SCID mice.1-4 These cells have a phenotype unlike bulk blasts but
similar in some respects to normal primitive progenitors in that most are CD34+, lack
expression of CD71, HLA-DR and CD38,2-4 however, they differ from normal progenitors
in their lack of expression of Thy.1 (CD90)5 and their lower c-kit (CD117) expression.6
These AML in vitro and in vivo proliferating populations share the same phenotype and are
likely also related to the cells capable of sustaining AML in the patient. It thus seems likely
that only the most primitive AML cells are responsible for maintaining the disease and
consequently are the most relevant cells to target for disease therapy. Human CD133 is a
novel 5-transmembrane molecule, which is expressed on primitive normal hematopoietic
progenitors.7,8 CD133 is of unknown function but is felt to be the human homologue of
mouse prominin.9 In the hematopoietic system, CD133 is expressed on a subset (30-70%)
of the CD34+ cells in the human bone marrow (BM), fetal liver, umbilical cord blood and
growth-factor primed peripheral blood (PB).8,10 In vitro colony assays using normal adult
BM, have shown that the majority of CFU-GM are contained in the
CD34+CD133+fraction, while the majority of BFU-E and CFU-Mix are in the
CD34+CD133- fraction.10 However, when clonogenic assays were performed using cord
blood, the majority of CFU-GM as well as the majority of BFU-E and CFU-Mix were
detected in the CD34+CD133+ subset.8 CD34+CD133+ cells successfully engraft primary
and secondary recipients using the fetal sheep model10 and only CD34+CD133+, but not
CD34+CD133- cord blood cells are capable of sustaining hematopoiesis long-term in the
presence of stroma (LTC-IC) and of repopulating NOD/SCID mice.8 These studies
suggest that CD133 can be useful as an additional marker to CD34 for the purification of
primitive hematopoietic progenitors. Furthermore, recent evidence suggests that cells with
stem cell properties are a rare subpopulation of CD34-lineage- cells,11,12 and these CD34-
cells also express CD133, allowing their purification.13
While the expression of CD133 on primitive AML cells is unknown, it has been reported
that CD133 is expressed on the majority of bulk CD34+ AML cells, whereas CD133
expression on CD34- AML cells is low to absent in most,7,14-16 but not all,14 cases. There
have been conflicting results regarding a correlation between CD133 expression and FAB
type, with increased CD133bright cells in the M4 and M5 FAB subtypes7 and in FAB M017
reported. CD133 expression on FAB M3 cases has been low to absent in all reports and
this is consistent with an absence of CD34 expression on those samples. No correlation
between CD133 expression and cytogenetics or prognosis has been reported. 
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To investigate whether CD133 selection is useful as a purging strategy in AML, CD133
expression on primitive AML cells capable of long-term in vitro and in vivo proliferation was
determined. Furthermore, a possible correlation between CD133 expression and CD34
expression and clinical parameters was studied. 
Materials and Methods
Patient Cells
Bone marrow (BM) cells from normal healthy donors and peripheral blood (PB) cells
from 102 patients at diagnosis of AML were obtained after informed consent and with
approval of the Clinical Research Ethics Board of the University of British Columbia. The
mean number of blasts in the samples was 63 ± 26%. Patients with FAB M3 type were
excluded because of a different treatment strategy given to M3 patients. Blood cells were
Ficoll separated to obtain a mononuclear cell population then frozen in Dulbecco’s
modified Eagle’s medium (DMEM) (StemCell Technologies Inc., Vancouver, B.C.) with
50% fetal calf serum (FCS) (StemCell Technologies Inc.) and 10% dimethylsulphoxide
(DMSO) and stored at -135oC. 
Patient Therapy
Of the 102 patients (pts) assessed, 92 patients received treatment with induction
chemotherapy and were analyzed for event-free and overall survival. Ten patients were not
treated as they were too ill and died prior to treatment initiation (2 pts) or treatment was
precluded due to age or medical problems (8 pts). The median age of the 92 patients was
51 (range 18-78) and there were 47 men and 45 women. Sixty-six patients received high-
dose cytarabine plus daunorubicin (29 pts) or mitoxantrone and etoposide (37 pts).
Twenty-four patients received low-dose cytarabine plus daunorubicin (7+3) and 2 patients
received other. Sixty-eight patients (74%) achieved a complete remission. Forty-five
patients went on to consolidation chemotherapy with high-dose (32 pts) or low-dose (13
pts) cytarabine plus daunorubicin (30 pts), mitoxantrone and etoposide (12 pts) or
carboplatin (3 pts). Twenty-four patients had a second cycle of consolidation
chemotherapy. Thirty-two patients underwent an allogeneic (25 pts) or autologous (7 pts)
transplantation after receiving high dose therapy.
AML Cell Phenotyping and Sorting
Prior to sorting, thawed AML cells were suspended in HFN (Hanks medium with 2%
FCS and 0.1% sodium azide) at 107 cells/ml. Cells were stained for 30 minutes on ice with
monoclonal antibodies CD34-FITC (Dr. Peter Lansdorp, Terry Fox Laboratory) used at
4 µg/ml and CD133-PE (Miltenyi Biotec Inc., Auburn, California) used according to
manufacturer’s instruction. Separate aliquots were stained with an irrelevant mouse IgG1-
FITC antibody (Becton Dickinson, San Jose, California) and mouse IgG1-PE antibody
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(Becton Dickinson) as an isotype control. Cells were then washed twice in HFN at 4oC,
propridium iodide (PI) at 2 µg/ml was added to the cells prior to the second wash, and the
cells were maintained on ice prior to sorting. Cells were analyzed and sorted on a dual laser
FACStarplus (Becton Dickinson) on the basis of fluorescence intensity after gating out
non-viable (PI+) cells. Gates were set to exclude 99.5% of isotype control stained cells
(Figure 1). Fractions were sorted into DMEM with 50% FCS in microcentrifuge tubes at
4oC. Sorted fractions were washed, resuspended at known cell concentrations and used to
initiate colony forming assays (CFU) and suspension culture (SC) assays or for injection
into NOD/SCID mice.
Primary CFU Assays
Immediately after FACS sorting, a known number of sorted and control unsorted PB cells
were plated in methylcellulose culture medium, (Methocult H4330, StemCell Technologies
Inc.), containing 20 ng/ml rhIL-3 (Sandoz, Basel, Switzerland), 20 ng/ml rhIL-6 (Terry
Fox Laboratory), 20 ng/ml rhG-CSF (Amgen Canada Inc., Mississauga, Ontario), 20
ng/ml rhGM-CSF (Sandoz) and 50 ng/ml rhSteel Factor (SF) (Terry Fox Laboratory).
After 10 days of incubation at 37oC in a 5% CO2 humidified incubator, AML blast clusters
(10-20 cells) or colonies (> 20 cells) were counted and the numbers were pooled to obtain
CFU counts. 
Figure 1: FACS profiles demonstrating gates for sorting of CD34-FITC and CD133-
PE subpopulations. A) PB of AML patient 319 was stained with IgG1-FITC and IgG1-
PE as isotype controls and analyzed by FACS. Sorting gates were set to exclude ≥ 99.5%
of isotype stained control cells. B) PB cells from the same patient were also stained with
CD34-FITC and CD133-PE and sorted according to the gates set using the isotype
controls. Gates were set for each patient using the patient specific isotype control.
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Suspension Culture Assays (SC)
Suspension cultures were initiated with a known number of sorted and unsorted cells and
maintained generally, as previously described,4,5 in 1.0 ml of serum free medium containing
the growth factor cocktail described above and 41.5 µg/ml low density lipoprotein (Sigma-
Alderich, Oakville, Ontario). Cultures were maintained at 37oC in a 5% CO2 humidified
incubator and 0.5 ml of fresh medium with growth factors was added weekly. Every
second week half the cells and volume of the SC were removed, the cells were washed in
DMEM with 10% FCS and cultured in methylcellulose to determine the CFU content of
the SC. SC were maintained for 8 weeks then the entire contents of the wells were
harvested and assessed for CFU content. To allow comparisons between experiments the
proportion of progenitors derived from each sorted fraction at each time point was
determined by comparison to a progenitor recovery of 100% from all fractions at that time
point. Using PB cells of the AML patients no formation of feeder layers in the SC was
observed.
Transplantation of Leukemic Cells into NOD/SCID Mice
Nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice (Jackson
Laboratory, Bar Harbour, ME) were bred and maintained in the animal facility of the
British Columbia Cancer Research Centre (Vancouver, B.C., Canada) under sterile
conditions in sterile micro-isolator cages and were provided exclusively with autoclaved
food and water containing 100 mg/l ciprofloxacin and HCl. Twenty-four hours prior to
transplantation, mice were irradiated with 3.5 Gy γ-irradiation from a 137Cs source at a
dose rate of 1.22 cGy/min. Unsorted AML PB cells and sorted subfractions were
suspended in 0.3 ml Alpha minimal essential medium (Alpha MEM)(StemCell
Technologies Inc.) with 5% FCS and injected intravenously into the lateral tail vein of 6-
8 week old NOD/SCID mice. Whenever possible, various cell concentrations were
injected as a semi-quantitative assessment of the number of cells required for
engraftment. Normal BM cells were given 15 Gy irradiation using 250kVp X-rays
(Philips RT-250, HVL 1.5 mm Cu) at a dose rate of 5.1 Gy/min. In each case, 2 x 106
irradiated BM cells were co-injected with the unsorted cells and sorted subfractions to
enhance engraftment potential. Eight weeks post-injection the mice were sacrificed by
CO2 inhalation. BM was removed from the femurs by flushing with Alpha MEM with 5% FCS.
Flow Cytometry Analysis of Murine Tissues
Cell suspensions from femoral BM were lysed in ammonium chloride (StemCell
Technologies Inc.) for 20 minutes and then washed in HFN with 5% human serum for
blocking of human Fc receptors and prepared for flow cytometric analysis as described.4,5
Briefly, cells were incubated on ice with an anti-mouse IgG Fc receptor monoclonal
antibody (2.4G2) (Dr. P. Lansdorp, Terry Fox Laboratory, Vancouver). Cells were then
stained with a human pan leukocyte antibody, 9.4 (anti CD45)-FITC (Dr. P. Lansdorp)
for 30 minutes on ice. Separate aliquots were stained with an irrelevant IgG1-FITC
antibody (Becton Dickinson) as an isotype control. Aliquots of normal human PB cells
and BM cells from a non-injected NOD/SCID mouse were also stained with CD45-FITC
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and the isotype control to serve as positive and negative controls for antibody specificity.
Samples were analyzed using a FACScan (Becton Dickinson), gate settings which
excluded ≥ 99.9% of the cells in the matched isotype control were used to determine the
CD45 expression of each sample. Any positive value (i.e. ≤ 0.1%) for the isotype control
was then subtracted from the percentage positive in the CD45 stained samples. We
defined human engraftment as expression of ≥ 0.1% CD45+ cells in a sample. Whenever
possible, the CD45+ cells derived from murine BM were sorted and plated in
methylcellulose with recombinant growth factors. The derived colonies were plucked
onto slides for subsequent cytogenetic analysis. Alternatively, cytospin preparations were
made from flow-sorted CD45+ cells and the slides were stained for morphological
analysis with May-Grünwald-Giemsa.
Cytogenetic Analysis
Colonies from primary CFU or from CFU which were derived from SC were evaluated
for the leukemia specific cytogenetic change by either standard cytogenetics or by
fluorescence in situ hybridisation (FISH) whenever possible. Likewise, sorted CD45+
cells from BM removed from NOD/SCID mice and CFU derived from these cells were
evaluated for the leukemic transformation. For analysis, single colonies were plucked and
plated onto slides after colony synchronisation with colcemid.18 Probes specific for
centromeric repeat sequences were used to detect cytogenetic abnormalities in 5 patients.
These included D8Z2 (ATCC, Rockville, MD) to detect the +8 abnormality, the Y probe19
pRY3.4, and a yeast artificial chromosome (YAC) clone 909g3 (Research Genetics) to
detect the +13 abnormality. Total plasmid DNAs containing the centromeric specific DNA
were labelled with digoxigenin (Boehringer-Mannheim, Mannheim, Germany) by nick
translation. The +8 probe was hybridised in Hybrisol VI (Oncor). The signal was
amplified by rabbit anti-sheep FITC (Jackson Immuno Research Laboratories, West
Grove PA) and detection by sheep anti-digoxigenin-FITC (Boehringer Mannheim,
Quebec, Canada). Counterstaining was in PI at 200 ng/ml in Vectashield (Vector
Laboratories, Inc. Burlingome, CA). Colonies were defined as positive whenever ≥ 60% of
cells contained the respective leukemic karyotype of that patient. Colonies containing only
40-60% of cells with the leukemic change were classed as undetermined and those with <
40% leukemic cells were defined as negative. Whenever both metaphase and interphase cells
could be scored approximately 200 cells (mean ± SE, 226 ± 11 cells) were counted per colony.
Calculations and statistical analysis
The Cox regression model was used to study the correlation of event-free and overall
survival with CD133 or CD34 expression, FAB subtypes, cytogenetic abnormality or
white blood cell count (WBC) in 92 pts. For the correlation between CD133 expression
and CD34 expression, FAB type, cytogenetic abnormality or WBC a Wilcoxon Rank Sum
Test was performed. To study the correlation between CD133 or CD34 expression and
NOD/SCID engrafting ability a Chi square test was performed. For statistical analysis
CD133 and CD34 were considered positive when more than 10% of the blasts expressed
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the surface marker and high when more than 40% of blasts expressed the marker. FAB
types were divided in a favourable group (FAB M1, M2 and M4) or unfavourable (FAB
M0, M5, M6 or AML with prior MDS). Cytogenetic abnormalities were divided into a
favourable, intermediate or poor groups according to the guidelines set by Grimwade et
al.20 The white blood cell count (WBC) was grouped into WBC under or over 50 x 109
cells/L. For all the tests a significant level of 0.05 was chosen.
RESULTS
Expression of CD34 and CD133 on AML blasts
Peripheral blood mononuclear cells from 102 AML patients were evaluated for co-
expression of CD34 and CD133 (Figure 2). These patients were FAB M0 (n=8), M1
(n=18), M2 (n=16), M4 (n=23), M4e (n=7), M5 (n=13), M5a (n=7), M5b (n=2). Four
patients had myelodysplastic syndrome (MDS) before developing AML and 4 patients
had an undetermined (UD) subtype. Expression of CD133 was heterogeneous in this
group of patients (range 0-92% CD133+). Of the 102 samples, 64 patients had a CD34+
expressing AML (CD34+ AML defined as CD34 expression in ≥ 10% of blood
mononuclear cells), whereas 38 patients had a CD34- AML (CD34- AML defined as
CD34 expression in ≤ 10% of blood mononuclear cells). In the 64 CD34+ expressing
samples, the mean proportion of CD34+CD133+ nucleated cells was 27 ± 25%, while 32 ±
24% were CD34+CD133-, 2.5 ± 6% were CD34-CD133+ and 39 ± 25% were CD34-
CD133-. In the 38 CD34- samples the mean proportion of CD34+CD133+ nucleated cells
was 0.7 ± 1.3%, while 1.4 ± 1.7% were CD34+CD133-, 8 ± 20% were CD34-CD133+ and
the majority, 90 ± 20% were CD34-CD133-. Interestingly, in 5 of the 38 CD34- samples a
significant CD133 expression (range 13-75% CD133+) was observed, while the other
CD34- samples were CD133- (0.05%-6.7% CD133+). 
Correlation of CD133 on AML blasts with CD34, WBC, FAB type, cytogenetic abnormality, overall
survival and NOD/SCID engrafting capacity
A subset of 92 patients was analyzed for the correlation between CD133 expression and
other prognostic factors and patient outcome. All patients received induction
chemotherapy. In this study no correlation between event-free or overall survival and
CD133 expression could be observed with analysis of CD133+ set at ≥ vs < 10%, and ≥
vs < 40% and used as a continuous variable (p > 0.05). Event-free and overall survival
were significantly associated with WBC < 50 x 109 cells/L (p=0.009, p=0.005 respectively)
and favorable cytogenetics (p=0.014, p=0.010) but not with CD34 expression or FAB
subtype in univariate analysis. The data obtained revealed a highly significant positive
correlation between the level of CD133 and CD34 expression (p<0.001 with CD133+ and
CD34+ ≥ 10%; p=0.003 with CD133+ and CD34+ ≥ 40%). No correlation could be
observed between CD133 expression and FAB type, cytogenetic abnormality or WBC.
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Figure 2: Expression of CD34 and CD133 on AML cells from 102 patients at
diagnosis. PB cells from 102 AML patients at diagnosis were stained with CD34-FITC
and CD133-PE and analyzed by FACS. The mean % of cells in the CD34+CD133+
subfraction (open bars), CD34+CD133- subfraction (filled bars), CD34-CD133+
subfraction (dotted bars) and the CD34-CD133- subfraction (hatched bars) of 64
CD34+ (CD34 expression ≥ 10%) and 38 CD34- (CD34 expression ≤ 10%) samples
was calculated.
PB = peripheral blood, NC= nucleated cells
In order to determine whether CD34 or CD133 expression was related to NOD/SCID
engrafting ability, unsorted PB mononuclear cells (0.5-1 x 107 cells) of 72 AML patients
were injected into NOD/SCID mice in duplicate. Cells of 36 patients engrafted in these
animals. Of the 36 samples capable of engrafting NOD/SCID mice 19 were CD133+
(CD133+ ≥ 10%) and 17 were CD133- (CD133+ ≤ 10%), while the 36 samples that failed
to engraft were CD133+ in 16 cases and CD133- in 20 cases. No statistical difference
(p=0.62 for CD133+ ≥ 10% and p=0.78 for CD133+ ≥ 40%) could be found between
CD133+ and CD133- AML regarding their NOD/SCID engrafting ability. Of the 36
engrafting samples, 26 were CD34+ AML (CD34+ ≥ 10%) whereas 10 were CD34- AML
(CD34+ ≤ 10%). Of the 36 samples that failed to engraft 19 were CD34+ and 17 were
CD34-. Again, there was no statistical difference (p=0.23) between CD34+ and CD34-
AML samples regarding their ability to engraft NOD/SCID mice (p=0.23 for CD34+ ≥
10% and p=0.34 for CD34+ ≥ 40%).
Expression of CD34 and CD133 on AML cells with long term proliferative ability in vitro
In order to determine the phenotype of AML cells capable of producing CFU after long-
term culture, PB cells from 12 patients were sorted in four fractions according to their
0
20
40
60
80
100
CD34+ CD34-
%
 o
f 
N
C
51C D 1 3 3  E X P R E S S I O N O N A M L  C E L L S A N D P R O G E N I T O R S
Chapter 2
52
expression of CD34 and CD133 and subsequently used to establish suspension cultures
(SC). Eight patients had high expression of CD34 (40 ± 27% CD34+), while the majority
of AML blasts in the other 4 patients were CD34- (99.6 ± 0.2% CD34-). The
CD34+CD133+ subfraction represented 9 ± 14% of nucleated cells in the 12 patients at
sorting, 18 ± 28% were CD34+CD133-, 3 ± 7% were CD34-CD133+ and the majority
were CD34-CD133- (70 ± 35%) (Figure 3). Cells capable of forming primary CFU were
present in all four subfractions. Similarly, CFU after 2 weeks in suspension culture (SC)
were also present in all four subfractions. However, with increasing culture time, the
proportion of total CFU at each timepoint that were from the CD34+CD133+ subfraction
increased, while the proportion of CFU from the other three subfractions decreased. After
8 weeks in SC, 83 ± 28% of CFU were from the CD34+CD133+ subfraction and 16 ± 28%
were from the CD34+CD133- subfraction with only 1 ± 4% from the CD34-CD133+ and
0.2 ± 0.7% from the CD34-CD133-subfractions (Figure 3).
Cytogenetic analysis of in vitro studies
Primary colonies as well as colonies after SC obtained from all 12 patients appeared
morphologically abnormal with often only small cluster-like colonies observed. It was
possible to analyse CFU and CFU derived from SC by FISH or standard cytogenetic
analysis in some fractions of 6 patients (Table 1). The majority CFU derived from unsorted
cells were found to have the respective leukemic change (22/28). CFU derived from SC of
unsorted cells at weeks 2-8 were also mainly leukemic (25/41). In 27/72 colonies derived
from primary CFU or SC from the CD34+CD133+ subfraction the leukemic change was
observed, 36/69 colonies from CD34+CD133- subfractions, 15/28 colonies from the CD34-
CD133+ subfraction and 12/25 of the CD34-CD133- subfraction were also leukemic.
Overall no selection of leukemic versus normal colonies was seen with CD133 sorting.
In vivo NOD/SCID assay
AML cells from 20 patients were sorted for co-expression of CD34 and CD133 and
evaluated for their ability to repopulate sublethally irradiated NOD/SCID mice (Table
2A). Human cells were detected in the BM of mice using unsorted cells from these
patients, although the number of human cells in the BM varied considerably (range 0.13-
89% CD45+ using 5 x 106 cells). With AML cells of 11 patients engraftment was also
achieved using cells sorted for CD34 and CD133, however the levels of engraftment were
very low in the majority of patients. With 2/11 patient samples, engraftment (0.15% and
1.53%) could only be obtained using cells from the CD34+CD133- subfraction, while no
engraftment was seen using an equal or higher number of CD34+CD133+ cells or CD34-
cells. With the other 9 AML samples engraftment was achieved with at least two
subfractions and 8 of those samples engrafted using CD34-CD133- cells (Table 2A). In
summary, from these 11 patient samples, 18 of the 20 mice injected with unsorted cells
engrafted, 8/21 mice injected with CD34+CD133+ cells, 19/34 mice injected with the
CD34+CD133- cells, 3/8 mice injected with CD34-CD133+ cells and 10/19 mice injected
with CD34-CD133- cells also engrafted.
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Figure 3: Proportion of AML PB cells and progenitors from 12 AML patients in
subfractions sorted for the expression of CD34 and CD133. Percentage of blood cells,
primary CFU and CFU after 2-8 weeks in SC in the CD34+CD133+ subfraction (open
bars), CD34+CD133- subfraction (filled bars), CD34-CD133+ subfraction (dotted bars)
and the CD34-CD133- subfraction (hatched bars). To allow comparison of the proportion
of progenitors in each subfraction, CFU frequencies were determined by comparison to a
progenitor recovery of 100% (UF) of all four subfractions at each time point. 
The mean CFU frequencies of UF of the 12 patient samples at the different time points
were 547 ± 965 CFU / 105 cells at week 0, 1224 ±1420 CFU / 105 cells at week 2, 2146±2168
CFU / 105 cells at week4 and 2059 ±3769 CFU / 105 cells at week 6-8.
PB = peripheral blood, SC = suspension culture, NC= nucleated cells, UF=unsorted
Histologic and cytogenetic analysis of transplanted cells
In 4 patients, CD45+ cells from all positive NOD/SCID mice injected with unsorted or
CD34 and CD133 sorted AML cells were sorted for analysis (Table 2B). Histologic
analysis of the CD45+ sorted cells showed > 80% blast cells in every case regardless the
subfraction injected. FISH could be performed on CD45+ cells from NOD/SCID mice
injected with cells of 2 patients (+13 and inv16). In both cases, cells derived from recipients
of unsorted cells had the leukemic karyotype. Furthermore, abnormal cells (+13) could be
detected in CD45+ cells from the recipient of the CD34+CD133- subfraction of 
one patient, while in the other patient CD45+ cells showed the abnormal karyotype
(inv16) in all mice regardless the subfraction of cells injected.
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Table 1: No. of Colonies detected with the leukemic change by FISH or 
Cytogenetics following in vitro Assays
Patient No. Karyotype Positive Colonies Positive Colonies Positive Colonies 
from CFU blast after 2-4 weeks after 6-8 weeks 
of SC of SC
Unsorted
069 +13 4/10 ND 5/8
201 +8 10/10 3/8 ND
230 -4q ND 7/11 ND
319 -Y 8/8 3/4 3/4
353 -Y ND 4/6 ND
CD34+CD133+
069 +13 2/8 ND 3/8
201 +8 0/8 0/8 ND
230 -4q ND 14/14 ND
319 -Y 8/8 ND ND
353 -Y ND 0/7 0/7
364 -Y 0/4 ND ND
CD34+CD133-
069 +13 2/7 ND 3/8
201 +8 ND 2/8 ND
230 -4q ND 9/12 ND
319 -Y 8/8 1/4 3/4
353 -Y ND 2/7 2/7
364 -Y 4/4 ND ND
CD34-CD133+
069 +13 3/7 2/7 4/8
319 -Y 6/6 ND ND
CD34-CD133-
069 +13 2/8 3/7 5/8
230 -4q ND 2/2 ND
Abbreviations: SC, suspension culture.
Positive colonies were defined as ≥ 60% cells with the leukemic karyotype in one colony.
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Table 2A: AML cells sorted for co-expression of CD34 and CD133 with multiple subfractions
capable of engrafting NOD/SCID mice
Patient Unsorted CD34+ CD34+CD133- CD34- CD34-
CD133+ CD133+ CD133-
069 2.4 0 0.15 0 0
284 38; 16; 45 0; 0.34; 0 1.5; 0; 0; 0 0; 0 0; 1.6; 0.14
212 89 16 24 30 16
319 0.83; 0.54 0; 0 1.53 0 0; 0
351 0.12; 0 0.20; 0.25 0; 0.2; 0; 0.13;0.21 ND 0.12
353 1.3; 0 0; 0 0; 0; 0; 0 ND 0.14; 0
267 0.14; 0.45 0; 0.22 0; 0; 0.15; 0 ND 0
142 0.24; 0.15 0.16 0.13; 0.13 ND 0; 0.16
373 0.19 0; 0; 0 0; 0.15; 0.14; 0.19 0.30
0.20; 0, 0.21; 0.26
272 0.16; 0.18 0; 0.28 0.12; 0.36; 0.18 0 0; 0.30; 0.30
379 1.85; 0.16 0; 0.10 0.18; 0 0.14 0.12; 0
Median 0.45 0.00 0.13 0.00 0.06
ND= not done
Table 2B: Cytogenetical or morphological analysis of CD45+ cells obtained from bone marrow of
NOD/SCID mice
Patient Subfraction Mean % Mean % Positive by FISH
engraftment blasts
069 Unsorted 2.4 91 Yes
CD34+CD133- 0.15 82 Yes
284 Unsorted 33 83 N/A
CD34+CD133+ 0.3 82 N/A
CD34+CD133- 1.5 85 N/A
CD34-CD133- 0.6 83 N/A
212 Unsorted 89 81 Yes
CD34+CD133+ 16 86 Yes
CD34+CD133- 24 85 Yes
CD34-CD133+ 30 86 Yes
CD34-CD133- 16 83 Yes
319 Unsorted 0.6 91 ND
CD34+CD133- 1.5 90 ND
N/A= not applicable, ND= not done
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Discussion
It now seems clear that primitive AML progenitors exist within the AML blast population
which are uniquely capable of extensive proliferation.1-4 It is likely that these cells are
responsible for maintaining the disease. CD133 is a newly identified cell surface protein
that is expressed both on normal CD34+ stem cells7,8 and on CD34- cells with in vivo
repopulating ability.13 The aim of this study was to investigate whether CD133 is expressed
on primitive AML cells with long term proliferation in vitro and NOD/SCID repopulating
capacity. Furthermore, we investigated the correlation between CD133 expression on
AML blasts and FAB subtype, cytogenetic abnormalities, WBC and event-free and overall
patient survival. 
The expression of CD133 on blood blast cells of 102 AML patients was heterogeneous,
with the majority of CD34- cases being CD133 negative (87%) and the majority of CD34+
samples being CD133 positive (69%). However, both CD34+ AML cells without CD133
expression and CD133 expression on CD34- blasts could be observed. This shows that
while CD133 and CD34 expression are correlated in AML, CD133 expression is not
limited only to CD34+ AML cells. Although some studies have reported a correlation
between CD34 expression and survival,21-23 we did not observe a correlation between
CD34 or CD133 and event-free or overall survival. CD133 expression was also not
correlated with the risk factors FAB type, cytogenetics or WBC. CD133 expression does
not seem to be useful as a prognostic factor in AML. NOD/SCID engrafting capacity has
been correlated with a poor prognosis in AML.24 In this study we also observed no
correlation between CD133 or CD34 expression and NOD/SCID engrafting ability.
The long-term in vitro proliferative ability of cells sorted for co-expression of CD34 and
CD133 was evaluated in 12 AML patients. While the majority of cells at sorting were
CD34-, the majority of cells capable of extensive proliferation for up to 8 weeks in SC were
derived from the CD34+CD133+ subfraction. Waller et al.25 demonstrated that the
Philadelphia chromosome-positive cells were equally distributed between the CD133+ and
CD133- subfractions of CD34+ PB cells from patients with CML. In this study we did not
do cytogenetics on sorted fractions directly but did find cytogenetically abnormal primary
CFU and abnormal CFU after SC in both the CD133+ and CD133- subfractions of
CD34+ and CD34- cells. 
With 11 patient samples examined, AML cells which were capable of engrafting
NOD/SCID mice were found to be derived from more than one CD34 and CD133 sorted
subfraction in most cases. With samples of 7 patients, engraftment with both
CD34+CD133+ and CD34+CD133- cells was seen, with AML cells from 1 patient sample
neither fraction engrafted, and using samples of 3 patients the CD34+CD133- fraction
engrafted but not the CD34+CD133+ fraction. The CD34-CD133+ subfraction of 4
patient samples was too small to be assessed in the NOD/SCID mice. However, of the
remaining 7 AML samples, both CD34-CD133+ and CD34-CD133- subfractions
engrafted using 3 samples, neither fraction engrafted using 2 patient samples and only the
CD34-CD133- fraction engrafted using the other 2 patient samples.
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Although, CD133 expression was thought to be exclusively expressed on CD34+ cells of
normal marrow, cord blood and fetal liver, Gallacher et al.13 identified a very rare
population of normal CD34-CD38-Lin- cord blood cells with long-term in vitro and in vivo
proliferative ability that express CD133. It has been suggested that the normal CD34-
CD133+CD38-Lin- progenitor is more primitive than the CD34+CD38-Lin- progenitor.
In AML, while the cells with long-term in vitro proliferative ability were mainly
CD34+CD133+, CD133 did not seem to be differentially expressed on AML CD34+ in vivo
engrafting cells. Similarly, unlike the normal situation, CD133 did not seem to be
differentially expressed on CD34- AML engrafting cells. CD34- cells with AML
producing ability are found in a minority of patients overall, but have been previously
reported.4,5,26 The high proportion of patients that had cells in all fractions producing low
level engraftment in this study is likely due to chance. It is not known whether these
CD34- cells represent a population that is more primitive or more differentiated than the
CD34+ AML progenitors.
It does not appear that CD133 will be useful to purify or purge AML progenitors and
other cell surface markers will be necessary. If the phenotype of AML progenitors differs
from normal primitive progenitors, new purging strategies could be developed, which
might improve the results of autologous stem cell transplantation in AML. The ability 
to purify AML progenitors and to study their functional characteristics in biological assays
would facilitate studies designed to investigate the molecular basis of human
leukemogenesis. 
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CD33 Expression is Absent on Primitive
Acute Myeloid Leukemia Progenitors from
Most Patients
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Abstract
Acute myeloid leukemia (AML) populations contain a hierarchy of progenitor cells, a
small subset of which can regenerate leukemia in immunocompromised mice or produce
clonogenic progeny in long-term cultures. CD33 is a myeloid marker that is expressed on
all normal myeloid progenitors and monocytes, but is absent on normal hematopoietic stem
cells. CD33 is expressed on 75-90% of the AML samples and therefore appears to be an
ideal cell surface marker for bone marrow (BM) purging strategies and antibody targeted
therapies. We determined expression levels of CD34 and CD33 on AML progenitors with
long-term in vitro proliferative ability and NOD/SCID engrafting ability. As in normal
hematopoiesis, CD33 is absent on the majority of AML progenitors after suspension
culture in serum-free medium for 6-8 weeks. NOD/SCID engrafting cells were found only
in the CD34+CD33- fraction in three patients while in the remaining six patient samples
engraftment was obtained with more than one fraction. In all 9 patient samples with which
engraftment was obtained CD33- cells contributed to the engraftment. These data suggest
that leukemic primitive progenitors of most AML patients lack the expression of CD33
and therefore these patients will be likely to relapse after CD33 targeted therapies, while
a smaller subset of patients have progenitors that express CD33 and may derive more
benefit from this approach.
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Introduction
AML is thought to arise as a result of a genetic change in an immature stem cell or a multi-
lineage progenitor cell, which results in an uncontrolled expansion of those cells and failure
to reach terminal differentiation.1-3 AML cells are heterogenous in phenotype and
functional ability. AML cells capable of initiating the leukemia in the immunocompromised
mice and generating clonogenic cells after long-term culture in vitro are similar in
phenotype and are CD34+, CD38-, HLA-DR- and CD71-.2,4-6 This phenotype has some
similarities to the phenotype of normal progenitors with these functional characteristics.
However, normal progenitors express higher levels of CD117 and CD90.7-9 Cells with the
primitive phenotype represent only a small minority of all AML blasts, but seem uniquely
capable of propagating the leukemia, suggesting they are AML stem cells. We have
observed a close correlation between the phenotypes of in vivo and in vitro leukemia
maintaining cells.10 This suggests that long-term growth in vitro can be used as an assay for
AML stem cells. 
Existing therapies to treat AML are largely directed against the bulk population of AML
cells. Therefore, even when a complete remission is obtained, enough AML stem cells
might be spared to allow reoccurrence of the leukemia. Furthermore, autologous stem cell
transplants, a treatment modality used in a substantial number of patients, can be
contaminated with AML stem cells.11 The ability to phenotypically distinguish between
AML and normal stem cells could be extremely useful to develop purging therapies aimed
specifically against AML stem cells for transplantation and to develop therapies which are
directed specifically against AML stem cells to target minimal residual disease. 
CD33 is a cell surface marker, which is exclusively expressed on myeloid cells.12 It is
expressed on all myeloid progenitors but is down regulated upon differentiation although it
is retained on monocytes. Because CD33 is absent on normal hematopoietic stem cells13,14,
but is expressed on the majority of AML patient samples,15-18 CD33 appears to be a good
candidate for purging strategies and antibody targeted therapy. One of the antibody
targeted therapies, gemtuzumab ozogamicin (GO or Mylotarg®) has recently been
approved by the United States Food and Drug Administration for the treatment of relapsed
CD33+ AML in patients older than 60 years. The long-term effects of GO have not yet been
established, but it appears that relapse often occurs.19,20 This could be due to the absence of
CD33 expression on AML stem cells. To address this question we determined whether
CD33 is expressed on AML progenitors with long-term proliferative ability in vitro and in
vivo repopulating ability. We demonstrate that, although CD33 is expressed on the majority
of AML samples it is absent on primitive AML progenitors with long-term in vitro ability
and is absent on some but not all repopulating cells of a substantial number of patients. 
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Materials and Methods
Patient Cells
Peripheral blood (PB) cells from 34 AML patients at diagnosis were obtained after
informed consent and with approval of the Clinical Research Ethics Board of the
University of British Columbia. Patient characteristics are depicted in Table 1. The mean
number of blasts in the samples was 69 ± 22%. Patients with FAB M3 type were excluded
because of a different treatment strategy given to M3 patients. Blood cells were Ficoll
separated to obtain a mononuclear cell population then frozen in Dulbecco’s modified
Eagle’s medium (DMEM) (StemCell Technologies Inc., Vancouver, B.C.) with 50% fetal
calf serum (FCS) (StemCell Technologies Inc.) and 10% dimethylsulphoxide (DMSO)
and stored at -135oC. 
AML Cell Phenotyping and Sorting
Prior to sorting, thawed AML cells were suspended in HFN (Hanks medium with 2%
FCS and 0.1% sodium azide) at 107 cells/ml. Cells were stained for 30 minutes on ice with
monoclonal antibodies CD34-FITC (Dr. Peter Lansdorp, Terry Fox Laboratory) used at
4 µg/ml and CD33-PE (Becton Dickinson, San Jose, California) used according to
manufacturer’s instruction. Separate aliquots were stained with an irrelevant mouse IgG1-
FITC antibody (Becton Dickinson) and mouse IgG1-PE antibody (Becton Dickinson) as
an isotype control. Cells were then washed twice in HFN at 4oC, propridium iodide (PI)
at 2 µg/ml was added to the cells prior to the second wash, and the cells were maintained
on ice prior to sorting. Cells were analyzed and sorted on a dual laser FACStarplus
(Becton Dickinson) on the basis of fluorescence intensity after gating out non-viable (PI+)
cells. Gates were set to exclude 99.9% of isotype control stained cells. Fractions were
sorted into DMEM with 50% FCS in microcentrifuge tubes at 4oC. Sorted fractions were
washed, resuspended at known cell concentrations and used to initiate colony forming
assays (CFU) and suspension culture (SC) assays or for injection into NOD/SCID mice.
Primary CFU Assays
Immediately after FACS sorting, a known number of sorted and control unsorted PB cells
were plated in methylcellulose culture medium, (Methocult H4330, StemCell Technologies
Inc.), containing 20 ng/ml rhIL-3 (Sandoz, Basel, Switzerland), 20 ng/ml rhIL-6 (Terry
Fox Laboratory), 20 ng/ml rhG-CSF (Amgen Canada Inc., Mississauga, Ontario), 20
ng/ml rhGM-CSF (Sandoz) and 50 ng/ml rhSteel Factor (SF) (Terry Fox Laboratory).
After 10 days of incubation at 37oC in a 5% CO2 humidified incubator, AML blast clusters
(10-20 cells) or colonies (> 20 cells) were counted and the numbers were pooled to obtain
CFU counts. 
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Table 1: Characteristics of AML samples 
No. ID Age Sex FAB Cytogenetics Abnormal % of Blasts
Subtype metaphases
1 117-91 36 M M0 -5, -7 22/25 92
2 122-02 72 F M0 +11 10/16 75
3 HL034 72 M M1 Normal 95
4 XO384 21 M M1 add(6)(p23), 16/16 80
t(6,11)(q27,q23)
5 119-16 39 M M2 +8 14/20 ?
6 MO225 68 M M2 +11 10/10 37
7 105-46 74 F M2 Normal ?
8 BC212 65 F M4 Normal 75
9 IX270 62 M M4 +8, +20 3/25 53
10 106-95 70 F M4 Normal 16
11 FP126 78 M M4 Complex 15/15 51
12 YS329 58 M M4 Complex 9/10 24
13 XZ300 34 M M4 inv16(p13,q22), ? ?
t(4,11)(q35,q14)
14 DW383 52 F M4 inv(16) ? 64
15 KM069 58 F M4 +13 6/10 46
16 DK367 53 M M4 Complex 8/11 61
17 ZU239 56 F M4 Inv(16), +22 15/15 89
18 MN282 48 M M4e Inv(16) 16/16 71
19 XU409 41 M M4e Inv(16) 13/20 75
20 FH142 48 M M5a Normal 53
21 JH201 46 M M5a +8 ? 54
22 LW364 68 M M5a +Y, +4, +20 ? 18
23 NV313 33 F M5a Complex 12/12 89
24 115-79 52 F M5a +8 10/20 94
25 123-46 17 F M5a +8, -5 11/25; 6/25 70
26 117-58 59 M M5a Normal 90
27 KE325 36 M M5a inv16(p13,q22), 13/13 37
47XY, +22
28 TH407 54 M M5a Complex 10/11 97
29 QP353 68 M M5a Complex 25/25 84
30 VX284 60 F M5a Normal 80
31 VD294 72 F M5b +8 11/15 65
32 ND319 55 M -Y ? 90
33 115-45 44 M M0/M4 Normal 86
34 116-23 68 M MDS/ +8 14/15 32
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Suspension Culture Assays (SC)
Suspension cultures were initiated with a known number of sorted and unsorted cells and
maintained generally, as previously described,2,7 in 1.0 ml of serum free medium containing
the growth factor cocktail described. Cultures were maintained at 37oC in a 5% CO2
humidified incubator and 0.5 ml of fresh medium with growth factors was added weekly.
Every second week half the cells and volume of the SC were removed, the cells were
washed in DMEM with 10% FCS and cultured in methylcellulose to determine the CFU
content of the SC. SC were maintained for 8 weeks then the entire contents of the wells
were harvested and assessed for CFU content. To allow comparisons between experiments
the proportion of progenitors derived from each sorted fraction at each time point was
determined by comparison to a progenitor recovery of 100% from all fractions at that time
point. Using PB cells of the AML patients no formation of feeder layers in the SC was
observed.
Transplantation of Leukemic Cells into NOD/SCID Mice
Nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice (Jackson
Laboratory, Bar Harbour, ME) were bred and maintained in the animal facility of the
British Columbia Cancer Research Centre (Vancouver, B.C., Canada) under sterile
conditions in sterile micro-isolator cages and were provided exclusively with autoclaved
food and water containing 100 mg/l ciprofloxacin and HCl. Twenty-four hours prior to
transplantation, mice were irradiated with 3.5 Gy γ-irradiation from a 137Cs source at a
dose rate of 1.22 cGy/min. Unsorted AML PB cells and sorted subfractions were
suspended in 0.3 ml Alpha minimal essential medium (Alpha MEM)(StemCell
Technologies Inc.) with 5% FCS and injected intravenously into the lateral tail vein of 6-8
week old NOD/SCID mice. Whenever possible, various cell concentrations were injected
as a semi-quantitative assessment of the number of cells required for engraftment. Normal
BM cells were given 15 Gy irradiation using 250kVp X-rays (Philips RT-250, HVL 1.5
mm Cu) at a dose rate of 5.1 Gy/min. In each case, 2 x 106 irradiated BM cells were co-
injected with the unsorted cells and sorted subfractions to enhance engraftment potential.
BM aspirations were performed every 4 weeks on anaesthetised mice as described
elsewhere.21 Eight or 12 weeks post-injection the mice were sacrificed by CO2 inhalation.
BM was removed from the femurs by flushing with Alpha MEM with 5% FCS.
Flow Cytometry Analysis of Murine Tissues
Cell suspensions from femoral BM were lysed in ammonium chloride (StemCell
Technologies Inc.) for 20 minutes and then washed in HFN with 5% human serum for
blocking of human Fc receptors and prepared for flow cytometric analysis as described.2,7
Briefly, cells were incubated on ice with an anti-mouse IgG Fc receptor monoclonal
antibody (2.4G2) (Dr. P. Lansdorp, Terry Fox Laboratory, Vancouver). Cells were then
stained with a human pan leukocyte antibody, 9.4 (anti CD45)-FITC (Dr. P. Lansdorp)
for 30 minutes on ice. Separate aliquots were stained with an irrelevant IgG1-FITC
antibody (Becton Dickinson) as an isotype control. Aliquots of normal human PB cells and
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BM cells from a non-injected NOD/SCID mouse were also stained with CD45-FITC and
the isotype control to serve as positive and negative controls for antibody specificity.
Samples were analyzed using a FACScan (Becton Dickinson), gate settings which
excluded ≥ 99.9% of the cells in the matched isotype control were used to determine the
CD45 expression of each sample. Any positive value (i.e. ≤ 0.1%) for the isotype control
was then subtracted from the percentage positive in the CD45 stained samples. We defined
human engraftment as expression of ≥ 0.1% CD45+ cells in a sample. 
Cytogenetic Analysis
Colonies from primary CFU or from CFU which were derived from SC were evaluated
for the leukemia specific cytogenetic change by either standard cytogenetics or by
fluorescence in situ hybridisation (FISH) whenever possible. Likewise sorted CD45+ cells
from BM removed from NOD/SCID mice were evaluated for the leukemic
transformation. For analysis, single colonies were plucked and plated onto slides after
colony synchronisation with colcemid.22 Probes specific for centromeric repeat sequences
were used to detect cytogenetic abnormalities in 18 patients. These included D8Z2
(ATCC, Rockville, MD) to detect the +8 abnormality, The Y probe23 pRY3.4, and a yeast
artificial chromosome (YAC) clone 909g3 (Research Genetics) to detect the +13
abnormality. Total plasmid DNAs containing the centromeric specific DNA were labelled
with digoxigenin (Boehringer-Mannheim, Mannheim, Germany) by nick translation. The
+8 probe was hybridised in Hybrisol VI (Oncor). The signal was amplified by rabbit anti-
sheep FITC (Jackson Immuno Research Laboratories, West Grove PA) and detection by
sheep anti-digoxigenin-FITC (Boehringer Mannheim, Quebec, Canada). Counterstaining
was in PI at 200 ng/ml in Vectashield (Vector Laboratories, Inc. Burlingome, CA).
Colonies were defined as positive whenever ≥ 70% of cells contained the respective
leukemic karyotype of that patient. Colonies containing only 40-70% of cells with the
leukemic change were classified as undetermined and those with < 40% leukemic cells were
defined as negative. Whenever both metaphase and interphase cells could be scored
approximately 100 cells were counted per colony.
Results
Expression of CD34 and CD33 on AML blasts
Peripheral blood mononuclear cells from 30 AML patients used for either our in vitro or in
vivo experiments were evaluated for co-expression of CD34 and CD33. These patients
were FAB M0 (n=2), M1 (n=2), M2 (n=2), M4 (n=9), M4e (n=1), M5a (n=10), M5b
(n=1). One patient had myelodysplastic syndrome with RAEB and two patients had an
undetermined (UD) subtype. Blasts represented 67 ± 23% of total blood cells. Of the 30
samples, 26 expressed CD33 on ≥ 10% of blood mononuclear cells, and 16 patients
expressed CD33 on ≥ 50% of blood mononuclear cells. Of the 30 patients, 19 patients had
a CD34+ AML (CD34+ AML defined as CD34 expression in ≥ 10% of blood mononuclear
cells), while 11 patients had a CD34- AML. In the 19 CD34+ expressing samples, the
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mean proportion of CD34+CD33+ nucleated cells was 18 ± 17%, while 43 ± 26% were
CD34+CD33-, 19 ± 21% were CD34-CD33+ and 19 ± 19% were CD34-/CD33- (Figure
1). In the 11 CD34- samples the mean proportion of CD34+CD33+ nucleated cells was 1.3
± 2.6%, while 0.4 ± 0.6% were CD34+CD33-, 59 ± 23% were CD34-CD33+ and 39 ± 24%
were CD34-CD33- (Figure 1). CD33 expression was higher in the CD34- samples (63 ±
24%) compared to the CD34+ samples (35 ± 27%). 
Figure 1: Expression of CD34 and CD33 on AML cells from 30 patients at diagnosis.
PB cells from 30 AML patients at diagnosis were stained with CD34-FITC and CD33-PE
and analyzed by FACS. The mean % of cells in the CD34+CD33+ subfraction (open bars),
CD34+CD33- subfraction (filled bars), CD34-CD33+ subfraction (hatched bars) and the
CD34-CD33- subfraction (dotted bars) of 19 CD34+ (CD34 expression ≥ 10%) and 11
CD34- (CD34 expression ≤ 10%) samples was calculated.
PB = peripheral blood , NC= nucleated cells
Expression of CD34 and CD33 on AML cells with long term proliferative ability in vitro
In order to determine the phenotype of AML cells capable of producing primary CFU and
CFU after long-term culture, PB cells from a subset of 26 patients were sorted in four
fractions according to their expression of CD34 and CD33 and subsequently used to
establish primary CFU assays and suspension culture (SC) assays. Fifteen patients had
high expression of CD34 (66 ± 25% CD34+), while the majority of AML blasts in the other
11 patients were CD34- (1.7 ± 2.7% CD34+). The CD34+CD33+ subfraction represented
12 ± 17% of nucleated cells in the 26 patients at sorting, 27 ± 30% were CD34+CD33-, 33
± 30% were CD34-CD33+ and 28 ± 24% were CD34-CD33- (Figure 2). Cells capable of
forming primary CFU were present in all four subfractions. After 2 weeks in suspension
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culture (SC) most CFU were found in the CD34+CD33- subfraction (61 ± 39%). Similarly
after 4, 6 and 8 weeks in SC the % CFU in the CD34+CD33- subfraction was 76 ± 33%,
63 ± 48% and 73 ± 44% respectively (Figure 2). After 6-8 weeks in SC, >90% of CFU were
observed in the CD34+CD33- subfraction in 11 of 17 patients. While in 2 of 17 patients,
>90% of the CFU at week 6-8 were observed in the CD34+CD33+ subfraction, in 3 of 17
patient samples >90% of CFU were observed in the CD34-CD33+ and CD34-CD33-
subfractions and in one patient CFU were distributed in all subfractions. These data
suggest that in the majority of patient samples the SC-IC is found in the CD34+CD33-
subfraction. 
Figure 2: Proportion of AML PB cells and progenitors from 26 AML patients in
subfractions sorted for the expression of CD34 and CD33. Percentage of blood cells,
primary CFU and CFU after 2-8 weeks in SC in the CD34+CD33+ subfraction (open
bars), CD34+CD33- subfraction (filled bars), CD34-CD33+ subfraction (hatched bars)
and the CD34-CD33- subfraction (dotted bars). To allow comparison of the proportion of
progenitors in each subfraction, CFU frequencies were determined by comparison to a
progenitor recovery of 100% (UF) of all four subfractions at each time point.
PB = peripheral blood, SC = suspension culture, NC= nucleated cells, UF=unsorted
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Cytogenetic analysis of in vitro studies
It was possible to analyse CFU and CFU derived from SC by FISH or standard
cytogenetic analysis in some fractions of 18 patients (Table 2). In Figure 3, an example of
abnormal cells in a colony derived from the CD34+CD33- subfraction after 4 weeks in SC
of a patient with trisomy 8 is depicted. The majority of colonies from primary CFU were
abnormal (abnormal defined as at least one abnormal colony of all colonies analyzed) with
11 of 14 patient samples showing an abnormal karyotype in the colonies of the unsorted
fraction, 9 of 11 patient samples were abnormal in the CD34+CD33+ subfraction, 8 of 13
samples in the CD34+CD33- subfraction, 6 of 7 in the CD34-CD33+ subfraction and 6 of
6 in the CD34-CD33- subfraction. CFU derived from SC at weeks 2-8 were abnormal in
6 of 10 samples using unsorted cells, 4 of 5 samples using cells from the CD34+CD33+
subfraction, 5 of 6 samples in the CD34+CD33- subfraction, 3 of 3 samples in the CD34-
CD33+ subfraction and 4 of 4 samples in the CD34-CD33- subfraction. Of the 11 patients
with >90% of CFU in the CD34+CD33- subfraction, 5 of 6 samples analyzed were
leukemic. In one patient, abnormal colonies could be obtained at any time point using
unsorted (12/20), CD34+CD33+ cells (11/20) or CD34-CD33+ cells (9/20), while only
normal colonies (6/6) were observed at all time points using CD34+CD33- cells. No
colonies could be obtained with CD34-CD33- cells of this patient. Overall these data
suggest that the majority of colonies of the patients were leukemic.
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Table 2: Total number of Colonies detected with the leukemic change by FISH or Cytogenetics of 18
patients following in vitro Assays
Fraction Positive Colonies Positive Colonies after Positive after 
From CFU blast 2-4 weeks of SC 6-8 weeks of SC
Unsorted 62/105 (59%) 33/87 (38%) 30/52 (58%)
CD34+CD33+ 46/73 (63%) 20/41 (49%) 23/33 (70%)
CD34+CD33- 50/91 (55%) 15/62 (24%) 27/42 (64%)
CD34-CD33+ 35/51 (69%) 18/21 (86%) 14/20 (70%)
CD34-CD33- 33/42 (79%) 24/32 (75%) 12/19 (63%)
Abbreviations: SC, suspension culture.
Positive colonies were defined as ≥ 60% cells with the leukemic karyotype in one colony
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Patient Subfraction % of NC Number of cells Engraftment
injected x 105 (% CD45+)
069 Unsorted 50 1.0
CD34+CD33+ 10 8; 8 0; 0
CD34+CD33- 7 12 0.1
CD34-CD33+ 42 10; 10 0.1; 0
CD34-CD33- 40 1.3 0
284 Unsorted 100; 10 76; 20
CD34+CD33+ 15 12 54
CD34+CD33- 3 3 0.1
CD34-CD33+ 61 10;10 0.5; 33
CD34-CD33- 21 12 0
212 Unsorted 100; 10 76; 1.7
CD34+CD33+ 9 5 0.5
CD34+CD33- 0.4 1 0.3
CD34-CD33+ 82 15; 15 0.2; 0
CD34-CD33- 8 3.2 0
383 Unsorted 100; 10 3; 0
CD34+CD33+ 2 9.4; 2.6 0
CD34+CD33- 63 2.6 0.1; 0
CD34-CD33+ 21 0.2 0
CD34-CD33- 14 10; 2.6 0
409 Unsorted 100; 10 0.4; 0.1
CD34+CD33+ 15 10 0.1
CD34+CD33- 70 10 0.1
CD34-CD33+ 8 15 0
CD34-CD33- 6 7.7 0
239 Unsorted 100; 10 0; 0.1
CD34+CD33+ 20 15 0;
CD34+CD33- 13 15 0
CD34-CD33+ 53 10; 10 0.1; 0
CD34-CD33- 19 10 0.1
Table 3: AML cells sorted for co-expression of CD34 and CD33 with multiple subfractions capable
of engrafting NOD/SCID mice.
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In vivo NOD/SCID assay
AML cells from 13 patients were sorted for co-expression of CD34 and CD33 and
evaluated for their ability to repopulate sublethally irradiated NOD/SCID mice (Table 3).
Human cells were detected in the BM of at least one of the mice injected with unsorted
cells from all of these patients, although the number of human cells in the BM varied
considerably (range 0.1-76% CD45+ cells). With AML cells of 9 patients engraftment was
also achieved using cells sorted for CD34 and CD33, however the levels of engraftment
were very low in the majority of patients. With 3 of 9 patient samples, engraftment (range
0.1%-5% CD45+ cells) could only be obtained using cells from the CD34+CD33-
subfraction, while no engraftment was seen using an equal or higher number of
CD34+CD33+ cells or CD34- cells. With the other 6 AML samples engraftment was
achieved with at least two subfractions and all of those samples engrafted using CD33-
cells (Table 3). In summary, from these 9 patient samples, 13 of 18 mice injected with
unsorted cells engrafted, 4 of 13 mice injected with CD34+CD33+ cells, 8 of 11 mice
injected with the CD34+CD33- cells, 7 of 13 mice injected with CD34-CD33+ cells and 2
of 8 mice injected with CD34-CD33- cells also engrafted.
Table 3 (Continued): AML cells sorted for co-expression of CD34 and CD33 with multiple
subfractions capable of engrafting NOD/SCID mice. 
Patient Subfraction % of NC Number of cells Engraftment
injected x 105 (% CD45+)
115-79 Unsorted 100; 10 0.2; 0
CD34+CD33+ 1 0.8 0
CD34+CD33- 0.05 0.3 5
CD34-CD33+ 77 20 0
CD34-CD33- 21 20 0
115-45 Unsorted 100; 10 0.2; 0.2
CD34+CD33+ 7 11 0.3
CD34+CD33- 32 20 0.5
CD34-CD33+ 47 10; 10 0.4; 0.1
CD34-CD33- 14 7 0.6
123-46 Unsorted 100, 10 0, 0
CD34+CD33+ 0.6 3.1 0
CD34+CD33- 2 1.7 0.7
CD34-CD33+ 76 ND
CD34-CD33- 21 ND
ND = not done
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Figure 3: Abnormal cells in the CD34+CD33- fraction of one AML patient with
trisomy 8 after 4 weeks in SC. Colonies from CFU which were derived from 4 weeks SC
were evaluated for the leukemia specific cytogenetic change by FISH. Single colonies were
plucked and plated onto slides after colony synchronisation with colcemid. The D8Z2
probe specific for the +8 abnormality was labelled with digoxigenin by nick translation.
The +8 probe was hybridised in Hybrisol VI. The signal was amplified by rabbit anti-sheep
FITC and detection by sheep anti-digoxigenin-FITC. Counterstaining was in PI at 200
ng/ml in Vectashield. Colonies were defined as positive whenever ≥ 70% of cells contained
the respective leukemic karyotype of that patient. Colonies containing only 40-70% of cells
with the leukemic change were classed as undetermined and those with < 40% leukemic
cells were defined as negative. Whenever both metaphase and interphase cells could be
scored approximately 100 cells were counted per colony.
CFU=colony forming unit, SC=suspension culture, FISH=fluorescent in vitro
hybridization, PI=propidium iodide
Discussion
Primitive AML progenitors exist within the AML blast population which are uniquely
capable of extensive proliferation and are likely responsible for maintaining the disease.24
CD33 is a cell surface protein that is expressed on both normal and leukemic myeloid
cells.15-18 Because CD33 is absent on normal hematopoietic stem cells,13,14 CD33 seems to
be a good target for antibody-targeted therapies or purging strategies to treat AML. The
aim of this study was to investigate whether CD33 is expressed on primitive AML cells
with long term proliferation in vitro and NOD/SCID repopulating capacity. 
Comparable with previous studies, we found CD33 expression on more than 10% of cells
in 88% of the samples.15-18 Interestingly, CD33 expression was higher on the CD34-
samples compared to the CD34+ samples. We can speculate that the CD34+ AML samples
are less differentiated and therefore express lower amounts of CD33. We found leukemic
clonogenic progenitors as measured in the primary CFU assay in all four sorted
subfractions. This is in contrast to previous reports, that showed that CD33 was expressed
on the majority of clonogenic progenitors.25-27 Of more interest was the expression of
CD33 on long-term in vitro and in vivo repopulating cells, because those cells are thought to
be responsible for maintenance of the leukemia in vivo. We found that suspension-culture
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initiating cells (SC-IC) with proliferative ability in SC for up to 8 weeks from most patients
lack the expression of CD33 and thus would not be targetted by CD33 antibody based
therapies. Cytogenetic analysis confirmed the leukemic nature of the SC-IC in the majority
of cases. However, one of the six patient samples that proliferated up to 8 weeks in culture
had normal CD34+CD33- SC-IC, while SC-IC in the other fractions had an abnormal
karyotype, suggesting that in this case the CD34+CD33- subfraction may contain normal
cells therefore a subset of patients could be identified that may have a more durable
remission with CD33 targeting approaches. Guan et al. found that using the Human
Androgen Receptor Assay, cytogenetically normal colonies were polyclonal in 80% of the
analyzed cases, suggesting that indeed these cells may be normal.28 In vivo experiments also
demonstrated that in a proportion of patients, the majority of primitive AML progenitors
express CD34 and lack the expression of CD33, like normal hematopoietic progenitors.
However, as we have observed in a previous study,29 engraftment with CD34- cells was
significant. A more primitive normal CD34- cell capable of long-term engraftment in
immunodeficient mice exists.30,31 Although a leukemic CD34- cell capable of engraftment
has also been identified,29,32 it is not clear whether this cell is more primitive or more
differentiated than the CD34+ AML progenitors. In general, we have reported a close
correlation between the long-term SC-IC and the SL-IC.10
The high expression of CD33 on the majority of AML blast cells but not on normal stem
cells makes it an obvious candidate for CD33 targeted therapies and CD33 based purging
strategies in this disease. However, our study indicates that the cell responsible for
maintaining the disease lacks the expression of CD33 in many but not all patients and will
therefore be spared by those therapies. Studies using gemtuzumab ozogamicin, a CD33
targeted toxin, indeed showed reduction of the bulk AML blasts and the survival of
patients appeared longer, but relapse was frequent even over the short follow-up
period.19,20 In this study we found a subset of patients who would be particularly good
candidates for CD33 based therapies as their AML stem cells expressed this antigen.
Selecting patients on the basis of CD33 expression on primitive progenitors for therapy
could reduce unnecessary toxicity for the patient and is cost effective. The search for cell
surface markers specifically expressed on leukemic primitive progenitors should be
continued in order to develop disease-specific treatments. 
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Abstract
Telomeres play an important role in the proliferation and senescence of normal and
malignant cells. To test the role of telomerase in acute myeloid leukemia (AML), we
expressed the telomerase reverse transcriptase (hTERT) gene, a dominant-negative DN-
hTERT (D868A, D869A) gene, or a gene encoding green fluorescence protein (GFP) in
the leukemia cell line K562 and in primary AML cells from different patients using
retroviral vectors. Cells transduced with hTERT exhibited elevated levels of telomerase
activity compared to GFP-controls, whereas cells expressing DN-hTERT had decreased
telomerase activity. K562 populations transduced with DN-hTERT showed reduced
clonogenicity, telomere dysfunction and increased numbers of apoptotic cells compared
to GFP or hTERT-transduced cells. Two of four clones transduced with DN-hTERT
died after 30 and 53 population doublings, respectively. Transduced AML cells were
tested in primary colony forming unit (CFU) and suspension culture assays. Relative to
hTERT and GFP-transduced controls, AML cells transfected with DN-hTERT
produced fewer CFU and showed lower engraftment after transplantation into
sublethally irradiated ß2-microglobulin
-/- NOD/SCID mice. We conclude that
telomerase is limiting the growth of the leukemic cell line K562 and primary AML
progenitor cells. Our data warrant further studies of the therapeutic use of telomerase
inhibitors in AML.
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Introduction
Telomeres in human cells consist of 2-15 kb of non-coding double-stranded T2AG3 repeats
and 50- to 150-nucleotide overhangs of single-stranded repeats1 and associated proteins.2
Telomeres protect the ends of chromosomes from fusion, exonucleolytic degradation,
aberrant chromosomal recombination and functional telomeres are required for proper
segregation of chromosomes during mitosis.3-6
The human telomerase complex, a ribonucleoprotein polymerase, is able to synthesize
terminal (T2AG3)n telomeric repeats de novo and can compensate for the loss of telomeric
DNA.7 It consists of a catalytic subunit with reverse transcriptase activity encoded by the
hTERT gene, a RNA template encoded by the hTERC gene and associated proteins.8,9 In
general, normal human somatic cells have only low or undetectable telomerase activity
with hematopoietic progenitor cells and activated T and B lymphocytes being notable
exceptions. Telomerase is required to compensate for the loss of telomeres resulting from
the end replication problem, exonuclease processing of 5’ ends and lesions induced by
radiation or oxidative stress.10-14 Cells from many tissues show progressive shortening in
vivo and in vitro which could result in their replicative senescence and selection of abnormal
cells.15-18
Numerous types of cancer, including acute myeloid leukemia (AML), use telomerase
activity to maintain telomeres and prevent replicative senescence or apoptosis. Variable
levels of telomerase have been detected in up to 85% of all AML's.19-21 AML is a highly
aggressive disease in which an uncontrolled proliferation and maturation of myeloid
progenitors is observed.22 AML is thought to arise from genetic changes in a primitive
hematopoietic progenitor or stem cell.23 As in normal hematopoiesis, heterogeneity in the
proliferative and self-renewal abilities of AML cells exists, suggesting that AML cell
populations within individual patients are organized in a hierarchy.24-26 AML progenitors
and stem cells can be detected using in vitro and in vivo assays.27 While a considerable
number of AML blasts is capable of forming colonies in colony forming assays,25,28,29 only
a minority of AML cells have the ability to initiate and sustain long-term proliferation in
vitro or to engraft non obese diabetic severe combined immune deficient (NOD/SCID)
mice.25,29 Cells with long-term in vitro proliferative capacity and cells capable of engrafting
immune deficient mice are thought to be uniquely capable of maintaining the disease.
These assays are therefore of great interest to determine the efficacy of treatment regimens
aimed to eradicate AML stem and progenitor cells.
Telomerase is expressed in most AML cells and telomerase inhibition could potentially lead
to eradication of leukemic stem cells. Several point mutants in the reverse transcriptase
motifs of the catalytic subunit of hTERT have been identified and shown to markedly
reduce telomerase activity upon overexpression in telomerase positive cells.30,31 Most likely,
dominant-negative constructs disrupt telomerase activity by binding to limiting levels of
the essential telomerase RNA template resulting in inactive telomerase complexes. In order
to study the role of telomerase in AML, we have examined the effect of overexpression and
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disruption of telomerase activity in the human leukemia cell line K562 and in primary
AML progenitors. Our results show that telomerase is a promising target to inhibit the
proliferation of AML cells. 
Materials and Methods
Patient cells
Peripheral blood (PB) cells from 12 AML patients at diagnosis were obtained with
informed consent and approval of the Clinical Research Ethics Board of the University of
British Columbia. Patients with FAB M3 type were excluded because of the unique
characteristics of this AML subtype. Blood cells were subjected to density separation using
Ficoll Hypaque (Amersham Biosciences, Uppsala, Sweden). Mononuclear cells were
frozen in Dulbecco’s modified Eagle’s medium (DMEM) (StemCell Technologies Inc.,
Vancouver, Canada) with 50% fetal calf serum (FCS) (StemCell Technologies Inc.) and
10% dimethylsulphoxide (DMSO) (Sigma-Aldrich, Oakville, Ontario) and stored at -135oC.
The patient characteristics of the samples used in this study are shown in Table 1. 
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Table 1: Characteristics of AML samples used in this study
No. ID Age Sex Source FAB Cytogenetics % TRAP
Subtype of Blasts
1 109-14 22 M PB M1 Normal 90 ++
2 110-36 37 F PB M1 Normal 78 +
3 NV253 78 F PB M1 n.a. 93 +
4 111-41 25 M PB M2 +4; t(8,21) 94 +/-
5 IT369 52 M PB M2/MDS Normal 17 +/-
6 105-46 74 F PB M2 Normal 30 ++
7 GHN323 50 F PB M4 eo inv 16; +22 55 +/-
8 DK367 53 M PB M4 -4; -12; -17; 61 +/-
del5(q12,q23) etc.
9 108-24 58 M PB M4 Normal 96 ++
10 114-04 60 F PB M4 Normal 26 +
11 BC212 65 F PB M4 Normal 75 +/-
12 VW372 65 F PB M4 Normal 89 +/-
N O R M A L A N D L E U K E M I C H E M A T O P O I E S I S
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Retrovirus production
Gene transfer was achieved using retrovirus-mediated gene transfection. We constructed
murine stem cell virus (MSCV)-based retroviral vectors32 containing the gene for
enhanced green fluorescent protein (GFP; Clontech, Palo Alto, CA) under the control of
the phosphoglycerate kinase (PGK) promoter with or without the full-length hTERT
cDNA (kindly provided by Dr. Robert Weinberg, Massachusetts Institute of Technology,
Boston, MA) or DN-hTERT (D868A, D869A) cDNA (kindly provided by Dr. Lea
Harrington, University of Toronto, Toronto, Canada). Helper-free retrovirus pseudotyped
with the Gibbon Ape leukemia virus envelope for efficient infection of human cells was
generated using PG13 packaging cells.33
Retrovirus-mediated transfection of K562 
K562 cells were cultured in DMEM with 10% FCS and 2 mM L-glutamine (StemCell
Technologies Inc.). Cells were harvested, washed once in phosphate-buffered saline (PBS)
(StemCell Technologies Inc.) and resuspended at a density of 1x106 cells/ml in retrovirus-
containing supernatant along with 4 µg/ml hexadimethrine bromide (Polybrene) (Sigma-
Aldrich). K562 cells were cultured overnight, washed once with PBS and further
expanded for 5 to 6 days prior to subsequent experiments.
Retrovirus-mediated transfection of AML cells
Primary AML cells were thawed and cultured in Iscove's Modified Dulbecco's Medium
(IMDM) (StemCell Technologies Inc.) containing 20% FCS, 50 ng/ml rhSteel Factor
(SF) (Terry Fox Laboratory, Vancouver, Canada) and 10 ng/ml rhIL-3 (Novartis, Basel,
Switzerland). At day 2 or 3, cells were harvested and counted. 1-5x106 cells were then
plated in this medium onto non-tissue culture 6-well plates (Falcon, Becton Dickinson,
Bedford MA) coated with 6-10 µg/cm2 RetroNectin™ (Takara Shuzo Ltd., Otsu, Japan)
preloaded with 4 ml of retrovirus-containing supernatant. Plates were coated either at 4°C
overnight or at 37°C for 2 hours (h), subsequently blocked with 2% bovine serum albumin
(BSA, Calbiochem-Novabiochem, San Diego, CA) for 30 min at 37°C, and then washed
once with PBS prior to use. After 4 h, cells were harvested from the wells by vigorous
pipetting and washed once with PBS. Cells were resuspended in IMDM containing 20%
FCS, 50 ng/ml SF and 10 ng/ml rhIL-3 and kept in 6-well plates for tissue culture (Falcon)
overnight. The transfection procedure was repeated on two consecutive days. After
transfection, cells were further expanded for 5 to 6 days and then sorted for GFP
expression. The efficiency of transfection was estimated from the percentage of cells
expressing GFP at around 0.8% to 34.3%.
Flow cytometry
Viable GFP+ K562 cells or GFP+ primary AML cells (PI-) were isolated at a purity of
>99% using a FACStarplus (Becton Dickinson, San Jose, CA) as described previously.34
Cells were sorted and known cell numbers were used to initiate proliferation assays, colony
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forming assays (CFU), suspension culture (SC) assays and transplantation assays. Both
single cell clones and bulk populations were obtained from the K562 cells and used in
proliferation assays.
Proliferation assays
A known number of sorted K562 clones and bulk cells were plated in media. Once a week,
cell counts were performed using trypan blue. The number of population doublings (PD)
was calculated from the average cell count, using the following equation: PD = 10log
(number of cells counted after expansion) - 10log (number of cells seeded)/10log 2. 
Primary CFU assays
Immediately after FACS sorting, a known number of sorted primary AML cells were
plated in methylcellulose culture medium (Methocult H4330, StemCell Technologies Inc.),
containing 20 ng/ml rhIL-3 (Novartis), 20 ng/ml rhIL-6 (Terry Fox Laboratory), 20 ng/ml
rhG-CSF (Amgen Canada Inc., Mississauga, Ontario), 20 ng/ml rhGM-CSF (Novartis)
and 50 ng/ml rhSteel Factor (SF) (Terry Fox Laboratory). After 10 days of incubation at
37oC in a 5% CO2 humidified incubator, AML blast clusters (10-20 cells) or colonies (> 20
cells) were counted and the numbers were pooled to determine the primary CFU
frequency per 105 cells calculated as follows: the number of colonies/ the number of cells
plated x105.
Suspension culture assays 
Suspension cultures (SC) were initiated with a known number of transduced AML PB
cells sorted for their GFP expression and maintained generally, as previously described,29,35
in 1.0 ml of serum free medium containing 20 ng/ml rhIL-3 (Sandoz, Basel, Switzerland),
20 ng/ml rhIL-6 (Terry Fox Laboratory), 20 ng/ml rhG-CSF (Amgen Canada Inc.,
Mississauga, Ontario), 20 ng/ml rhGM-CSF (Sandoz) and 50 ng/ml rhSteel Factor (SF)
(Terry Fox Laboratory). Cultures were maintained at 37oC in a 5% CO2 humidified
incubator and 0.5 ml of fresh medium with growth factors was added weekly. Every
second week, half the cells and volume of the SC were removed, the cells were washed in
DMEM with 10% FCS and cultured in methylcellulose to determine the CFU content of
the SC. SC were maintained for 8 weeks then the entire contents of the wells were
harvested and assessed for CFU content. To allow comparisons between experiments, the
frequency of progenitors per 105 cells at each time point was calculated from the number
of colonies obtained by plating a given number of cells. No feeder layers were formed in
SC initiated with PB cells of the AML patients.
Transplantation of transduced AML cells into in ß2-m-/- NOD/SCID mice
ß2-microglobulin deficient nonobese diabetic/severe combined immunodeficient (ß2-m
-/-
NOD/SCID) mice (Jackson Laboratory, Bar Harbor, ME) were bred and maintained in
the animal facility of the British Columbia Cancer Research Centre (Vancouver, Canada)
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under sterile conditions in sterile micro-isolator cages. The animals were provided
exclusively with autoclaved food and water containing 100 mg/l ciprofloxacin and HCl.
Twenty-four hours prior to transplantation, mice were irradiated with 3.5 Gy γ-irradiation
from a 137Cs source at a dose rate of 1.22 cGy/min. A known number of sorted AML PB
cells transduced with the MSCV vector alone or with the MSCV vector containing
hTERT or DN-hTERT were suspended in 0.3 ml Alpha minimal essential medium (Alpha
MEM)(StemCell Technologies Inc.) with 5% FCS and injected intravenously into the
lateral tail vein of 6-8 week old ß2-m
-/- NOD/SCID. BM aspirations were performed every
4 weeks on anaesthetized mice as described elsewhere.36 Eight or 12 weeks post-injection
the mice were sacrificed by CO2 inhalation. BM was removed from the femurs by flushing
with Alpha MEM with 5% FCS.
Flow Cytometry analysis of murine tissues
Cell suspensions from femoral BM were lysed in ammonium chloride (StemCell
Technologies Inc.) for 20 min and then washed in Hanks medium (StemCell Technologies
Inc.) with 5% human serum for blocking of human Fc receptors and prepared for flow
cytometric analysis as described.29,35 Briefly, cells were then stained with a Cy5-labeled
anti-human CD45 antibody for 30 min on ice. Unlabeled cells were used as control.
Samples were analyzed using a FACScan (Becton Dickinson), to determine the
percentage of cells expressing CD45 using gate settings that excluded ≥ 99.9% of the
events in the unlabeled control cells. Human engraftment was defined as expression of
≥ 0.1% CD45+ cells in a sample. 
Telomerase repeat amplification protocol assay
Telomerase activity was measured by telomeric repeat amplification protocol (TRAP)
assay using an end-labeled telomerase substrate (TS) primer as described.37 Cell extracts
were obtained from a positive control cell line (K562). Extension of the TS primer by
telomerase was performed for 30 min. at room temperature, and the products generated
were amplified by 30 cycles of polymerase chain reaction (PCR) at 95°C for 60 seconds,
50°C for 45 seconds and 72°C for 60 seconds using the ACX anchored return primer. Half
of the amplified products were resolved on a 12% polyacrylamide gel and visualized by a
phosphoimaging system (Storm 820, Molecular Dynamics Inc., Sunnyvale, CA). The
results of the semi-quantitative TRAP assay were used to rank telomerase activity in
primary AML cells relative to the activity measured in K562 cells. High telomerase levels
(++) were defined as levels comparable to the telomerase level in K562 cells. Intermediate
levels (+) are defined as readily detectable levels but lower compared to K562. The
definition of low levels (+/-) of telomerase activity is telomerase activity that is just
detectable using this assay.
Telomere length analysis
The telomere length of cells before and after transfection and selection was measured using
in situ hybridization and flow cytometry (flow FISH) as described.38
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Cytospin preparation
Cells were counted and 2-4x104 cells were resuspended in 100 µl medium containing 10%
BSA (Calbiochem-Novabiochem) and spun at 1250 rpm for 1 min. with high acceleration
in a cytocentrifuge (Cytospin-2, Thermo Shandon). The slides were air dried overnight,
stained with Wrights Giemsa stain (Hematek 2000, Bayer Diagnostics, Tarrytown, NY)
and analyzed.
Calculations and statistical analysis
The Friedman Ranks Test was used to study the correlation between the telomere length
of K562 cells transduced with GFP, hTERT and DN-hTERT (n=8). For a correlation
between GFP and DN-hTERT-transduced primary AML cells the non-parametric
Wilcoxon Signed Ranks Test was used (n=7). For both tests a significant level of 0.05 was
chosen.
Results
Disruption of telomerase activity in K562 leads to telomere dysfunction and cell death
To study the role of telomerase in leukemia, we first transduced the leukemia cell line K562
with retroviral vectors encoding hTERT, DN-hTERT (D868A, D869A) and GFP.
Transduced cells were sorted on the basis of GFP expression. Cells transduced with DN-
hTERT showed a reduced clonogenicity (frequency of proliferating clones from
transduced cells immediately after sorting) compared to the GFP-control or hTERT-
transduced cells (DN-hTERT 4.2 ± 0.9%; GFP 2.6 ± 28.9%; hTERT 1.9 ± 27.3%; n=2).
When DN-hTERT cells were sorted for high and low GFP expression, we observed that
clones expressing high levels of GFP showed a reduced proliferation rate. No such effect
was seen for clones with low GFP expression. These results suggest that GFP expression
in cells transduced with the DN-hTERT gene corresponds to the level of transgene
expression and suppression of telomerase activity. Two of four DN-hTERT-transduced
clones (clone 2 and 3) died after, respectively, 90 days (53 PDs) and 60 days (30 PDs) in
culture. Another clone showed reduced proliferation while still expressing a low level of
GFP and another clone lost GFP expression altogether and continued to proliferate like
the GFP-control. Overexpression of hTERT in four K562 clones did not alter the
proliferation compared to controls (Figure 1).
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Figure 1: Proliferation of K562 cells transduced with hTERT, DN-hTERT (D868A,
D869A) and a GFP-control vector. After transfection cells were sorted and cloned. For
each vector four clones were expanded up to 4 months and every week cell counts were
performed. Two of the four clones (triangles and circles) transduced with the DN-hTERT
died after 60 days (30 PDs) and 90 days (53 PDs). Clone 4 (diamonds) exhibited a reduced
proliferation while expressing a low level of GFP. In clone 1 (squares) GFP expression
could not be detected after several weeks in culture, suggesting that either the transgene
was lost or silenced.
Morphological analysis of the DN-hTERT clones at day 14-20 after cloning revealed
multiple anaphase bridges indicative of telomere dysfunction (Figure 2).31,39 Furthermore,
many cells showed morphological features typical of apoptosis such as nuclear chromatin
condensation, cell shrinkage and cell fragmentation into apoptotic bodies. GFP-control
and hTERT-transduced cells exhibited similar morphology as untransduced K562 cells. 
To determine the telomerase activity in the transduced clones after 14 days in culture, we
performed telomerase (TRAP) assays. Telomerase activity in DN-hTERT clones that later
died in culture was severely reduced. Both the hTERT and the GFP-control clones
contained high levels of telomerase activity. Telomere length analysis by flow-FISH
revealed shorter telomere length in DN-hTERT clones compared to the GFP-control
(Figure 3). Interestingly, although telomerase activity appeared high in both the GFP-
control and the hTERT clones, telomere length in the hTERT clones was significantly
longer compared to the GFP-control clones (p=0.002). 
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Figure 2: Microscopic appearance of clones 2 and 3 of K562 cells transduced with DN-
hTERT (D868A, D869A) after 20 days of expansion. Cytospins of different clones were
prepared and stained with Wrights Giemsa stain. As shown DN-hTERT (D868A,
D869A)-transduced cells displayed anaphase bridges indicative of telomere dysfunction
and apoptotic morphology. No changes relative to untransduced K562 cells were seen for
GFP-control or hTERT-transduced cells.
Transduction of primary AML cells with hTERT, DN-hTERT and GFP
To determine the role of telomerase in primary AML cells, we determined telomerase
activity in samples from 12 patients with various AML subtypes and cytogenetic
abnormalities (Table 1). In all 12 samples, telomerase activity could be readily detected
although at variable levels (Figure 4). The primary AML cells from all patients were
transduced with DN-hTERT and GFP-control and in 8 cases also with the hTERT vector
using a modification of our transfection protocol for human T-lymphocytes.40 Using this
strategy, gene transfer was obtained in all cases be it at variable efficiency ranging from
0.8 to 34.3%. Examples of results are shown in Figure 5a. No major differences in
transduction efficiency between the three vectors were observed (10.7 ± 9.0% for the DN-
hTERT, 13.1 ± 10.9% for the hTERT and 8.4 ± 6.9% the GFP-control). After 5 to 6 days
in culture, the transduced AML cells were sorted for GFP expression and a TRAP assay
was performed to determine telomerase activity and the efficiency of gene transfer. High
telomerase activity was detected in hTERT-transduced cells compared to GFP-controls. In
contrast, telomerase activity in DN-hTERT cells appeared to be reduced compared to the
GFP-controls (Figure 5b).
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Figure 3: Loss of telomere repeats in K562 cells transduced with DN-hTERT. K562
cells transduced with hTERT, DN-hTERT (D868A, D869A) and a GFP-control vector
were sorted and cloned. The telomere fluorescence histograms of representative clones
following flow FISH38 are shown. Note, compared to the GFP-control, that the telomere
fluorescence in DN-hTERT-transduced cells was lower whereas the telomere fluorescence
in hTERT-transduced cells was higher.
Telomerase activity in AML cells influences mean CFU frequency
To study the function of telomerase in AML progenitor cells, a known number of DN-
hTERT or GFP-control cells were plated into primary colony forming unit (CFU) and
suspension culture (SC) assays to determine the CFU and SC initiating cell content (SC-
IC). In the primary CFU assays, colonies could be observed in all 7 samples and no
differences in CFU frequency between DN-hTERT and GFP-control-transduced cells
were observed (mean CFU frequency 4.0 x103 ± 4.3 x103 vs. 2.8 x103 ±1.9 x103 CFU/105
cells, respectively). However, after 4 weeks in SC, colonies were observed in only 2/7
samples transduced with DN-hTERT, while growth was observed in 5/7 of GFP-control
samples. In the two DN-hTERT samples (BC212 and NV253) in which growth was
observed, the frequency of SC-IC was reduced in sample BC212, while in sample NV253
it was comparable to the GFP-control (Figure 6). In two samples (GHN323 and IT369),
no growth in either GFP-control or DN-hTERT transduced cells was observed. Overall,
the CFU frequency after four weeks of suspension culture was 7.9x102 ± 1.8x103 CFU/105
cells in DN-hTERT transduced cells compared to 1.1x104 ± 2.7x104 CFU/105 cells for the
GFP-control. 
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Figure 4: Telomerase activity in primary AML cells. Telomerase activity in 2.0 x 103
AML blast after 2 days in culture was analyzed by TRAP assay. Negative controls using
DEPC-water and positive control extracts obtained from the cell line K562 were used in each
experiment. All primary AML samples showed various degrees of telomerase activity.
One AML sample (110-36) was transduced with hTERT, DN-hTERT and GFP-control
(Figure 6). The primary CFU assay again revealed no differences in primary CFU
frequency for all 3 populations. After 2 weeks in SC, the CFU content of the DN-hTERT-
transduced cells was reduced, while no colonies were observed after 4 weeks in SC. In
contrast, colonies could be observed following SC for up to 6 weeks in the hTERT cells
and up to 4 weeks in the GFP-control cells.
hTERT-transduced AML cells show high engraftment in ß2-m
-/- NOD/SCID mice
Two primary AML samples (105-46 and 108-24) transduced with hTERT, DN-hTERT
and GFP-control vectors were sorted for GFP expression and similar cell numbers were
transplanted into sublethally irradiated ß2-m
-/- NOD/SCID mice in duplicate (Table 2).
BM was aspirated after 4 weeks and analyzed for engraftment of GFP-positive and CD45-
positive cells. In general, higher engraftment levels were obtained using the hTERT-
transduced AML cells compared to GFP-transduced cells, while AML cells transduced
with DN-hTERT engrafted at lower levels compared to the GFP-control (Table 2). After
8 weeks, no human cells were observed in any of the mice except in one animal injected
with hTERT-transduced cells from sample 105-46 (0.5%).
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Figure 5: Effective transduction of primary AML cells. After transduction with
retroviral vectors, AML cells were expanded for 10 days and analyzed for GFP expression. 
(a) GFP expression in AML cells from sample 105-46 transduced with hTERT, DN-
hTERT and GFP. (b) AML samples 105-46 and 114-04 transduced with hTERT, GFP-
control and DN-hTERT (D868A, D869A) were analyzed for telomerase expression by
TRAP assay (2.103 cells). Negative control using DEPC-water and positive control
extracts obtained from the cell line K562 were used.
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Table 2: NOD/SCID assay using two AML samples
Patient Sample Numbers of cells % of CD45 expression at week 4
injected (x105) GFP hTERT DN-hTERT
105-46 50 5.6 11.3 2.6
50 9.6 1.4
36 5.3
108-24 1.5 10.5
1.25 7.4 12 3.6
0.7 2.9 2.6
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Figure 6: DN-hTERT-transduced AML cells show reduced CFU frequencies 4 weeks
after SC. Cells were sorted for GFP expression and a known number of GFP-positive cells
were subjected to primary colony forming unit assays (CFU) (week 0) and suspension
culture assays (SC). Every 2 weeks, half of the cells were plated in methylcellulose and
colonies were counted at day 10 to calculate the progenitor frequency per 105 cells. The
CFU frequency of the AML cells from the five patients in which growth was observed are
shown. The table shows the progenitor frequencies of the primary CFU assay and the
progenitor frequencies after 4 weeks in SC. Cells from one patient (110-36) were
transduced with hTERT in addition to GFP and DN-hTERT. The hTERT-transduced
showed a higher progenitor frequency compared to the GFP-control. 
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  GFP DN-hTERT hTERT GFP DN-hTERT hTERT 
1 DK367 4.8X103 5.2X103 ND 7.3X104 0 ND 
2 110-36 8.3X102 6.7X102 8.8X102 6.5X102 0 2.5X103 
3 VW372 1.9X103 2.4X103 ND 6.4X102 0 ND 
4 BC212 4.4X103 3.8X102 ND 1.3X103 6.5X102 ND 
5 NV253 3.0X103 2.8X103 ND 4.4X103 4.9X103 ND 
6 GHN323 1.9X102 3.0X102 ND 0 0 ND 
7 IT369 4.5X103 1.3X104 ND 0 0 ND 
Mean  2.8X103 4.0X103 8.8X102 1.1X104 7.9X102 2.5X103 
SD  1.9X104 4.3X103  2.7X104 1.8X103  
93T E L O M E R A S E I S L I M I T I N G T H E G R O W T H O F A C U T E M Y E L O I D L E U K E M I A C E L L S
Chapter 4
Discussion
Activation or upregulation of telomerase is believed to play an important step in the
progression of most human malignancies.41 To study the effect and significance of
telomerase activity in AML, we disrupted and overexpressed telomerase activity in the
human leukemia cell line K562 as well as in various primary leukemia samples from
different patients using retroviral vectors encoding hTERT, DN-hTERT (D868A,
D869A) or GFP genes. 
While telomerase levels in K562 and primary leukemia cells transduced with DN-hTERT
were reduced, no direct obvious effect on the proliferation of these cells was observed.
However, delayed effects were observed that appeared to be triggered by telomere
dysfunction as cells exhibited anaphase bridges, apoptotic cell death and a reduced colony
forming ability several weeks after transfection and expansion.31 The effect was specific to
the inhibition of telomerase activity as the overexpression of wild-type hTERT, which
differs from the mutant DN-hTERT (D868A, D869A) by two amino acids, did not affect
viability or proliferation. In contrast, we observed an increase in the CFU content in
hTERT-transduced AML cells as well as a higher engraftment into sublethally irradiated
ß2-m
-/- NOD/SCID mice. Our results support the idea that telomerase activity is required
for telomere maintenance and proliferation in leukemic cells.42
Interestingly, two of four K562 clones transduced with the DN-hTERT developed
resistance to the effect of the DN-hTERT expression. One clone remained GFP-positive
with a very low level of GFP expression, indicative of a very low expression of the
transgene. Another clone completely lost GFP expression, possibly through gene silencing
or loss of the transgene. These results suggest that inhibition of telomerase acts as strong
selective disadvantage for telomerase positive malignant cells. In view of the difficulty to
completely inhibit telomerase activity using DN-hTERT and retroviral transduction
strategies, our results may have underestimated the effect of telomerase inhibitors. More
effective telomerase inhibition most likely will result in increased genomic instability due
to telomere dysfunction and may possibly favor selection of cells that can bypass the effect
of telomerase inhibition.43
The transfection of primary AML progenitor cells with retroviral vectors has been
problematic.44,45 This is the first report of effective transfection of AML progenitor cells
with retroviral vectors for hTERT and DN-hTERT (D868A, D869A). The protocol
described in this study may find application to genetically mark AML cells and to modify
leukemia cells to test novel therapeutic approaches and generate tumor vaccines.44-49
Further improvements in transfection efficiency could probably be obtained by targeting
noncycling cell populations using lentiviral vectors.50
Our results support the notion that telomerase activity in AML is associated with disease
progression and that high levels of telomerase activity indicate a poor prognosis.19,20,51-53
As telomerase activity appears largely restricted to malignant cells, telomerase activity
measurements may help with the prognosis and the evaluation of antileukemic treatments
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and disease progression. The value of telomerase inhibition in leukemia treatment needs to
be established in clinical trials in combination with standard antileukemic agents.42,54,55
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Constitutively Active Notch4 Promotes
Early Human Hematopoietic Progenitor
Cell Maintenance While Inhibiting
Differentiation and Causes Lymphoid
Abnormalities in Vivo
Suzanne M. Vercauteren and Heather J. Sutherland
Abstract
Notch transmembrane receptors are known to play a critical role in cell fate decisions in
multiple tissues including the hematopoietic system. Notch4 is structurally distinct from
Notch1-3 and has not been extensively studied in hematopoiesis. By PCR we find Notch4
expression in human marrow cells and in CD34+ and CD34- populations. When the
constitutively active intracellular domain (IC) of Notch1 or 4 was overexpressed in normal
human marrow or cord cells, we found a reduced colony forming and short-term
proliferative ability. The primitive progenitor content of stromal based myeloid long-term
cultures was significantly increased. Notch4-IC/green fluorescence protein (GFP)
transduced cord cells transplanted into ß2-microglobulin deficient NOD/SCID mice
resulted in significantly higher levels of engraftment of both GFP+ and GFP- populations
as compared to controls. GFP+ cells in bone marrow and spleen of transplanted animals
gave rise to an immature T cell population, while B cell development was blocked. These
results indicate that activation of Notch4 results in enhanced stem cell maintenance, a
block in monocytic and erythroid differentiation and the adoption of a T cell fate by the
common lymphoid progenitor.
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Introduction
The highly conserved Notch gene family plays an important role in cell fate decisions in a
wide range of lineages in invertebrates and vertebrates.1,2 In mammals four Notch
receptors have been identified (Notch1-4) and five ligands Jagged1, Jagged2, and Delta1,
3 or 4. Notch activation in mammals occurs through binding to one of its ligands, which
results in the translocation of the intracellular domain (IC) to the nucleus.3,4 Notch
receptors have an extracellular domain, containing tandem epidermal growth factor
(EGF) repeats and 3 Notch repeats, a single transmembrane domain and an IC, containing
6 cdc10/ankyrin repeats, putative nuclear localization signals and a C-terminal OPA/EST
region.1 Although the four Notch receptors are similar in structure, Notch4 appears to be
evolutionary the most distant from other Notch members with fewer EGF repeats, a
significantly shorter IC, no transactivating domain and no cytokine responsive elements.5
Notch4 also differs from the other Notch receptors by its expression pattern in the mouse,
which is strongest in endothelial cells and male germ cells.6 Notch4 has known effects on
embryonic endothelial development7 and active forms of Notch4 inhibit angiogenesis.8
Furthermore, the constitutively active IC of Notch4 (Int-3) has oncogenic activity in the
mouse mammary gland9 and is detected in human breast, lung and colon carcinoma cell
lines.10
The hematopoietic system is a complex and tightly regulated process in which pluripotent
stem cells undergo proliferation and differentiation to produce mature blood cells of the
various lineages, while maintaining a compartment of uncommitted cells. A role for Notch
receptors in hematopoiesis was first proposed after a translocation in human T cell
leukemia was identified involving the Notch1 gene.11 Overexpression of the IC of Notch1
in murine bone marrow resulted in T cell leukemia and thymoma in mice receiving
transduced marrow.12 Furthermore, Notch1-IC overexpression has been shown to induce
thymic-independent accumulation of double-positive (DP) T cells at the expense of B cells
in the marrow of mice, suggesting that Notch1 signalling could favor the T cell fate in a
common lymphoid precursor.13 Activated forms of Notch2 and Notch3 have been
implicated in thymic lymphoma,14-16 while a role in T cell leukemia has not been reported
so far. Notch signalling also plays a role in the maintenance of hematopoietic stem cells17-
21 and in the inhibition of differentiation.22-24 The role of Notch4 in the hematopoietic
system has not been studied. However, Notch4 has GATA recognition sites, transcription
factors which play a role in lineage commitment in hematopoiesis,25,26 in its promoter
region suggesting that Notch4 transcription plays a role in hematopoiesis just like Notch1,
2 and 3.5 Furthermore, Singh et al. detected Notch4 expression in maturing macrophages
using single cell PCR.27
To study the role of Notch4 in hematopoiesis we determined expression of Notch4 in bone
marrow cells and expressed the constitutively active form of Notch4 in human cord and
marrow cells and compared it to Notch1-IC overexpression. Our studies indicate that
Notch4 is expressed in normal marrow as well as in its CD34+ and CD34- populations. In
addition, Notch1-IC and Notch4–IC overexpression results in an inhibition of short-term
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proliferation, with a decrease in monocytic and erythroid differentiation, but an increased
long-term proliferative ability. Furthermore, transplantation of Notch4-IC transduced
cord cells results in higher levels of human engraftment in the bone marrow. and the
development of immature T cells in the bone marrow of immunodeficient mice. These
results suggest, that Notch4 activation in primary human hematopoietic cells is similar to
Notch1 activation in that it results in a decrease of differentiation into some of the mature
blood cells. Furthermore, as is seen with Notch1 activation, the common lymphoid
progenitor may adapt a T cell fate instead of a B cell fate when Notch4 is overexpressed in
human cord cells. 
Materials and Methods
Virus production 
The cDNA of the intracellular domain (IC) of Notch1 (kindly provided by S. Artavanis-
Tsakonas) and HA-tagged Notch4-IC (kindly provided by L. Li)5 were cloned into a
MSCV-IRES-GFP vector (MIG, from R.K. Humphries) to generate MSCV-Notch1-IC-
IRES-GFP and MSCV-Notch4-IC-IRES-GFP vectors. Helper-free virus was obtained
by transfecting amphotrophic Phoenix packaging cells28 cultured in DMEM plus 10% fetal
calf serum (FCS, StemCell Technologies, Vancouver, BC) using CaPO4 and harvesting the
virus-containing medium (CM) 24 hours later as described.29 Virus-CM was filtered
through a 0.45 µm filter and used freshly each time. 
Cells 
Bone marrow cells from normal healthy donors were obtained after informed consent and
with approval of the Clinical Research Ethics Board of the University of British Columbia.
Low-density (<1.077 g/ml) cells were isolated by centrifugation on Ficoll-Hypaque
(Amersham Pharmacia) and fractionated directly, or later, after being cryopreserved in
10% DMSO plus 90% FCS. Cord blood cells were obtained with informed consent from
the mothers undergoing caesarean delivery of normal full-term infants and low density
(<1.077 g/ml) cells isolated using Ficoll-hypaque (Pharmacia, Piscataway, NJ). Primary
lineage (CD2, CD3, CD14, CD16, CD19, CD24, CD56, CD66b, glycophorin A) depleted
cord cells, which are highly enriched for CD34+ cells (~70%), were obtained using
StemSep™ columns (StemCell Technologies).
Retroviral Transduction 
Cells to be transduced were first cultured at 1-2x105 cells/mL for 48 hours in complete
serum free medium consisting of Iscove’s medium supplemented with BSA, Insulin and
Transferrin (BIT‘, StemCell Technologies), 40 µg/ml low density lipoproteins and 10-4 M
2-mercapto-ethanol (both from Sigma Chemicals, St. Louis, MO) to which the following
5 purified recombinant human growth factors (GFs) were added: Flt-3 ligand (FL, 100
104N O R M A L A N D L E U K E M I C H E M A T O P O I E S I S
Chapter 5
ng/mL, Immunex Corporation, Seatlle, WA), Steel Factor (SF, 100 ng/mL, produced in the
Terry Fox Laboratory), interleukin-3 (IL-3, 20 ng/mL, Novartis, Basel, Switserland),
interleukin-6 (IL-6, 20 ng/mL, Cangene, Mississauga, ON), and granulocyte colony-
stimulating factor (G-CSF, 20 ng/mL, StemCell Technologies Inc.) as previously
described.30 At the end of this 2 day pre-stimulation period, the cells were resuspended in
filtered virus-CM supplemented with the same 5 GFs. Protamine sulfate (5 mg/mL, Sigma)
was added and the cells were placed in fibronectin coated petri dishes previously loaded
twice with virus-CM (30 minutes each). After 12 hours the cells were harvested and
resuspended in fresh virus-CM containing the 5 GFs and protamine sulfate. This infection
procedure was performed 3 times. After 36 hours the cells were transferred to fresh serum
free media. Cells for in vivo studies were used at this time-point, while cells for in vitro studies
were incubated for a further 48 hours prior to harvesting and further analysis. Expression
of the Notch4-IC construct was confirmed in 3 cord samples with real-time PCR with
primers to the IC of Notch4. Notch4-IC expression was about 1000x higher in the Notch4-
IC transduced cord cells than in the MIG transduced cord cells in all 3 samples.
Flow Cytometry 
Viable GFP+ cord or normal marrow cells (PI-) were isolated at a purity of >99% using a
three laser FACStarplus (Becton Dickinson, San Jose, CA) as described previously.31
Cells were sorted into serum free media in microcentrifuge tubes at 4oC and known cell
numbers were used to initiate colony forming assays (CFU), suspension culture (SC)
assays and long term cultures. For the phenotype analyses, cells were stained with anti-
CD34 (8G12)-Cy5 (Dr. P. Lansdorp), anti-Glycophorin-A(10F7)-PE, anti-CD71 (OKT-
9)-PE (both from Dr. P. Lansdorp), anti-CD41a-PE (Pharmingen, Mississauga, ON),
anti-CD38-PE, anti-CD13-PE, anti-CD33-PE, anti-CD11b-PE, anti-CD20-PE or anti-
CD3-PE  (all from Becton Dickinson). Cells were then analyzed on a FACScalibur using
Cell Quest software (Becton Dickinson) with gates set to exclude ≥ 99.9% of the cells in
the matched isotype control.
RT-PCR Analyses 
cDNA from 2 human marrow samples and FACSsorted CD34+ cells or CD34-
subpopulations was kindly provided by Dr. C. Eaves. Aliquots of 1-5 µl of the first round
of PCR generated from the initial amplification of total cDNA were subjected to a second
round of PCR amplification in 50 µl volumes of 1xPfx amplification buffer
(GIBCO/BRL), 0.3 mM each dNTP (Amersham Pharmacia), 1mM MgSO4, 1 unit of
Platinum Pfx DNA polymerase, and 10 pmol of specific primers for the extracellular
domain of Notch4 (5'-TAGGGCTCCCCAGCTCTC-3' and 5'-GGCAGGTGCCCCCATT-3')
to give a DNA fragment of 486 bp. The primers started in different exons, to make sure
that genomic DNA contamination did not interfere with the results. As a positive control
cDNA of Human Aortic Endothelial Cells (kindly provided by Dr. A. Karsan), known to
express human Notch4, was used. Forty cycles (94°C for 30 sec, 60°C for 1 min, 72°C for
30 sec) were then performed.
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Real-Time PCR
Primers for Notch1, Notch2, Notch3, Notch4 and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) specific amplification were designed using the Primer Express
software (PE Applied Biosystems, Fostercity, CA, USA). For Notch1 the sense primer
CGGGTCCACCAGTTTGAATG and anti-sense primer GTTGTATTGGTTCGGCACCAT
were used, for Notch2 sense primer TTTGGCAACTAACGTAGAAACTCAAC and
anti-sense primer TGCCAAGAGCATGAATACAGAGA, for Notch3 the sense
primer ATGCAGGATAGCAAGGAGGA and the anti-sense primer
AAGTGGTCCAACAGCAGCTT, for Notch4 the sense primer
CCCAGGAATCTGAGATGGAA and anti-sense primer CCACAGCAAACTGCTGACAT
and for GAPDH the sense primer CGACAGTCAGCCGCATCTT and the anti-sense primer
ACCTTCCCCATGGTGTCTCA were used. One step Real-Time PCR was performed using
the GeneAmp 5700 Sequence Detection System Mix (PE Applied Biosystems). Reactions
were performed in triplet in a 50 µl total volume containing 25 µl SYBR Green Master Mix
(PE Applied Biosystems), 1-10 ng cDNA, sense and anti-sense primers and ddH20. The primer
concentrations used were the minimum primer concentrations giving the lowest threshold cycle
(Ct) and maximum ∆Rn, while minimizing non specific amplification. The optimal
concentration for both the sense and anti-sense primer for Notch1 and Notch2 was 100nM and
for Notch3, Notch4 and GAPDH was 300nM in a 50 µl reaction. Dissociation curves were run
to detect non-specific amplification, however in none of the experiments non-specific
amplification was observed. To relatively quantitate Notch expression the ∆∆Ct method was
performed as described in User Bulletin #2: ABI PRISM 7700 Sequence Detection System.
Cultures 
A known number of transduced cord cells (5-10x104) were cultured in complete serum free
media with the same 5 growth factors described above and maintained at 37oC in a 5% CO2
humidified incubator and cell counts were performed at day 3, 7, 14 and 21 using trypan blue
staining. At day 7 and 21 cells were also harvested for FACS analyses. To detect long-term-
culture-initiating-cells (LTC-IC) 1x105 transduced cord cells were placed in 2.7 mL Myelocult
media (StemCell Technologies) with 10-6 M Solucortef and seeded onto a confluent layer of
irradiated (80 cGy) mouse embryonic fibroblasts engineered to produce human SF, human
IL-3 and human G-CSF).32 Cultures were incubated at 37oC in a 5% CO2 humidified
incubator and received a weekly half-media change. After 5 weeks both the adherent and the
non-adherent cells were harvested, pooled, counted and plated into methylcellulose-based
medium (StemCell Technologies Inc.) supplemented with 20 ng/ml rhIL-3 (Sandoz), 20 ng/ml
rhIL-6 (Terry Fox Laboratory), 20 ng/ml rhG-CSF (Amgen Canada Inc., Mississauga,
Ontario), 20 ng/ml rhGM-CSF (Sandoz), 50 ng/ml rhSteel Factor (SF) (Terry Fox
Laboratory) and 3 units/ml erythropoietin (StemCell Technologies Inc.). Colonies were
counted after 21 days of culture. To detect primary colony forming cells 500 transduced cord
or marrow cells were plated in serum free media-containing methylcellulose cultures
(StemCell Technologies) with human SF (50 ng/mL) and 20 ng/mL of each IL-3, IL-6, G-
CSF and GM-CSF. After 10 days colonies were counted. 
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Transplantation of Notch transduced Cord Blood cells into in ß2-microglobulin
-/- NOD/SCID mice
ß2-microglobulin deficient nonobese diabetic/severe combined immunodeficient (ß2-
microglobulin-/- NOD/SCID) mice (Jackson Laboratory, Bar Harbour, ME) were bred
and maintained in the animal facility of the British Columbia Cancer Research Centre
(Vancouver, Canada) under sterile conditions in sterile micro-isolator cages. The animals
were provided exclusively with autoclaved food and water containing 100 mg/l
ciprofloxacin and HCl. Twenty-four hours prior to transplantation, mice were irradiated
with 3.5 Gy γ-irradiation from a 137Cs source at a dose rate of 1.22 cGy/min. A known
number of unsorted cord cells transduced with MIG or MIG-Notch4-IC were
resuspended in 0.3 ml Alpha minimal essential medium (Alpha MEM)(StemCell
Technologies Inc.) with 5% FCS and injected intravenously into the lateral tail vein of 6-8
week old ß2-microglobulin
-/- NOD/SCID. BM aspirations were performed every 4 weeks
on anaesthetized mice. Twelve weeks post-injection the mice were sacrificed by CO2
inhalation. BM was removed from the femurs by flushing with Alpha MEM with 5% FCS.
Spleens and thymus were removed and single cell suspensions were made for FACS
analysis.
Flow Cytometry analysis of murine tissues
Cell suspensions from femoral BM and spleens were lysed in ammonium chloride
(StemCell Technologies Inc.) for 20 min and then washed in Hanks medium (StemCell
Technologies Inc.) with 5% human serum for blocking of human Fc receptors and
prepared for flow cytometric analysis. Thymus cells were also incubated with 5% human
serum in Hanks medium. Cells were then stained with a Cy5-labeled anti-human CD45
antibody (Dr. P. Lansdorp, Terry Fox Laboratory) in combination with CD71-PE, CD34-
PE, CD33-PE, GlycophorinA-PE, CD41a, CD11b-PE, CD20-PE, CD3-PE, CD4-PE or
CD8-PE for 30 min on ice. Unstained cells were used as control. Samples were analyzed
using a FACScan (Becton Dickinson), gate settings which excluded ≥ 99.9% of the cells
in the unstained control, were used to determine the lineage markers on CD45+/GFP+
cells in each sample. We defined human engraftment as expression of ≥ 0.1% CD45+ cells
in a sample.
Statistical analysis
Results are shown as the mean ± SD of values obtained in independent experiments.
Differences between groups were assessed using the 2-tailed Student’s t-test. For the in vivo
data a paired t-test was performed with the mean values of the marrow aspirations at week
9 and 12. A significant level of 0.05 was chosen.
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Results
Notch4 is expressed in human marrow cells with highest levels in primitive progenitors
To investigate the expression of Notch4 in human hematopoietic cells, cDNA from low
density human marrow cells and the primitive progenitor population selected by
FACSsorting based on the CD34 expression was subjected to RT-PCR. As shown in
Figure 1, Notch4 expression was readily detectable in total marrow and in both the CD34+
cells and the CD34- subpopulations of two marrow samples. In order to quantify
expression in subpopulations of the most primitive progenitors (CD34+/CD38-), more
mature progenitors (CD34+/CD38+) and non-progenitor marrow (CD34-), real-time
PCR on cDNA extracted from FACSsorted populations from marrows was performed.
Notch1 and 4 expression was significantly higher in the most primitive CD34+CD38-
populations as compared to unsorted cells (Figure 2A) with the same trend observed for
Notch2 and 3. Notch1 expression levels varied between unsorted marrows approximately
4 fold (range 0.34-1.42) as compared to an unsorted bone marrow sample 1. When the
expression of Notch2, 3 and 4 were compared to Notch1 expression using the ∆∆Ct
analysis in 5 unsorted bone marrow samples, Notch2 was expressed at 1.8±1.0x Notch1,
Notch3 was expressed at 0.5±0.9x Notch1 and Notch4 was expressed at 0.3±0.5x Notch1
on average. In the CD34+CD38- progenitor population Notch4 expression was 1.4±1.7x
Notch1, while Notch3 and Notch4 had a lower expression.
Constitutively active Notch1 or 4 decreases myeloid colony formation and short-term in vitro
proliferation
To examine the effect of constitutively active Notch1 and 4 on human myeloid
differentiation, human marrow and lineage depleted cord blood (cord) cells were
transduced with Notch1-IC or Notch4-IC in the MIG vector or control MIG. In four
experiments the mean marrow transduction efficiency was 11.1 ± 8.9% for MIG 0.3 ± 0.3%
for Notch1-IC and 5.0 ± 3.3% for Notch4-IC as measured by GFP positivity on FACS two
days after transduction. The mean transduction efficiency in cord blood experiments was
27.5 ± 12.5% for MIG (n=10), 7.8 ± 2.1% for Notch1-IC (n=9) and 18.3 ± 9.3% for
Notch4-IC (n=10). For both cord and normal marrow cells, GFP+ cells were sorted and
used to initiate primary colony assays. Total myeloid colony forming cells were markedly
(3-10 fold) and significantly reduced in the Notch1-IC and Notch4-IC transduced cultures
as compared to control (Figure 3). Interestingly, although BFU-E were observed with
MIG control transduced marrow, these colonies were not observed using Notch1-IC or
Notch4-IC transduced marrow cells (Figure 3a). Using cord cells erythroid colonies were
also significantly reduced in the Notch4-IC transduced cultures (p=0.001) (Figure 3b).
Using marrow cells a significantly lower number of granulocyte-macrophage colonies were
seen with the Notch4-IC as compared to the MIG control (Figure 3b). However this effect
was not significant when cord blood cells were assessed. 
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Figure 1: Notch4 expression in human marrow samples as detected by RT-PCR. cDNA
of a positive control and two human marrow samples and their CD34+ and CD34-
subpopulations were subjected to RT-PCR. In all 7 samples Notch4 was readily detectable.
1= human aortic endothelial cell line; 2 = normal marrow sample 1; 3 = CD34+ cells of
marrow sample 1; 4 = CD34- cells of marrow sample 1; 5 = normal marrow sample 2; 6 =
CD34+ cells of marrow sample 2; 7 = CD34- cells of marrow sample 2.
Transduced cord blood cells sorted for GFP+ were also used to initiate suspension cultures
(SC) in serum free media with growth factors as described. GFP expression in GFP sorted
cultures after 1 and 3 weeks was 47 ± 33% and 19 ± 11% respectively (n=7) for Notch1-
IC, 42 ± 30% and 27±18% respectively for Notch4-IC (n=10) and 75 ± 23% and 68 ± 12%
respectively for MIG control cultures. GFP expression in the Notch1-IC and Notch4-IC
cultures was significantly reduced as compared to the MIG control (p≤ 0.01 in all cases).
Cell numbers at day 3 were 2-4 fold lower in the Notch1-IC and Notch4-IC transduced
cord cultures compared to the control (p < 0.001 and p=0.003 resp.) and remained reduced
at day 7 (p=0.1 and p=0.05), day 14 (p=0.03 and p=0.02) and day 21 (p=0.05 and p=0.003). 
The phenotype of the cells present was analyzed at week 1 and 3 (Table 1). Total GFP+
cells from progenitor (CD34+), erythroid (GlycophorinA+), myelomonocytic (CD33+,
CD13+ and CD11b+) and megakaryocytic (CD41a+) lineages were all reduced in the
Notch1-IC and Notch4-IC cultures as compared to the MIG control with the exception of
megakaryocytic lineage cells, which were unchanged by Notch1-IC. Glycophorin A+ cells
were reduced more profoundly than the others (18-37 fold). However, due to
heterogeneity of Glycophorin A expression in the MIG control this only reached
significance in the Notch4-IC transduced cultures at week 1. These results suggest, that
transduction with Notch1-IC and Notch4-IC results in inhibition myeloid differentiation
when cultured with myeloid promoting growth factors.
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Figure 2: Relative Notch expression in human marrow samples and human
hematopoietic progenitors as measured by real-time PCR. cDNA of unsorted marrow
and marrow sorted for CD34 and CD38 were used for real-time PCR using Notch primers
and SybrGreen. Notch expression in the sorted subpopulations was compared to its
unsorted population and relative expression of Notch1-4 in the progenitors expressed. The
expression of the sorted population was compared to the unsorted population in a paired
t-test. Notch1 black bars; Notch2 white bars; Notch3 shaded bars; Notch4 dotted bars. *
p≤ 0.05
Notch1 or Notch4 activation results in an increase in long-term culture initiating cells in vitro
To determine whether the long-term proliferative ability of cord cells was also altered by
the overexpression of Notch1-IC or Notch4-IC, a known number of GFP+ cord cells were
maintained in stromal based long-term cultures for 5 weeks as described and then
subcultured in semisolid medium for colony counts. As shown in Table 2, a significant
increase in colonies derived from long term cultures initiated with Notch1-IC (p=0.04 and
n=5) and Notch4-IC (p=0.04 and n=5) transduced cord cells as compared to the control
was observed. There was no difference in phenotype of the colonies between the control
and the Notch-IC transduced cells in that all cultures produced similar proportions of
mixed granulocytic-erythroid colonies, granulocyte-macrophage colonies and erythroid
colonies with similar morphology. This suggests that although Notch1 or 4 overexpression
results in inhibition short-term proliferation it increases long-term proliferation of cord
blood cells.
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Figure 3: Decreased colony-forming ability of Notch1-IC and Notch4-IC transduced
normal marrow and cord cells compared to MIG transduced cord blood cells. Normal
marrow cells (A) (Notch1-IC n=3, Notch4-IC n=4) and cord blood (B) (Notch1-IC n=4,
Notch4-IC n=5) were retrovirally transduced with MIG, Notch1-IC and Notch4-IC and
sorted for GFP. Cultures were initiated with 1000 normal marrow cells (A) or 500 cord
blood cells (B) into methylcellulose in the presence of IL-3, IL-6, G-CSF, GM-CSF and
Steel Factor (SF) and colonies were counted 10 days after initiation. A paired t-test was
performed to determine statistical differences between colony numbers in Notch1-IC,
Notch4-IC and MIG. Erythroid colonies black bars; granulocyte-monocytic colonies
dotted bars; total colonies shaded bars. * p≤ 0.05
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Table 1: Cell surface marker expression on cultured lineage depleted cord blood cells transduced with
MIG, Notch1-IC or Notch4-IC.
A)
Week 1 MIG Notch1-IC Fold MIG Notch4-IC Fold
GFP+ cells (x104) (x104) ∆ (x104) (x104) ∆
CD34+ 2.6±2.5 0.6±0.3 4 1.6±1.8 0.5±0.6 3
GlycophorinA+ 9.4±12.3 0.4±0.6 24 11.2±11.5 0.3±0.4* 37
CD33+ 70.9±28.6 38.5±29.6 2 134±152 24.6±18.9 5
CD13+- 81.5±37.1 38.1±29.0 2 154±150 28.1±21.7 5
CD41a+ 2.6±2.3 3.0±3.8 1 6.2±10.7 1.8±1.7 3
CD11b+ 56.2±29.8 7.1±8.9* 8 72.1±59.2 7.6±9.7* 9
Total 223.2 87.7 379.1 62.9
B)
Week3 MIG Notch1-IC Fold MIG Notch4-IC Fold
GFP+ cells (x104) (x104) ∆ (x104) (x104) ∆
CD34+ 13.9±6.6 1.7±1.3* 8 8.9±8.7 2.1±1.1 4
GlycophorinA+ 3.8±7.6 0.2±0.2 19 1.8±3.1 0.1±0.1 18
CD33+ 513±380 28.5±16.7* 18 503±105 77.2±64.8* 7
CD13+- 484±247 34.9±20.3* 14 486±72.1 83.5±85.0* 6
CD41a+ 4.8±5.0 4.1±3.8 1 7.5±12.5 1.6±1.5 5
CD11b+ 360±202 21.1±13.9* 17 295±90.1 35.5±15.7* 8
Total 1380 90.5 1302 200.0
Table 1: Cell surface marker expression on cultured lineage depleted cord blood cells
transduced with MIG, Notch1-IC or Notch4-IC. Lineage depleted cord cells were
transduced with MIG, Notch1-IC (n=7) or Notch4-IC (n=10). Cells were sorted for GFP+
and placed in suspension culture. After 1(A) and 3(B) weeks in culture cells were stained
with monoclonal antibodies against CD34, Glycophorin A, CD33, CD13, CD41a and
CD11b and the numbers of GFP positive cells per 105 input cells expressing the markers
calculated from cell counts and analysis with FACS.
* p<0.05
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Cord cells overexpressing the intracellular domain of Notch4 give rise to a CD4+CD8+ population in
the bone marrow and spleen of ß2-microglobulin
-/- NOD/SCID mice
To assess the effect of Notch4 overexpression in lineage depleted cord cells in vivo, cord
cells were retrovirally transduced with MIG or Notch4-IC for 36 hours. The average
transduction efficiency of the four cord samples used in these experiments was 22.6 ± 13.4%
for MIG and 15.3 ± 10.7% for Notch4-IC. Unsorted transduced cord cells (1.5x105 - 1x106
cells/mouse with 3 mice in each group) were harvested and injected into the tail vein of sub-
lethally irradiated ß2-microglobulin
-/- NOD/SCID mice and the bone marrow evaluated for
engraftment (CD45+ cells) at week 6, 9 and 12 and spleen and thymus evaluated at week
12. The mean level of marrow engraftment in the 4 experiments was significantly higher in
the mice injected with Notch4-IC transduced cord blood cells as compared to the control at
week 6 and week 9 in both the GFP+ and the GFP- population (Figure 4). Cells from week
9 and 12 mouse marrow were co-stained with CD45 and the lineage markers CD71, CD34,
CD33, GlycophorinA, CD41a, CD11b, CD20, CD3, CD4 and CD8. CD34+ cells were
more frequent in the GFP+CD45+ population of the Notch4-IC mice as compared to the
control (14 ± 18% versus 1 ± 3% p=0.05 at week 9 and 12). CD33 expression on
GFP+CD45+ cells of Notch4-IC mice was lower compared to the control mice (5 ± 13% in
Notch4-IC mice versus 44 ± 45% in MIG mice p=0.05). CD11b expression was only
analyzed at week 12 and the expression of this marker on GFP+CD45+ cells of Notch4-IC
mice was significantly lower compared to the control (10 ± 9% versus 37± 24% resp.
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Table 2: Colony numbers from week 5 LTC of 1x105 of Notch1-IC, Notch4-IC and MIG transduced
cord cells
MIG Notch1-IC MIG Notch4-IC
Cord 1 250 450 Cord 6 114 245
Cord 2 200 820 Cord 7 430 1140
Cord 3 1730 2930 Cord 8 910 1290
Cord 4 535 600 Cord 4 535 700
Cord 5 863 1730
Mean ± SD 716±626 1318±1025* Mean ± SD 522±290 847±408*
Table 2: Colony numbers from week 5 LTC of 1x105 of Notch1-IC, Notch4-IC and
MIG transduced cord cells. Lineage depleted cord cells were retrovirally transduced with
MIG (n=9), Notch1-IC (n=5) and Notch4-IC (n=4) and sorted for GFP. 1x105 GFP+ cord
cells were put into long-term cultures. Cultures were maintained at 37oC in humidified
incubators and had weekly media changes with long-term culture media. After 5 weeks
cultures were trypsinized and cells were plated into methylcellulose in the presence of IL-
3, IL-6, G-CSF, GM-CSF, Steel Factor and erythropoietin and colonies were counted 20
days after plating. * p≤ 0.05
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p=0.05). Mice injected with Notch4-IC transduced cord cells had an increased GFP+CD3+
population with 50 ± 20% of GFP+ cells expressing CD3+ in the Notch4-IC mice as
compared to 8 ± 21% in the MIG mice (p<0.01) at week 9 and 12 combined. Cells were
stained for CD4 and CD8 and analysis revealed a CD4+CD8+ population in the bone
marrow of mice injected with Notch4-IC transduced cord cells (27 ± 21% of GFP+CD45+
cells), which was not seen in the mice injected with MIG transduced cord cells (0 ± 0% of
GFP+CD45+ p<0.01) (Figure 5). When cells were stained for CD20 a slightly lower
percentage of GFP+CD45+ cells from the bone marrow Notch4-IC mice (6 ± 11%) were
positive for CD20 as compared to the control (22± 19% resp. p=0.13).
Figure 4: Increased engraftment of Notch4-IC transduced cord cells compared to MIG
transduced cord cells in ß2-microglobulin
-/- NOD/SCID mice. Lineage depleted cord
cells were retrovirally transduced with MIG and Notch4-IC (n=4) and injected in
sublethally irradiated ß2-microglobulin
-/- NOD/SCID mice. Every 3 weeks bone marrow
aspirations were performed and cells were stained with CD45-Cy5. Cells were analyzed by
FACS to determine human engraftment. CD45+GFP+ cells black bars; CD45+GFP- cells
dotted bars; Total CD45+ cells shaded bars. * p≤ 0.05
In the spleens the average engraftment in the Notch4-IC mice was 10.2 ± 18.2% compared
to 3.1 ± 5% in the MIG mice. GFP+ cells were observed in the spleens of the mice in only
2 of the 4 experiments. In those 2 experiments GFP+ cells in the MIG mice contributed to
the CD20+ B cell population (63 ± 24% of GFP+CD45+ cells), while GFP+ cells in the
Notch4-IC mice did not (0.1±0.1% cells of GFP+CD45+). Moreover, in 4/6 Notch4-IC mice
GFP+ cells gave rise to a GFP+CD3+ population (1.1±1.3% of CD45+ cells), which was
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primarily CD4+CD8+ (0.8±0.3% of CD45+ cells). No GFP+CD3+ population in the
spleens of the MIG mice was observed. In the four experiments no human engraftment was
observed in the thymus of the sacrificed animals. However, in an earlier individual
experiment prior to deciding on our techniques, in which we cultured the transduced cord
cells for three days before injecting them in the mice, engraftment was seen. High levels of
engraftment (CD45+ cells) were observed in the thymus of all three Notch4-IC mice (94 ± 3%),
whereas in the three MIG mice engraftment in the thymus was lower (23 ± 37%).
Interestingly, although the majority of CD45+ cells in the thymus of the Notch4-IC mice
were GFP- (98 ± 1%), in the MIG mice a substantial number of CD45+ cells were GFP+
(43 ± 32%). The mean percentage of total CD45+ cells expressing CD3 was 69 ± 6% in the
Notch4-IC mice and 41 ± 36% in the MIG mice. The percentage of CD4+CD8+CD45+ cells
in the thymus of the mice was 92 ± 4% in the Notch4-IC mice and 52 ± 24% in the MIG
mice. We are currently further investigating this finding.
Figure 5: Notch4-IC transduced cord cells give rise to a CD4+CD8+ population in the
bone marrow of ß2-microglobulin
-/-
NOD/SCID mice. Marrow from week 9 and 12 ß2-
microglobulin-/- NOD/SCID mice transplanted with MIG and Notch4-IC (n=4)
transduced cord blood cells was analyzed for phenotype by FACS. Murine marrow cells
were stained with CD4-PE and CD8-APC along with PI. A) marrow from MIG mouse
within viable cells B) marrow from Notch4-IC mouse within viable cells.
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Discussion
Emerging evidence suggests an important role for Notch genes in influencing cell fate
decisions during early hematopoiesis. It is also known that Notch is important during
development, and dysregulated Notch is associated with malignancy. However, with the
availability in mammals of four Notch receptors, five ligands, and numerous co-regulatory
molecules, Notch signalling is complex, and the extent of redundancy which might exist in
Notch functions is unknown. It is known that both Notch1 null mice and Jagged1 null
mice are embryonic lethal,33,34 suggesting non-overlapping functions for Notch genes and
ligands, at least during development. We have evaluated the expression and function of
Notch4 in human hematopoiesis, a molecule previously poorly studied in this setting. 
Here we demonstrate that Notch4, like Notch1, 2 and 3 is expressed in human marrow
cells and like Notch1 has the highest expression in the more primitive CD34+CD38-
sorted cells. Using a quantitative PCR method we find the expression Notch1 and 2
somewhat higher as compared to Notch3 and 4 in unsorted human marrow cells. In order
to evaluate the role that Notch4 could play in the differentiation and maintenance of
primitive progenitor cells we overexpressed constitutively active forms of Notch4 in
human lineage depleted cord cells or bone marrow and functionally and phenotypically
analyzed these cells.
Constitutively active Notch4 produced a marked reduction in primary colony formation
and inhibited short-term in vitro proliferation affecting both the erythroid and the
myelomonocytic lineages. This is consistent with some previous reports, in which an
inhibition of short-term proliferation and colony-forming ability was also observed after
Notch activation through its ligand Jagged1.35,36 Other groups reported an increase in
colony-forming ability upon Jagged stimulation17-19 or overexpression of Notch1-IC. 24
However, in most cases cells were cultured for up to 14 days with Jagged1 before colony
assays were performed. When we cultured Notch1-IC or Notch4-IC transfected cells on
growth factor producing stromal cells in long-term cultures for 5 weeks, before plating
them into semisolid media we also observed an increase in colonies, suggesting that Notch4
or Notch1 signalling results in an increase in more primitive myeloid progenitors. This is
consistent with the higher expression levels of these genes in the CD34+CD38-
populations. In this study the Notch1 and Notch4 induced inhibition of differentiation was
most dramatic in the erythroid lineage cells. Hadland et all. reported an increase in
erythroid colony formation by Notch1-/- embryonic stem cells, suggesting the erythroid
lineage may be differentially more influenced by Notch activity.37 Erythroid differentiation
requires the erythroid cell- and megakaryocyte-specific transcription factor GATA-1, but
this factor does not appear to be regulated by Notch1 nor is the hematopoietic-specific
transcription factor TAL-1.38 One of the downstream effectors could be GATA-2, which is
necessary to keep primitive progenitors in an undifferentiated state. It has been shown that
Notch1 signalling can sustain GATA-2 expression and thereby prevents differentiation.23
Whether Notch4 can also sustain GATA-2 expression has not been studied thus far.
However, other transcription factors could play a role in Notch mediated inhibition of
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erythropoiesis. For example, erythroid Kruppel-like factor (EKLF), which plays a role in
erythroid differentiation, interacts with the corepressors mSin3A and histone deacetylase
HDAC1, proteins which also interact with downstream targets of Notch signalling. 39
When Notch4-IC cord cells were evaluated for their engraftment potential in ß2-
microglobulin-/- NOD/SCID mice, engraftment levels were higher in bone marrow and
spleen as compared to the control cord cells. Increased repopulating ability has been
observed upon overexpression of Notch1-IC in murine cells40,41 as well as upon stimulation
of human cells with Delta1 and Jagged1 ligand,17,20,42 but increased engraftment of human
hematopoietic cells upon overexpression of Notch-IC has not been previously
demonstrated. Engraftment was increased in both the GFP+ and the GFP- population,
suggesting the possibility that Notch signalling might influence the expression levels of
Notch receptor and or ligands on both GFP+ and GFP- cells. A non-cell autonomous effect
of Notch1 has been proposed by Kawamata.43 However, it also may be that the expression
of the Notch4-IC or Notch1-IC gene is differentially downregulated after homing and/or
engraftment. This is suggested by the much lower expression of GFP in Notch1-IC and
Notch4-IC GFP+ sorted cells after 3 weeks in culture (19 ± 11% and 27 ± 18%
respectively) as compared to the GFP expression in MIG control GFP+ sorted cells in
culture (68 ± 12%). Consistent with the higher levels of engraftment we also observed a
higher percentage of CD34+GFP+ cells and a decrease in the percentage of myeloid and
monocytic cells in the marrow of the animals. 
The function of Notch on the myeloid compartment in vivo is still controversial. Both
promotion and inhibition of myeloid differentiation upon Notch signalling has been
suggested.41,43-45 Human cord cells overexpressing the intracellular domain of Notch1, have
limited potential to develop into monocytes in the marrow of NOD/SCID mice.44 This is
consistent with our in vivo data in which we saw a marked reduced CD11b expression on
Notch4-IC transduced cord cells both in vivo and in vitro. This system is not suitable to
analyze the effect of Notch overexpression on erythroid differentiation because erythroid
development does not occur in the mice upon transplantation of human cells. 
Suppression of B cell proliferation and abnormal maturation of T cells have been observed
in mice transplanted with Notch1-IC transduced murine marrow and human cord cells.43
Notch4-IC cord cells like Notch1-IC transduced cord cells can become immature
CD4+CD8+ T cells in marrow and spleen and are unable to differentiate into B cells. We
only found abnormal T cells and inhibited B cell differentiation in the GFP+ population
consistent with results from De Smedt et al. who reported abnormal B and T cell
development in Notch1-IC transduced human cord cells but not in untransduced cells.44
This suggests that the common lymphoid progenitor may adapt a T cell fate instead of a B
cell when Notch4-IC is overexpressed. It is interesting that overexpression of the
downstream effectors of Notch, HES1 and HES5, causes a partial block in B cell
development but no T cell abnormalities were seen, suggesting that other downstream
effectors play a role.45 The thymic engraftment we observed in one experiment after
culturing Notch4-IC cord cells for 3 days before injection into the mice could have been
due to the culture, because Ohishi et al showed that human cord cells cultured with soluble
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Delta1 resulted in high levels of thymic engraftment.42 It is possible that cells
overexpressing Notch4-IC in culture up-regulate other Notch genes or ligands e.g. Delta1.
However, further experiments are needed to elucidate the role of Notch4-IC in thymic
engraftment and the effect of culturing of Notch4-IC transduced cord cells. 
Altogether, our data show that Notch4-IC, like Notch1-IC, plays a role in hematopoiesis
in that it enhances engraftment, maintains stem cells, suppresses B cell development while
inducing abnormal double positive T cells and suppresses myeloid differentiation. This
suggests that Notch4 dysregulation could be involved in lymphohematopoietic
malignancies.
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Chapter 6
Acute Myeloid Leukemia Progenitors
Express Abnormal Levels of Notch
Receptors and Respond Differently to
Jagged1 Stimulation Compared To 
Normal Progenitors
Suzanne M. Vercauteren, Rick Zapf 
and Heather J. Sutherland
Abstract
Members of the Notch gene family are found on primitive hematopoietic progenitors and
play a role in the differentiation and proliferation of hematopoietic cells. This study
examines the expression of the four Notch receptors in AML cell lines and primitive AML
progenitors using quantitative real-time PCR and the proliferative response of AML cells
to stimulation of Jagged1. The expression of the four Notch receptors in AML cell lines
and primary AML cells was heterogeneous compared to normal bone marrow (BM). In
normal BM cells the ratio of Notch1-4 expression in the CD34+CD38- fraction/unsorted
cells was higher compared to the ratio’s of CD34+CD38+ fraction/unsorted cells and the
CD34- fraction/unsorted cells. In AML cells the ratio’s of Notch1 and Noth2 expression
in the three sorted fraction were very similar to each other, suggesting that the usual
upregulation of Notch1 and 2 seen in normal primitive progenitors, with subsequent lower
expression in CD34- cells, is dysregulated during differentiation in AML. The ratio’s of
Notch3 and Notch4 expression in the CD34+CD38- fraction/unsorted cells,
CD34+CD38+ fraction/ unsorted cells and CD34- fraction/unsorted cells in AML cells
was heterogeneous with both extremely high and low expression levels observed. When
normal BM cells and AML cells were cultured for 3 days on S17 or S17+Jagged1 cells and
subsequently analyzed phenotypically and in in vitro assays, we observed an increase in
total CD34+CD38- cells in normal BM but not in AML samples. Furthermore, a
significant increase in primary CFU was observed with normal BM cells pre-stimulated
with Jagged1 compared to control, while this was not observed with AML cells.
Interestingly, long-term culture’s (LTC) on S17 or S17+Jagged1 cells resulted in a
significant decrease in LTC-initiating cell (LTC-IC) content when normal BM cells were
cultured on S17+Jagged1 cells compared to S17 cells, while a significant increase in AML
LTC-IC content was observed on S17+Jagged1 stroma.
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Introduction
In normal hematopoiesis a hierarchical organisation of progenitor cell types is observed.
The phenotype of those different subsets of progenitors has been identified using in vitro
and in vivo functional assays. The long-term culture-initiating cell (LTC-IC) is
preferentially detected in the CD34+CD38- subpopulation,1 whereas the more
differentiated colony-forming cells (CFU) are frequently detected in the CD34+CD38+
subpopulation.2 Normal progenitors capable of repopulating non obese diabetic/severe
combined immunodeficienct (NOD/SCID) mice have been detected in the CD34+CD38-
subpopulation and with a low frequency in the CD34- populations.3-6
Although in acute myeloid leukemia (AML) a deregulation of proliferation and a block in
differentiation is observed, the same hierarchical organisation as in normal hematopoiesis
persists.7-9 Largely, the same phenotype of subpopulations has been observed in AML with
the NOD/SCID leukemia initiating cell and the suspension-culture-initiating cell (SC-IC)
being CD34+CD38-9,10 while the phenotype of CFU’s is more heterogenous.
So far, the mechanisms controlling proliferation and differentiation in normal
hematopoiesis have been poorly understood. However, more and more evidence arises for
a role of the Notch receptor family in controlling cell fate decisions as well as proliferation
in a wide variety of tissues including the hematopoietic system.11 A role for Notch in
hematopoiesis was first proposed after the human homologue of Notch1 was cloned from
T cell acute lymphatic leukemia cells containing a translocation involving the Notch1
gene.12 In mammals, four Notch receptors have been identified (Notch1-4), which are
highly conserved transmembrane glycoprotein receptors.13 The Notch receptors consist of
an extracellular domain, containing a variable number of epidermal growth factor (EGF)-
like repeats and lin-12/Notch repeats, which are involved in ligand binding and Notch
activation, a single transmembrane domain and a intracellular domain.14 The intracellular
domain contains a RAM domain, which binds CSL proteins (CBF1, Su(H), LAG-1),
cdc10/ankyrin repeats, a nuclear localisation signal and a C-terminal OPA/EST region.
Physiological activation of Notch occurs through the binding of Notch to one of its ligands
(Jagged and Delta in mammals). These ligands are members of the DSL (Delta, Serrate,
LAG-2 in non-vertebrates) family. Following activation, Notch is cleaved within the
transmembrane domain, resulting in the translocation of the Notch intracellular domain to
the nucleus where it activates transcription of HES genes via association with the CSL
proteins.15,16 HES genes encode for basic Helix-Loop-Helix (bHLH) proteins, which
function as transcriptional repressors. Notch signalling can also occur via a CBF-1
independent pathway.17,18
Notch1 is expressed on both CD34+Lin- and CD34+Lin+ cells in human BM as well as on
CD34- cells although in reduced levels.19 Furthermore, single cell RT-PCR has revealed a
wide expression of Notch receptors, its ligands and modulators of Notch signalling within
the hematopoietic system.20 We have compared the expression of the four Notch receptors
in human normal BM and its progenitors and found that all four Notch receptors are
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expressed in the hematopoietic system and the expression of the four Notch receptors is
higher in the progenitor cell population compared to more mature populations (Chapter 5). 
Functional studies of Notch1 in normal hematopoiesis have shown that, in general, Notch1
activation by ligand binding or overexpression of a constitutively active form of Notch
results in maintenance of primitive progenitor cells and in some studies even an expansion
of the animal repopulating cells.21-28 Although the role of Notch receptors in lymphoid
development has been well established, 29-31 32,33 the role of Notch in myeloid differentiation
remains controversial. Initial reports suggested that Notch signaling inhibits the
differentiation of the murine myeloblast cell line 32D upon stimulation with G-CSF or
GM-CSF.34,35 In contrast, more recent reports suggest the promotion of differentiation of
the 32D cell line in response to growth factor stimulation upon activation of Notch.36,37
Notch signalling through its ligands also plays a role in monocyte apoptosis and
differentiation.38,39 Overexpression of the intracellular domain of Notch1 in the
erythroleukemia cell line K562 resulted in suppression of erythroid but not of
megakaryocytic differentiation.40 We found that the overexpression of the intracellular
domain of Notch1 or Notch4 resulted in the maintenance of primitive progenitors, with an
inhibition of erythroid, myeloid and monocytic differentiation both in vitro and in vivo
(Chapter 5). It is likely that the Notch family is important in the orderly progression of
normal events in hematopoietic differentiation. Thus, it seemed relevant to investigate how
expression of the four Notch receptors in the development of AML compared with their
normal counterparts. Therefore, we sorted normal and AML cells in the CD34+CD38-,
CD34+CD38+ and the CD34- populations and determined the Notch expression in these
defined populations and in AML cell lines using Real-Time PCR. We observed a relatively
low level of Notch1 and Notch2 expression in the CD34+CD38- population compared to
the CD34- population in the majority of AML patients, while expression of Notch3 and 4
was more heterogeneous in this population. To investigate whether AML and normal BM
cells function differently after ligation with the Jagged1 ligand, AML and normal BM cells
were cultured for 3 days on S17 or S17+Jagged1 stroma cell lines and analyzed for
phenotypic changes using FACS and functional differences by determining the number of
primary CFU and CFU after suspension culture (SC) and long-term culture (LTC). The
total number of CD34+CD38- normal BM cells was expanded at a significant higher level
when cultured on S17+Jagged1 stroma cells compared to S17 cells, while in AML cells the
total number of this phenotypic population decreased with or without Jagged1
stimulation. Primary CFU frequency of normal BM was significantly higher on
S17+Jagged1 stroma compared to S17 while CFU frequency after SC or LTC was lower
compared to S17. In contrast, LTC-IC frequency of AML cells was significantly higher on
S17+Jagged1 cells compared to S17 cells. These results demonstrate a deregulated
expression of the Notch genes in the majority of AML samples and abnormal responses to
Jagged1 stimulation, suggesting a possible role for the Notch regulatory pathway in the
etiology of this disorder.
126N O R M A L A N D L E U K E M I C H E M A T O P O I E S I S
Chapter 6
Materials and Methods
Patient Cells and Cell lines
Bone marrow (BM) cells from normal healthy donors and peripheral blood (PB) cells
from patients at diagnosis of AML were obtained after informed consent and with
approval of the Clinical Research Ethics Board of the University of British Columbia. The
mean number of blasts in the samples was 74 ± 23%. Patients with FAB M3 type were
excluded because of specific characteristics of this subtype of AML. Blood cells were Ficoll
separated to obtain a mononuclear cell population then frozen in Dulbecco’s modified
Eagle’s medium (DMEM) (StemCell Technologies Inc., Vancouver, B.C.) with 50% fetal
calf serum (FCS) (StemCell Technologies Inc.) and 10% dimethylsulphoxide (DMSO)
and stored at -135oC. The cell lines K562 (ATCC Rockville, MD, USA), NB4 and Kasumi-
1 (Quadra Logic Technologies) were cultured in RPMI (StemCell Technologies Inc.) +
10% FCS. KG-1 (ATCC) was cultured in DMEM + 20% FCS, AML193 was maintained
in Iscove’s Modified Eagle’s Medium (StemCell Technologies Inc.) supplemented with 5
µg/ml transferrin + 5 µg/ml insulin + 2 ng/ml GM-CSF and the cell line Mo7e was cultured
in DMEM + 10% FCS + 10% 5637 conditioned medium (Terry Fox Laboratory) + 5 x 10-5 M
ß-mercapto-ethanol (Terry Fox Laboratory) + 5ng/ml rIL-3 (Sandoz, Basel, Switzerland).
The stromal cell lines S17 and S17 expressing human Jagged1 (Dr. Tariq Enver, Institute
of Cancer Research, London, UK) were cultured in α-Minimal Essential Medium
(StemCell Technologies Inc.) + 20% FCS. All cultures were maintained at 37oC in a 5%
CO2 humidified incubator. 
AML Cell Phenotyping and Sorting
Prior to sorting, thawed AML cells were suspended in HFN (Hanks medium with 2%
FCS and 0.1% sodium azide) at 107 cells/ml. Cells were stained for 30 minutes on ice with
monoclonal antibodies CD34-FITC (Dr. Peter Lansdorp, Terry Fox Laboratory) used at
4 µg/ml and CD38-PE (Becton Dickinson, San Jose, California) used according to
manufacturers instruction. Separate aliquots were stained with an irrelevant mouse IgG1-
FITC antibody (Becton Dickinson) and mouse IgG1-PE antibody (Becton Dickinson) as
an isotype control. Cells were then washed twice in HFN at 4oC, propridium iodide (PI)
at 2 µg/ml was added to the cells prior to the second wash, and the cells were maintained
on ice prior to sorting. Cells were analyzed and sorted on a dual laser FACStarplus (Becton
Dickinson) on the basis of fluorescence intensity after gating out non-viable (PI+) cells.
Fractions were sorted into DMEM with 50% FCS in microcentrifuge tubes at 4oC. Sorted
fractions were washed, resuspended and used to extract RNA.
RT-PCR and Real-Time PCR
Total cellular RNA from sorted and unsorted BM cells, sorted and unsorted PB of AML
patients and the AML cell lines was prepared using Trizol reagent (Life Technologies,
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Burlington, Canada). RNA was DNAse I treated to remove any contaminating DNA
following the manufacturer’s instructions (Life Technologies). Synthesis of first-strand
cDNA was carried out as according to manufacturer’s instructions using random primers.
Primers for Notch1, Notch2, Notch3, Notch4 and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) specific amplification were designed using the Primer Express
software (PE Applied Biosystems, Fostercity, CA, USA). For Notch1 the sense primer
CGGGTCCACCAGTTTGAATG and anti-sense primer GTTGTATTGGTTCGGCACCAT
were used, for Notch2 sense primer TTTGGCAACTAACGTAGAAACTCAAC 
and anti-sense primer TGCCAAGAGCATGAATACAGAGA, for Notch3 
the sense primer ATGCAGGATAGCAAGGAGGA and the anti-sense primer
AAGTGGTCCAACAGCAGCTT, for Notch4 the sense primer
CCCAGGAATCTGAGATGGAA and anti-sense primer CCACAGCAAACTGCTGACAT
and for GAPDH the sense primer CGACAGTCAGCCGCATCTT and the anti-sense primer
ACCTTCCCCATGGTGTCTCA were used. One step Real-Time PCR was performed using
the GeneAmp 5700 Sequence Detection System Mix (PE Applied Biosystems). Reactions
were performed in triplet in a 50 µl total volume containing 25 µl SYBR Green Master
Mix (PE Applied Biosystems), 1-10 ng cDNA, sense and anti-sense primers and ddH20.
The primer concentrations used were the minimum primer concentrations giving the
lowest threshold cycle (Ct) and maximum ∆Rn, while minimizing non specific
amplification. The optimal concentration for both the sense and anti-sense primer for
Notch1 and Notch2 was 100nM and for Notch3, Notch4 and GAPDH was 300nM in a
50 µl reaction. Dissociation curves were run to detect non-specific amplification, however
in none of the experiments published here non-specific amplification was observed. To
relatively quantitate Notch expression the ∆∆Ct method was performed as described in
User Bulletin #2: ABI PRISM 7700 Sequence Detection System and relative Notch
expression levels of all samples compared to unsorted cells of normal BM1 were calculated. 
Functional studies of primary AML cells cultured on Jagged1 expressing stromal layers.
S17 cells and S17 cells + Jagged1 were irradiated and plated at 1.5x105 cells in 24 well
plates and maintained overnight. After 16-24 hours, the media was removed and AML
cells or normal BM cells resuspended in serum-free media containing 20 ng/ml rhIL-3
(Sandoz, Basel, Switzerland), 20 ng/ml rhIL-6 (Terry Fox Laboratory), 20 ng/ml rhG-
CSF (Amgen Canada Inc., Mississauga, Ontario), 20 ng/ml rhGM-CSF (Sandoz), 50
ng/ml rhSteel Factor (Terry Fox Laboratory) and 3 units/ml erythropoietin (StemCell
Technologies Inc.) were added to the stroma layers. After 3 days in culture the wells were
trypsinized (StemCell Technologies Inc.) resuspended in serum free media, counted and aliquots
used in primary CFU assays, suspension culture (SC) assays and used for FACS analysis. 
Primary CFU Assays
A known number of cultured normal BM and AML cells were plated in methylcellulose
culture medium, (Methocult H4330, StemCell Technologies Inc.), containing 20 ng/ml
rhIL-3, 20 ng/ml rhIL-6, 20 ng/ml rhG-CSF, 20 ng/ml rhGM-CSF, 50 ng/ml rhSteel Factor
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and 3 units/ml erythropoietin. After 10 days of incubation at 37oC in a 5% CO2 humidified
incubator, AML blast clusters (10-20 cells) or colonies (> 20 cells) were counted and the
numbers were pooled to obtain CFU frequencies. 
Suspension Culture Assays 
A known number of cultured normal BM and AML cells were plated in SC. SC were
maintained at 37oC in a 5% CO2 humidified incubator and 0.5 ml of fresh medium with
growth factors was added weekly as previously described.10,41 Every second week half the
cells and volume of the SC were removed, the cells were washed in DMEM with 10% FCS
and cultured in methylcellulose to determine the CFU frequency of the SC-IC. SC were
maintained for 8 weeks then the entire contents of the wells were harvested and assessed
for SC-IC frequency. 
Long-term Culture Assays 
To detect long-term-culture-initiating-cells (LTC-IC) a known number of AML or normal
BM cells (5-10x105 cells) were placed in 2.7 mL Myelocult media (StemCell Technologies
Inc.) with 10-6 M Solucortef and seeded onto a confluent layer of irradiated S17 or S17+
Jagged1 stroma cells. Cultures were incubated at 37oC in a 5% CO2 humidified incubator
and received a weekly half-media change. After 5 weeks both the adherent and the non-
adherent cells were harvested, pooled, counted and plated into methylcellulose-based
medium supplemented with 20 ng/ml rhIL-3, 20 ng/ml rhIL-6, 20 ng/ml rhG-CSF, 20
ng/ml rhGM-CSF, 50 ng/ml rhSteel Factor and 3 units/ml erythropoietin. Colonies were
counted after 21 days of culture.
Statistical Analysis
Comparison of relative Notch expression levels between AML populations and normal
BM populations was performed by Student’s t-test. To study differences between AML
cells cultured on S17 cells and S17+ Jagged1 expressing cells the Student t-test was also
performed. Statistical significance was assigned when the probability that there was no
difference between two variables was ≤ 0.05. 
Results
Expression of the four Notch receptors in AML cell lines, primary AML cells and AML progenitors
In order to determine whether Notch receptors are abnormally expressed in AML, we first
investigated the relative Notch1-4 levels in normal BM of 9 healthy volunteers and 6 AML
cell lines using real-time PCR. Normal BM1 was set as the reference at 1.00. Table 1 enlists
the relative Notch expression levels in normal BM and the AML cell lines K562, Kasumi-
1, KG-1, AML193, Mo7e and NB4. In normal BM, Notch1 was expressed at 0.6-8.8x the
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level of normal BM1. In the AML cell lines, Notch1 was barely detectable in AML 193
(0.04x) and low in NB4 (0.3x), whereas in K562 (3.4x), Kasumi-1 (1.1x), KG-1 (1.8x),
and Mo7e (1.9x) expression levels were similar to normal BM. Notch2 expression in
normal BM was 0.1-2.1x normal BM1. Notch2 expression in the AML cell line Mo7e was
barely detectable, whereas in the other 5 cell lines the Notch2 expression levels ranged
from 0.2-0.6x. Notch3 expression in normal BM was very heterogeneous (range 2.4-49x
normal BM1) and the same pattern was observed in the AML cell lines. In the Kasumi-1
cell line (376x normal BM1) and the AML 193 cell line (249x normal BM1) Notch3
expression was very high. Notch4 expression in normal BM ranged from 0.25-35x NBM1,
while in the AML cell lines Notch4 was barely detectable in the cell lines KG-1 (0.01x
normal BM1) and NB4 (0.01x normal BM1).
To investigate whether Notch is abnormally expressed in primary AML cells and AML
progenitors, PB cells from 11 AML patients at diagnosis and normal BM cells of 7 healthy
donors were sorted into CD34+CD38-, CD34+CD38+ and the CD34- fractions. In
unsorted primary AML cells Notch expression was similar to normal BM with Notch1
expressed at 3.3±4.6x normal BM1 (range 0.16-15.5), Notch2 expressed at 1.5±1.3x
normal BM1 (range 0.04-4.1), Notch3 expressed at 1.3±1.6x normal BM1 (range 0.01-4.5)
and Notch4 expressed at 0.8±2.2x normal BM1 (range 0-6.1). Interestingly, similar to the
generally very low expression of Notch4 in the cell lines, Notch4 expression was ≤0.02x
normal BM1 in 5 of 8 AML patients. 
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Table 1: Relative Notch expression of normal BM and AML cell lines. 
Notch1 Notch2 Nocth3 Notch4
(x normal BM1) (x normal BM1) (x normal BM1) (x normal BM1)
Normal BM 3.8±3.4 1.0±0.7 18±23 14±15
K562 3.4 0.2 37 15
Kasumi-1 1.1 0.2 249 0.3
KG-1 1.8 0.6 5.4 0.01
AML193 0.04 0.6 376 1.3
Mo7e 1.9 0.01 45 0.2
NB4 0.3 0.5 11 0.01
Table 1: Relative Notch expression of normal BM and AML cell lines. RNA was
extracted from 9 normal BM samples and 6 AML cell lines. RNA was used in Real-time
PCR experiments using the ∆∆Ct method. Notch expression levels were calculated as a
relative increase or decrease compared to normal BM1. 
BM bone marrow
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Figure 1: Ratio’s of Notch expression in normal BM and AML progenitors. RNA was
extracted from sorted CD34+CD38- cells, CD34+CD38+ cells and CD34- cells and from
unsorted cells from 5 normal BM samples (closed bars) and from peripheral blood of 13
AML patients (open bars). Relative Notch expression was determined by the amount
increase/decrease compared to normal BM1. Ratio’s were calculated by dividing the
relative Notch expression in the subpopulation by the relative expression in the unsorted
cells. A) Ratio’s of relative Notch1 expression in normal BM and AML subpopulations. B)
Ratio’s of relative Notch2 expression in normal BM and AML subpopulations. 
BM bone marrow * p<0.05
To allow comparison of Notch expression levels in the different populations per sample, we
calculated the ratio of Notch expression in the sorted populations divided by the Notch
expression in unsorted cells of that sample. In normal BM, Notch1 and Notch4 expression
is significantly higher (p=0.05 and p=0.04 respectively) in the primitive progenitor fraction
(CD34+CD38- fraction) compared to unsorted cells, with the same trend observed for
Notch2 and 3 (Chapter 5). When the results from normal cells were compared to AML
there was a significant difference between the ratio of Notch1 expression in the
CD34+CD38- fraction/unsorted cells in normal BM (mean 3.1 ± 1.0) as compared to the
ratio in AML cells (mean 1.0 ± 0.6) (p<0.01)(Figure 1). The same trend was observed with
the ratio of Notch2 expression in the CD34+CD38- fraction/ unsorted cells (normal BM
mean 1.3 ± 0.3; AML cells mean 0.7 ± 0.7; p=0.07). Furthermore, a significant lower ratio
of Notch2 expression was observed in the CD34+CD38+ fraction/unsorted cells in AML
samples (mean 0.7±0.3) compared to normal BM (mean 1.0±0.1; p=0.01). Overall, in AML
samples, the ratio of Notch1 expression in the 3 sorted populations was very similar, while
the ratio of Notch2 expression increased slightly upon maturation. We have determined
Notch3 and 4 expression in 5 patient samples and both Notch3 and 4 expression were very
heterogeneous in these samples. In two patient samples Notch3 expression was similar to
normal BM in all three fractions, in two patients, Notch3 was barely detectable in all
fractions and in one patient a very high (137x normal BM1) level of Notch3 expression
was observed in the CD34+CD38- fraction, while in other fractions a normal expression
level was observed. Notch4 was barely detectable in 3 of 5 AML patient samples. In one
sample a relatively high (5x normal BM1) Notch4 expression level was observed in the
CD34- fraction with barely detectable Notch4 expression in the CD34+CD38- fraction or
the CD34+CD38+ fraction. In the same patient with high Notch3 expression in the
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CD34+CD38- fraction cells a very high level (526x normal BM1) of Notch4 expression
was observed in the same fraction with very low levels of Notch4 in the other 2 fractions.
Interestingly, the ratio of Notch1 (0.2x normal BM1) and Notch2 (0.7x normal BM1)
expression in the CD34+CD38- fraction/unsorted cells of this patient seemed relatively
low. These results suggest that the usual upregulation of Notch1 and 2 in the CD34+
subpopulation with subsequent downregulation in the CD34- subpopulation is
dysregulated in AML progenitor cells. Notch3 and 4 expression in AML progenitors is
more heterogeneous.
132
Table 2: Total number and number of CD34+CD38- cells of normal BM and AML cells pre-
cultured on S17/S17+Jagged1 stroma cell lines.
Per 105 Cell number CD34+CD38- Cell number CD34+CD38-
input cells (x104) cells(x104) (x104) cells (x104)
S17 S17J S17 S17J S17 S17J S17 S17J
NBM 1 3.8 5.3 ND ND AML 1 2.4 1.6
NBM 2 6.7 12 ND ND AML 2 6.8 6.5 15 15
NBM 3 9.4 10 ND ND AML 3 5.7 5.2 9.1 8.9
NBM 4 7.7 8.0 ND ND AML 4 5.4 5.7 3.5 5.2
NBM 5 4.4 3.4 19 17 AML 5 8.7 7.8 0.8 2.5
NBM 6 4.9 6.7 72 78 AML 6 2.5 4.2 0.8 1.2
NBM 7 4.4 3.4 8.7 18 AML 7 1.0 1.1 0.1 0.3
NBM 8 4.4 6.0 14 29 AML 8 4.1 4.1 0.3 0.2
NBM 9 5.0 7.2 17 56 AML 9 3.6 4.5 0.5 0.9
NBM 10 3.0 4.0 9.4 31 AML 10 0.7 1.0 0.4 0.4
NBM 11 1.9 2.6 3.2 8.5 AML 11 1.7 2.5 0.8 1.0
NBM 12 1.8 3.6 3.1 11 AML 12 4.2 4.9 0.1 0.9
NBM 13 14 13 18 21 AML 13 4.0 2.1 0.1 1.8
NBM 14 18 21 24 48
NBM 15 16 19 137 182
Mean ± 7.0 ± 8.4 ± 30 ± 45 ± Mean ± 3.9 ± 0.8 ± 2.7 ± 3.2±
SE 5.0 5.7* 40 50* SE 2.3 0.1 4.6 4.6*
Table 2: Total number and number of CD34+CD38- cells of normal BM and AML cells
pre-cultured on S17/S17+Jagged1 stroma cell lines. 15 normal BM samples and 13 AML
samples were cultured for 3 days on irradiated S17 or S17+Jagged1 cells. Cells were counted
and analyzed for CD34 and CD38 expression by flow cytometry. The number of total or
CD34+CD38- cells at day 3 on S17 or S17+Jagged1 cells per 105 input cells was calculated. 
BM bone marrow NBM = normal bone marrow * p<0.05
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Stromal Jagged1 expression influences the number of normal BM and AML progenitors
To investigate whether Notch signalling alters the functional abilities of AML progenitors
as compared to normal cells, we used cultured AML and normal cells with the stromal cell
line S17 which expresses the Notch ligand Jagged1. We first evaluated whether the
phenotype of bulk normal BM and AML cells is altered when stimulated with a Notch
ligand. 1.2-2.5 x 106 AML cells (n=13) or 0.4-2.5 x 106 normal BM cells (n=15) were
placed for 3 days on S17 or S17+Jagged1 cells in duplicate. After 3 days cells were
counted, placed in MC and SC or analyzed by FACS for CD34 and CD38 expression
(Table 2). After 3 days of culture the mean number of total viable normal BM cells was
significantly higher (p<0.01) on S17+Jagged1 stroma cells compared to S17 cells. There
was no difference between the mean number of total AML cells on S17 and S17+Jagged1
cells at day 3. A significant higher number of CD34+CD38- normal BM cells (p<0.01) and
CD34+CD38- AML cells (p=0.02) was observed after culture on S17+Jagged1 cells
compared to S17 cells. However, although the total number of CD34+CD38- normal BM
cells increased after 3 days on S17 and S17+Jagged1 cells, the total number of
CD34+CD38- AML cells decreased when cultured for 3 days on S17 or S17+ Jagged1
cells. This suggests that Notch ligation can increase slightly both normal and AML
primitive progenitors as compared to controls. 
Figure 2: Ratio of the CFU frequency of normal BM cells and AML cells maintained
in SC on S17+Jagged1 divided by the frequency of cells maintained on S17 cells. A
known number of cultured normal BM (closed bars) and AML cells (open bars) were plated
in SC. Every second week half the cells and volume of the SC were removed and cultured in
methylcellulose to determine the CFU content of the SC. SC were maintained for 8 weeks
then the entire contents of the wells were harvested and assessed for CFU content. 
CFU colony forming cell, BM bone marrow, SC suspension culture * p<0.05
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Stromal Jagged1 expression influences the functional ability of normal BM and AML progenitors
To investigate whether Jagged1 influences the maintenance of functional AML progenitors in
vitro, a known number of normal BM and AML cells cultured for 3 days on S17 or
S17+Jagged1 stroma cells were plated into MC. In addition, cultured normal and AML cells
were placed in SC for up to 8 weeks. There was a significant increase (p<0.01) in mean CFU
frequency of normal primary CFU when cells were cultured on S17+Jagged1 cells compared
to S17 cells (Figure 2). This effect was not observed when AML cells were used. When normal
BM cells were cultured in SC with S17 or S17+Jagged1, a lower CFU frequency was observed
when BM cells were cultured on S17+Jagged1 cells compared to S17. In contrast, AML CFU
after SC showed a higher CFU frequency on S17+Jagged1 cells compared to culture on S17
cells with time. To further investigate this phenomenon we cultured normal BM (n=5) and
AML (n=12) cells in LTC with S17 and S17+Jagged1 as stroma feeders. After 5 weeks in LTC,
the LTC-IC frequency of normal BM cells on S17+Jagged1 cells was significantly lower
(p=0.04) compared to the LTC-IC frequency on S17 cells (Table 3). In contrast, the LTC-IC
frequency of AML cells cultured on S17+Jagged1 cells was significantly higher (p=0.02)
compared to the LTC-IC frequency on S17 cells. These data suggest that Jagged1 stimulation
of normal BM cells results in a decrease of primitive progenitors or a decrease in their
functional ability. In contrast, stimulation of AML cells with Jagged1 increases the number or
functional ability of primitive progenitors.
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Table 3: CFU frequency of 5 normal BM samples and 12 AML samples after 5 weeks in LTC on
S17 or S17+Jagged1 stroma cells.
CFU/105 after LTC CFU/105 after LTC
S17 S17J S17 S17J
NBM 1 21 2.1 AML 1 0.2 0.6
NBM 2 13 0.4 AML 2 9.1 37
NBM 3 52 45 AML 3 8 16
NBM 4 24 6.1 AML 4 0.4 1.0
NBM 5 21 22 AML 5 0.5 0.5
AML 6 0.1 0.3
AML 7 0.1 3.3
AML 8 0.0 3.1
AML 9 74 93
AML 10 57 79
AML 11 1.7 14
AML 12 4.0 4.1
Mean ± SE 26 ± 15 15 ± 19* Mean ± SE 13 ± 25 21 ± 32*
Table 3: CFU frequency of 5 normal BM samples and 12 AML samples after 5 weeks in
LTC on S17 or S17+Jagged1 stroma cells. 5 normal BM samples and 12 AML samples
were cultured in LTC on irradiated S17 or S17+Jagged1 cells. After 5 weeks both the
adherent and the non-adherent cells were harvested, pooled, counted and plated into MC
assays. Colonies were counted after 21 days of culture. 
NBM normal bone marrow, CFU colony forming cell, LTC long-term culture, MC methyl
cellulose * p<0.05
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Discussion
It seems clear that the Notch gene family plays an important role in cell fate decisions
within the hematopoietic system. We and others have shown that constitutively active
Notch genes or Notch ligation promotes in vivo repopulating cell proliferation and
maintenance while blocking terminal erythroid and myelomonocytic differentiation
(Chapter 5).28,34,40,42 These findings suggest that Notch is an important regulator of the fate
of stem cells and myeloid committed progenitors. Notch genes have also been implicated
in a wide variety of malignancies including lymphoid leukemias and lymphomas, and
downstream pathways of Notch interact with other known oncogenic pathways such as
Hox. As a key feature of AML is the failure of terminal myeloid differentiation, we were
interested to see whether Notch genes are abnormally expressed, either as a primary or
secondary event, in bulk AML cells and in the phenotypically defined primitive AML
progenitors thought to be responsible for maintaining the disease. 7,9,10 Furthermore, in order
to evaluate the functional response of AML progenitors to Notch we co-cultured AML
cells and normal BM cells with a stromal cell line expressing the Notch ligand Jagged1. 
We have evaluated Notch gene expression as a potential marker for altered Notch
signalling. While a direct correlation may not exist, some evidence for a correlation is
suggested in that Notch receptors are expressed at the highest levels in the primitive
CD34+CD38- subpopulation where it has been shown to be active in cell fate
determinations (Chapter 5).19 A marked overexpression of Notch, which might be
predicted if Notch were important in driving AML cell behavior, was only seen in the
AML cell lines Kasumi-1 (FAB type M2, myeloblastic leukemia) and AML193 (FAB type
M5, monocytic leukemia) in which Notch3 expression was extremely high. We also
observed very high levels of Notch3 and Notch4 in the primitive AML progenitor
population of one patient with FAB M5. In the AML cell lines NB4 (FAB type M3,
promyelocytic leukemia) and KG-1 (FAB type M6, erythroleukemia) all four Notch
receptors were expressed at a very low level compared to normal BM. Constitutively active
forms of Notch1 and Notch4 inhibit erythroid differentiation. It is possible that the Notch
receptors are downregulated to try to overcome this block in differentiation possibly
caused by other genetic changes. While normal cells have higher Notch expression in the
CD34+CD38- population, in AML cells, Notch1 and 2 are expressed in the CD34+CD38-,
the CD34+CD38+ and the CD34- subpopulation at comparable levels in the majority of
the samples, suggesting that the usual downregulation of Notch1 and 2 is perturbed in
AML samples. 
The effect of Jagged1 and other Notch ligands on hematopoietic progenitors in in vitro
assays is still unclear. While some studies report an increase in CFU frequency after
stimulation with Jagged1,21,26,27 other groups have reported a decrease in CFU
frequency.43,44 Differences may be related to the length of exposure to Jagged1 before
plating the cells in CFU assays or to other factors. In addition, some groups have used
Jagged1 expressed by stroma cell lines,43 whereas others have used a soluble form of
Jagged1.21,26,44 It is not clear whether soluble forms of Notch ligands are activating the
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Notch pathway or might actually block Notch signalling. Recently, two papers have
demonstrated that Jagged1 and Delta1 are capable of translocating to the nucleus
themselves suggesting that they may signal as well.45,46 In this study, we found a modest but
significant increase in CD34+CD38- cells in both normal and AML cells after 3 day
exposure to the Jagged1 expressing S17. Primary CFU from normal BM cells also
increased significantly after a 3-day exposure to Jagged1 expressing S17 cells, while AML
CFU were slightly but not significantly increased as compared to the S17 control. After 2,
4, and 6 weeks in SC, derived CFU from normal BM was slightly lower in the cultures
previously exposed to 3 days of Jagged1, while CFU from the S17+Jagged1 AML
cultures were increased 2–4 fold as compared to the control, however neither change was
significant. Similar findings were observed when normal BM or AML cells were co-
cultured with the S17 or S17+Jagged1 for 5 weeks and then analyzed for CFU. In normal
BM, CFU frequencies from LTC, co-cultures were significantly lower when cells were
cultured on S17+Jagged1 cells as compared to S17 cells, while in AML the Jagged1
exposure increased CFU. It seems clear that constitutively active forms of Notch promote
the maintenance of primitive progenitors (Chapter 5).23,28,47 However, the signal that Notch
receptors receive through Jagged1 ligation may be different than signalling through
constitutively active forms of Notch or other Notch ligands.48 In AML, we found similar
effects of Notch-Jagged1 ligation as compared to normal BM cells when we analyzed
phenotype or primary CFU, however using assays that measure more primitive
progenitors, opposite effects were observed with significant increases in the LTC assays.
This suggests, that either the frequency or the functional ability of primitive AML
progenitors increases upon Jagged1 stimulation. 
Abnormal Notch expression in AML progenitor cells and an abnormal proliferative
response to Jagged1 ligation suggest that the Notch gene family may play a role in AML.
Whether abnormal Notch expression has a causative role in this disease or whether
abnormal Notch expression is a consequence of other dysregulated genes remains to be
elucidated. 
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Chapter 7
Summary and General Discussion
Acute Myeloid Leukemia (AML) is characterized by an uncontrolled proliferation and
accumulation of myeloid blast cells in the bone marrow, blood and other organs of patients.
It is thought that the disease is sustained by a small subset of cells capable of extensive self-
renewal and proliferation, which gives rise to the more mature myeloid blast cells.1-3 These
cells, uniquely capable of sustaining the disease, are called AML stem cells. Despite
remarkable progress in the treatment of AML over the last decades, the disease is still often
fatal mainly due to relapse of the disease.4,5 Relapse is often the result of minimal residual
disease or, in case of an autologous stem cell transplant, contamination of the transplant
with leukemic stem cells.6 Eradication of these AML stem cells is essential to cure the
disease. Characterization of the AML stem cells both functionally and phenotypically is
important not only to develop new treatment strategies that are disease specific and
curative, but also because it will give us new insights into the etiology of this disease. 
7.1 Normal and AML Stem Cells: the Phenotypic Characteristics
AML occurs as a result of genetic changes in normal hematopoietic cells.1,7 Typically, a
normal hematopoietic stem cell instead of progenitor cell is the target for transformation
for two reasons. First, stem cells have the machinery for self-renewal, while more
differentiated cells have to turn that machinery on de novo. Therefore, fewer mutations
may be required to maintain self-renewal than to re-activate this potential in progenitor
cells. Secondly, because of the relative longevity of stem cells compared to more mature
progenitors, there is also a higher change of an accumulation of genetic changes that may
lead to the transformation to occur.
To date normal hematopoietic stem cells can only be defined functionally: they self renew
and they differentiate into all the lineages of mature blood cells. Intensive efforts have been
made to identify the phenotype of the hematopoietic stem cell. The majority of
hematopoietic stem cells lack the expression of CD38, CD71, HLA-DR8-10 and common
lineage specific markers such as CD33, CD13, CD20, CD11b, CD3, CD4 and CD811 and
express CD34 and CD90.12 The estimated frequency of the competitive repopulating units
(CRU) in immuno-deficient mice, a surrogate marker for hematopoietic stem cells, is about
30 times higher in the CD34+ population of the BM (1 per 105 CD34+ cells)13 compared
to total BM cells (1 per 3x106 total BM cells).14 Although CD34 is used extensively in the
clinic for the purification of normal hematopoietic stem cells, recent studies have
demonstrated the existence of CD34- stem cells, which appear to be more primitive than
the CD34+ cells.15,16
AML stem cells share many phenotypic similarities with normal stem cells adding to the
body of evidence that the malignant transformation occurs at the stem cell level. AML
progenitors can be detected in the same in vitro and in vivo assays as their normal
counterparts.1,2,17 We have observed a close correlation between the malignant progenitors
with long-term in vitro proliferative ability and the cell capable of engrafting in the
NOD/SCID mouse.18 The frequency of the SCID-Leukemia Initiating Cell (SL-IC) varies
in different reports from as high as 20-1000 SL-IC per 106 AML cells1 to as low as 0.7-45
SL-IC per 107 AML cells.19 A 3 log purification in leukemic stem cells was obtained when
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AML cells were sorted for their CD34+CD38-HLA-DR- phenotype.3 However,
engraftment with CD34- cells has also been reported.20 Whether the CD34- AML cell
capable of engraftment is a more primitive progenitor than the CD34+ cell, as has been
suggested in normal hematopoiesis, is unclear. One of the few differences between normal
and leukemic stem cells is that normal stem cells express CD90, while most leukemic stem
cells do not.21 We could speculate that an initial genetic change in a CD90+ hematopoietic
stem cell is followed by additional mutations in a downstream CD90- progenitor cell that
is still capable or regained the ability of engrafting. Another possibility is that mutations in
the hematopoietic stem cell result in the loss of CD90 expression.
CD133 is a cell surface antigen that is expressed on a wide variety of stem cells and is
rapidly downregulated upon differentiation. In the hematopoietic system, CD133 is
expressed on both the CD34+ and CD34- cells capable of engrafting in immuno-deficient
mice, suggesting that this marker is more useful to detect normal hematopoietic stem
cells.16,22 Our data demonstrate that CD34 and CD133 expression is not unique to normal
hematopoietic stem cells, because CD34 and CD133 expression could be seen on the
majority of AML cells capable of engrafting in immuno-deficient mice. Autologous
transplants based on CD34 or CD133 selection could therefore be a source of leukemic
stem cells that ultimately could contribute to relapse of the disease.
CD33, a myeloid specific cell surface antigen, is absent on normal hematopoietic stem
cells,11,23,24 but is expressed on the majority of AML cells.25-27 Hence, this antigen appears
to be an ideal candidate for AML specific treatment strategies. Over the last decade,
several therapeutic strategies have been developed that use a CD33 antibody for the
specific delivery of the anti-leukemic agent.28-30 Although most patients initially respond to
these treatments, relapse often occurs. This is not so surprising given the fact that we
showed that the majority of AML stem cells do not express CD33 and will be spared by
any of these treatments. However, in our study a few AML patient samples could be
selected with CD33 expression on their leukemic stem cells and these patients might
benefit by CD33 based therapies. It would be too time consuming to set up functional
assays for each individual patient to determine their CD33 expression on primitive AML
progenitors. An alternative would be to check for abnormal karyotype in the
CD34+CD33- population, which according to our study contains the majority of primitive
AML progenitors. 
Immunophenotypic instability of AML cells has been reported and could limit the
potential use of the phenotype of AML cells as a possible target for therapeutic
interventions. A recent study has reported immunophenotypic changes in 91% of the AML
samples upon relapse.25 Given the instability of the immunophenotype of AML cells, loss
of expression of cell surface antigens might occur as a mechanism of resistance to antibody
based therapies. Therefore, patients receiving these therapies should be monitored for the
development of this mechanism of resistance.
The identification of the immunophenotype of both normal and AML stem cells is not only
useful for the development of new treatment or positive selection strategies, it is also a
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powerful tool to determine the gene expression profile in leukemic stem cells. In the last
decade various methods have been developed to quantitatively determine gene expression
in a particular population. For example, gene expression in a certain population can be
detected using Real-Time PCR,31 which can only detect known genes or Serial Analysis of
Gene Expression (SAGE), which also detects unknown genes.32 In addition, methods have
been developed to directly compare two different populations (e.g. normal versus leukemic
stem cells). Recently, DNA micro-arrays, which can only detect known genes, have been
used to compare gene expression profiles of different types of stem cells and of
hematopoietic stem cells of different species.33,34 These methods of gene expression
profiling could provide useful information about gene expression or silencing in AML stem
cells versus normal stem cells. This information may give us new insights into the fine line
between normal and leukemic stem cell behaviour. It may also provide us with new targets
for the treatment of AML. 
One of the challenges for the applicability of these methods is to obtain a relatively pure
stem cell population. In addition, normal and leukemic stem cells only represent a small
subset of total hematopoietic cells and because expansion of these cells in vitro does not
seem to maintain the stem cell properties, it is still a challenge to obtain enough RNA
necessary for these procedures. However, considerable progress is being made to amplify
RNA from extremely low amounts of RNA35 and combined with an increasing sensitivity
of the methods detection of gene expression in a small number of cells will soon be
achievable. 
7.2 Normal and AML Stem Cells: Telomerase and Telomeres
The enzyme telomerase is capable of maintaining telomere length, thereby preventing
replicative senescence of cells.36-38 Not surprisingly, many malignant cells, including the
majority of AML cells, have found mechanisms to upregulate telomerase.39 The marked
reduction in long-term growth in our in vivo and in vitro assays indicates that telomerase
inhibition decreases the proliferative potential of primitive AML progenitors. Therefore,
telomerase is a potential target to eradicate AML stem cells. Although telomerase itself is
not an oncogene, it can extend the replicative lifespan of cells, one of the necessities for
malignant growth. Interestingly, the telomere length in malignant cells is often shorter than
in normal cells upon senescence.40 This suggests that malignant cells can escape apoptosis
for a longer period of time than normal cells. However, if malignant cells can not maintain
telomere length, in other words if they do not have telomerase, apoptosis occurs. Four
major concerns exist with the use of telomerase inhibitors for the treatment of cancer. First,
selection of resistant clones may emerge during anti-telomerase therapy and these clones
may be harder to eradicate. We have observed some K562 clones transduced with the
dominant negative form of hTERT (DN-hTERT), which returned to proliferate after a
period of quiescence. This return of proliferation coincided with the loss of the transgene.
However, we also observed one DN-hTERT transduced K562 clone, which dramatically
upregulated its endogeneous telomerase activity, while the DN-hTERT transgene was still
expressed. Second, an alternative telomerase independent pathway (alternative
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lengthening of telomeres, ALT) to maintain telomere length has been described, suggesting
that telomerase inhibition may activate telomerase independent pathways. Bryan et al.
demonstrated that of the 113 tumors or tumor cell lines studied, 8 cell lines (7%) had
ALT.41 In addition, some tumors used both telomerase and ALT to maintain their telomere
length. This suggests that a combination of telomerase and ALT inhibitors may be
necessary for the eradication of the malignancy. Third, inhibition of telomerase can lead to
telomere shortening, which in turn can cause genetic instability and chromosome fusions.
Genetic instability or chromosomal abnormalities may result in the development of
malignancies. Indeed, patients with the inherited syndrome dyskeratosis congenita (DKC)
have a mutation in one of the components of telomerase, resulting in a deficiency of
telomerase activity.42,43 These patients have a high incidence of certain tumor types,
suggesting that the absence of telomerase can cause malignancies.44 Lastly, normal stem
cells, including hematopoietic stem cells, express low levels of telomerase.45-48 Inhibition of
telomerase in stem cells may cause a lack of mature cells of certain types. For example,
telomerase inhibition in hematopoietic stem cells may cause bone marrow failure. In
patients with DKC, pancytopenia occurs after a median onset of 10 years, indicating that
continuous administration of telomerase inhibitors may be relatively safe for several
years.49,50 However, further studies are necessary to determine the effects of telomerase
inhibition on normal stem cells. 
7.3 Normal and AML Stem Cells: Regulatory Pathways
One of the most important issues in stem cell biology is understanding the mechanisms that
regulate the relative balance between self-renewal and differentiation. Cancer can be
considered to be a disease of unregulated self-renewal. Many pathways that regulate stem
cell self-renewal and differentiation are also associated with cancer. For example, Wnt,
Hox, Sonic Hedgehog and Notch signalling all regulate stem cell self-renewal and lead to
tumorigenesis when dysregulated. The only exception to date is the HoxB4 gene.
Overexpression of HoxB4 results in a 40 fold expansion of murine hematopoietic stem
cells in vitro and mice transplanted with these cells retain their full lympho-myeloid
repopulating potential without malignant transformation.51
As Notch receptors are known to play a role in maintaining proliferative cell populations
in the undifferentiated state, their putative role in cancer would be to prevent malignant
cells from responding to differentiation signals in their immediate environment. Notch
could also give malignant stem cells the ability of continuous self-renewal. Interestingly,
Notch1 can also act as a tumor suppressor,52 suggesting that there is a fine balance in
Notch expression and that disturbance of this balance causes malignant transformation of
the cells. Clearly, constitutive activation of Notch1 causes T cell malignancies in
humans.53,54 Notch activation can inhibit the differentiation of myeloid cells especially
erythroid and monocytic differentiation and it maintains normal hematopoietic
progenitors.55-57 In search of differences between normal and AML progenitors we found
that Notch receptors are abnormally expressed on AML progenitors. Primitive AML
progenitors failed to downregulate Notch1 and 2, while Notch3 and Notch4 expression
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appeared very high in certain patients. Further investigations in the expression of Notch
in AML would be greatly facilitated by the availability of Notch receptor antibodies. 
To date it is not clear whether constitutively active forms of Notch and activation of Notch
by the various Notch ligands result in the same downstream effects. It appears that not all
ligands have the same effect on the hematopoietic stem cells.58 In addition, it is unknown
whether the use of soluble forms of Notch ligands mediates the same downstream effects
as ligands expressed on cells. It has been speculated that soluble forms may actually act as
antagonists of this pathway. This knowledge would be helpful to create new ways to
selectively expand normal versus leukemic stem cells. 
Overall, we can conclude that normal and AML stem cells are very similar in phenotype,
hampering strategies to separate them from each other. However, insights in the
mechanisms that immortalize AML stem cells and give them the ability to escape
regulatory differentiation and self renewal signals will give us new insights in the etiology
of AML and may create new treatment strategies. 
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Acute Myeloïde Leukemie (AML) wordt gekenmerkt door een ongecontroleerde celdeling
en een blokkade in de differentiatie van myeloïde cellen. Hierdoor ontstaat in het
beenmerg van de patient een tekort aan de overige rijpe bloedcellen zoals rode bloedcellen,
bloedplaatjes en leukocyten. De meeste patiënten met AML worden behandeld met
chemotherapie al dan niet gevolgd door een allogene (van een donor) of autologe (van de
patient zelf) stamcel transplantatie. Ofschoon het grootste deel van de patiënten in
complete remissie raakt, keert bij de meeste patiënten de ziekte terug.
In het beenmerg vindt de aanmaak van bloedcellen, hematopoïese, plaats. Dit proces
wordt in stand gehouden door een kleine populatie stamcellen. Een stamcel moet aan twee
eisen voldoen. Ten eerste moet het in staat zijn zichzelf te vervangen (zelf-replicatie). Ten
tweede moet een stamcel via tussenstadia van gecommitteerde voorlopercellen kunnen
differentieren tot alle rijpe cellen in het bloed. Verschillende functionele testmethoden zijn
ontwikkeld om hematopoïetische stamcellen en gecommitteerde voorlopercellen te
bestuderen. Hematopoïetische stamcellen kunnen voor reconstitutie van hematopoïetische
zorgen in (sub) letaal bestraalde immunodeficiënte dieren, zoals NOD/SCID muizen. Het
is tot nu toe onduidelijk of de echte hematopoïetische stamcellen gedetecteerd kunnen
worden in beschikbare in vitro testen. Er zijn echter kweekcondities bekend waarin
primitieve cellen langdurig kunnen worden gekweekt. Gecommitteerde voorlopercellen
kunnen gekweekt worden in een kolonie vormende assay. Deze functionele testen in
combinatie met flowcytometrische analyse hebben aangetoond dat hematopoïetsiche stam-
en voorlopercellen bepaalde antigenen op het cel oppervlak tot expressie brengen. Over
het algemeen wordt aangenomen dat normale stamcellen CD34 en CD90 tot expressie
brengen maar dat CD38, CD71 en andere met differentiatie geassocïeerde antigenen
ontbreken. Gecommitteerde voorlopercellen zijn vaak nog positief voor CD34 maar
brengen ook CD38 tot expressie. Op dit moment wordt CD34 in de kliniek gebruikt voor
de purificatie van stamcellen. Er blijft echer onduidelijkheid bestaan over het fenotype van
stamcellen, want onlangs zijn er studies verschenen die hebben aangetoond dat CD34-
cellen primitiever zijn dan de CD34+ cellen. Aangezien het gebruik van de combinatie van
de bovenstaande antigenen slechts een verrijking van het percentage stamcellen geeft maar
geen pure stamcel populatie oplevert, kan een hematopoïetische stamcel tot nu toe alleen
functioneel gedefinïeerd worden.
AML ontstaat door een genetische mutatie in een hematopoïetische stamcel, die de
leukemie kloon voortbrengt. Ondanks de afwezigheid van rijpe leukocyten is er toch een
zekere mate van differentiatie van de leukemie stamcellen. Dit wijst op de aanwezigheid
van een hierarchie in AML, waarin alleen de AML stamcellen verantwoordelijk zijn voor
het in stand houden van de ziekte. Door het fenotype van AML stamcellen te bepalen
kunnen we eventuele verschillen in het fenotype van normale en AML stamcellen
gebruiken voor de ontwikkeling van methoden om autologe stamcel transplantaties te
zuiveren van AML stamcellen. Als er verschillen zijn kunnen we ook nieuwe therapiëen
ontwikkelen, die specifiek gericht zijn op leukemie stamcellen. Dezelfde functionele testen
en flowcytometrische analyses, die gebruikt zijn om het fenotype van normale
hematopoïetische stam- en voorlopercellen te bepalen, kunnen gebruikt worden om AML
stam- en voorlopercellen te detecteren. Over het algemeen zijn er weinig verschillen tussen
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het fenotype van normale stamcellen en leukemie stamcellen met uitzondering van het
antigeen CD90 dat tot expressie gebracht wordt op normale stamcellen maar vaak niet
aanwezig is op leukemie stamcellen. 
Onlangs is er een nieuw antigeen ontdekt, CD133, dat aanwezig is op normale CD34+ en
CD34- hematopoïetische stamcellen en daarom beter zou zijn dan CD34 voor de isolatie
voor normale stamcellen. Wij hebben echter aangetoond dat ook de meeste leukemie stam-
en voorlopercellen CD133 tot expressie brengen, waardoor autologe stamcel
transplantaties gebaseerd op CD133 selectie ook AML stamcellen kunnen bevatten. 
Het CD33 antigeen wordt niet tot expressie gebracht op normale hematopoïetische
stamcellen, maar is aanwezig op het oppervlak van alle myeloïde voorlopercellen en op
AML cellen van 75-90% van de patiënten. Daarom wordt CD33 gebruikt als antigeen in
de ontwikkeling van AML specifieke therapiëen. Wij hebben aangetoond dat CD33
meestal afwezig is op AML stamcellen. Bepaalde patiënten kunnen echter geselecteerd
worden die CD33+ leukemie stamcellen hebben. De meeste patiënten zullen dus weinig
baat hebben bij het gebruik van CD33 specifieke therapiëen, maar voor een specifieke
groep patiënten kunnen deze therapiëen erg nuttig zijn.
Telomeren bevinden zich aan het eind van chromosomen en worden gekarakteriseerd door
specifieke DNA sequenties en bijbehorende eiwitten. Telomeren voorkomen genetische
instabiliteit en zorgen ervoor dat chromosomen niet met elkaar fuseren. Met iedere
celdeling worden telomeren korter tot een kritiek punt bereikt wordt en de cel apoptose
ondergaat. Dit mechanisme zorgt ervoor dat cellen niet onbeperkt kunnen delen.
Telomerase is een enzym dat in staat is om de lengte van telomeren in stand te houden. Dit
is noodzakelijk in sommige cellen zoals stamcellen, die een leven lang moeten kunnen
delen. Verschillende types kankercellen hebben mechanismen ontwikkeld waardoor ze
telomerase tot expressie kunnen brengen. Dit heeft tot gevolg dat kankercellen schijnbaar
onbeperkt kunnen delen. AML cellen van de meeste patiënten brengen ook telomerase tot
expressie. Wij hebben AML cellen getransfecteerd met een dominant negatief telomerase
gen met tot gevolg dat het telomerase enzym niet meer werkt. Functionele testen met deze
getransfecteerde cellen hebben aangetoond dat deze AML stamcellen niet meer goed
kunnen groeien en waarschijnlijk apoptose ondergaan. De remming van telomerase kan
dus een goede methode zijn om AML te behandelen. Echter het effect van telomerase op
normale stamcellen moet eerst goed onderzocht worden.
Ook hebben we gekeken naar de Notch receptoren in normale hematopoïese en in AML.
Het is aangetoond dat activatie van de Notch receptoren leidt tot het behoud van normale
stamcellen. Verder veroorzaakt constante activatie van Notch, abnormaliteiten in
lymfocyten. Het is echter ook aangetoond dat activatie van de Notch receptoren kan leiden
tot een blokkade in de differentiatie van myeloïde cellen. Om dit fenomeen te onderzoeken
hebben we eerst een geactiveerde vorm van Notch1 en Notch4 tot expressie gebracht in
CD34+ geselecteerde navelstreng bloedcellen. Dit had tot gevolg dat deze navelstreng
bloedcellen een hoger percentage aan primitieve cellen hadden en minder goed in staat
waren om tot myeloïde cellen te differentieren in in vitro testen. Verder waren deze cellen
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beter in staat om het beenmerg en bloed van immunodeficiënte muizen te reconstitueren.
Echter alle muizen hadden afwijkingen aan de T en B lymfocyten en er waren ook minder
myeloïde cellen. Het effect dat Notch activatie op normale bloedcellen heeft, bracht ons tot
de hypothese dat Notch een rol zou kunnen spelen in het ontstaan van AML. Wij hebben
bepaald dat Notch expressie in primitieve AML cellen anders is dan in normale cellen.
Activatie van Notch door zijn ligand Jagged1 zorgt voor een hogere proliferatie van AML
cellen, terwijl normal primitieve cellen juist minder prolifereren na ligatie met Jagged1.
Blokkering van de Notch-Jagged1 route zou daardoor kunnen leiden tot specifieke
remming van de proliferatie van primitieve AML cellen. 
Wij kunnen concluderen, dat het fenotype van AML stamcellen veel gelijkenis vertoont
met normale stamcellen, waardoor het moeilijk is om deze stamcellen van elkaar te
onderscheiden en specifieke therapiëen tegen AML stamcellen te ontwikkelen. Het enzym
telomerase is wel een goed doelwit om AML te behandelen. Nieuw routes, die
zelfvernieuwing en differentiatie van normale en leukemie stamcellen reguleren, zoals de
Notch route, kunnen ook leiden tot nieuwe inzichten in het ontstaan en het behandelen van
AML.  
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